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Abstract 
The dose of a number of pharmacological agents in clinical use differ from that initially 
recommended when the compound was first introduced into clinical use. For some time now, 
anecdotal reports have suggested that glibenclamide, a widely used oral hypoglycaemic in 
type 2 diabetic patients, is being used at doses that exceed those likely to produce clinical 
control of elevated blood glucose. This is also reflected by the discrepancy in the maximum 
recommended dose from different manufacturers and in different countries - some 
recommend 15 mg as the maximum dose and others recommend 20mg. 
A survey of 6 state institutions in the greater eThekwinilDurban area revealed that up to 25% 
(range 7-45%) of patients were prescribed 20 mg of glibenclamide per day, confirming the 
use of high doses of glibenclamide. Even more disconcerting was the observation that elderly 
patients, who are potentially more susceptible to the adverse effects of glibenclamide, are 
given this high dose. 
A clinical study was therefore conducted to determine whether patients benefit from the use of 
these high doses of glibenclamide. Twenty two type 2 diabetics who attended an outpatient 
diabetes clinic were recruited into a within-subject dose escalation study. In order to evaluate 
the dose-response relationship of glibenclamide, blood glucose, blood insulin and blood 
glibenclamide concentrations were measured in these subjects. After an initial washout 
period, a zero dose study was conducted followed by dose escalation through 2.5, 5, 10, 15 
and 20mg daily doses at 14 day intervals. Dose escalation was guided by careful clinical 
examination, monitoring of blood glucose concentrations and checks for symptoms of 
hypo glycaemia. The relationship between dose and selected metrics of pharmacokinetic and 
pharmacodynamic (PKPD) response on glucose and insulin were investigated. Data analysis 
procedures included graphical exploration, use of conventional statistical methods and 
mathematical modeling using the non-linear mixed effects models as implemented in the 
software package, NONMEM. 
Clinical evaluation of glycaemic control based on the Society for Endocrinology, Metabolism 
and Diabetes of South Africa (SEMDSA) conservative criteria indicated that only 57% of 
subjects benefited clinically even when their dose was escalated to the maximum dose of 20 
mg per day. Exploratory graphical analysis suggested that doses beyond 5 - 10 mg per day 
were unlikely to provide any additional reduction in blood glucose concentrations. Subsequent 
PKPD modeling revealed that the maximum mean reduction in blood glucose concentrations 
(Emax) was only - 34% from a baseline of -15 mMoVL. The glibenclamide dose producing 
50% inhibition of glucose concentration (EDso) was estimated from the models to be in the 
region of 2.5 to 5mg per day. These 2 parameters in combination confirm that on average, 
escalating doses of glibenclamide in these subjects was unlikely to produce any substantial 
clinical benefit. 
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The subjects included in this study were considered to be typical diabetic patients that 
attended this clinic. Factors that were identified for the poor response to dose-escalation were 
the duration of diabetes and insulin resistance. Diabetic patients who share characteristics of 
the diabetic population and who are insulin resistant and on glibenclamide therapy, are more 
likely to benefit from combination therapy i.e., the addition of insulin sensitizers and/or 
insulin. This approach to their therapeutic control should be used rather than escalation of 
doses beyond 5 - IOmg per day since the use of high doses of glibenclamide is not without 
risk. High doses can mask the severity of a myocardial infarction, increase cardiovascular 
mortality with the added disadvantage that many patients are not likely to benefit from this 
expensive dose escalation. 
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STRUCTURE OF THE DISSERTATION 
Introduction 
The motivation for the study based on the observations of effectiveness of low dose 
glibenclamide and a survey on high dose glibenclamide use are presented. 
Literature review 
In this section a clinical overview of diabetes is presented followed by the pharmacology and 
treatment of the disease. The pharmacokinetics and pharmacodynamics of glibenclamide and 
modeling are also reviewed. 
Patients and Methods 
The demographics of the study population, the study design and the methods of analyses are 
presented 
Results and Discussion 
Results and discussion are presented separately for demographics, insulin resistance, dose-
exposure-response relationship, clinical benefit, NeA, Population-PK and PKPD modeling. 
Limitations 
Limitations identified in the study are presented. 
Recommendations 
Recommendations based on the findings with respect to optimal dose, high dose, PK and 
PKPD models are presented. 
Summary of Findings 
A global summary of the research concludes the thesis. 
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Introduction 
A prerequisite for optimal drug therapy is an appropriate dose. A review of the literature by 
Heerdink et al. (2002) suggests that doses of a wide variety of pharmacological agents 
currently used in clinical practice differ from the doses initially recommended at the time of 
drug registration. Some of the classes of drugs for which doses have been changed include 
antibiotics, cardiovascular, respiratory, neurological agents and others. Oral antidiabetic 
agents, in particular sulphonylureas, thus far lack, this degree of post-approval evaluation. 
1 Diabetes - an epidemic 
Diabetes mellitus (DM) is a global problem which is expected to reach epidemic proportions. 
DM is classified into type 1 (insulin-dependent DM or IDDM) and type 2 (non-insulin-
dependent DM or NIDDM). Approximately 70-80% of diabetic patients have type 2 diabetes 
(Alberti and Zimmet, 1998). The World Health Organisation (WHO) estimates that the global 
number of persons with diabetes will rise from 151 million in the year 2000 to 221 million by 
the year 2010, and to 300 million by 2025 (Zimmet, 1999). Most of this increase will occur in 
the developing countries and will be due to population ageing, unhealthy diets, obesity, 
sedentary lifestyle and rural-urban migration. 
Diabetes is approaching epidemic proportions in South Africa (Naicker, 2002). The present 
prevalence in South Africa is estimated to be between 4% and 5% and is expected to increase 
to 8% by the year 2010 i.e., from 1.6 million to 3.5 million and possibly 10 million. In South 
Africa, the magnitude of the diabetes epidemic is reflected in its prevalence in the different 
population groups. It is estimated that 8-10 % of coloureds, 13-18% South Africans of Indian 
origin, the majority of whom reside in the province of Kwazulu-Natal and 3.5-4% of whites 
are diabetic (Naicker, 2002; Trutter, 1998). The incidence in South African blacks is 5-8% 
and rising due to urbanisation e.g., the prevalence of DM in blacks in rural QwaQwa (Free 
State province) is 4.8% whilst in urbanised Mangaung (Free State Province) it is 6% 
(Mollentze et aI., 1995). It may thus be postulated that lifestyle and dietary changes have 
contributed to this trend. 
Motala et al. (2003) in their community-based study on a cohort of South Africans of Indian 
origin, aimed to determine the incidence of type 2 DM and the risk factors associated with its 
development, over a 10 year period. The crude cumulative incidence of DM in this population 
was 9.5% and significant predictors were body mass index (BMI) and a high baseline blood 
glucose. 
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2 Glibenclamide - which dose? 
Oral hypoglycaemic agents (OHA's) are the mainstay of pharmacological management of 
type 2 diabetes mellitus. Glibenclamide, a second generation high potency sulphonylurea 
(SU) (Feldman, 1985), is one of the most widely used oral hypoglycaemic agents (OHA's) in 
public health institutions. It has been used in clinical practice for the past two decades both 
worldwide and in South Africa. The low cost and ready availability to the state makes it a 
popular agent in the management of type 2 diabetes mellitus. Glibenclamide is available as a 
generic preparation at a fraction of the cost of the original product. As at October 2003, 
Glycomin® was 50% the price of Daonil® in the private sector and only 14% of the cost of 
Daonil® in the public sector. Glycomin® is much cheaper in provincial institutions (R16 for 
500 tablets) because of the highly competitive tender system. 
The package insert for DiaBeta® (glyburide USP, 2003) states that the usual maintenance 
dose is in the range 1.25 to 20 mg daily. The maximum dose, it cautions, should not exceed 20 
mg per day. The package insert for Daonil® (glibenclamide) in South Africa limits the 
maximum daily dose to 15 mg and for Glycomin® the maximum dose is 20 mg .. Therefore, 
manufacturers are inconsistent and even in conflict in their recommendations on the 
maximum dose of glibenclamide. 
This discrepancy in dose recommendation amongst the manufacturers, has translated to 
inappropriate doses of glibenclamide being prescribed. 
In South Africa, the case against the use of high dose glibenclamide came from Robertson 
and Jackson (1989). They showed that a reduction in the dose of glibenclamide from 15 
mg/day to 2.5 mg/day in 15 type 2 DM patients resulted in 12 (80 %) patients achieving a 
reduction in fasting blood glucose. As there were no reported hypoglycaemic episodes, they 
suggested that their patients were often eating to 'keep up with their glibenclamide.' 
However, despite this study and the manufacturers' recommendations, glibenclamide 
continues to be used in high doses in clinical practice in South Africa. 
A long term study comparing glibenclamide and glipizide showed little or no improvement in 
blood glucose control at doses greater than 10 mg/day (Groop et aI., 1987). In the case of 
glipizide, dosage increases from 15 to 25 mg/day resulted in increased rather than decreased 
blood glucose levels (Wahlin-Boll et aI., 1982). The authors therefore concluded that there 
may be a narrow range of plasma concentration below which sulphonylureas (SU's) are 
ineffective and above which there is little additional pharmacological benefit. 
23 
High dose glibenclamide is not without risk. Firstly, because of its high potency and long 
duration of action, it carries the risk of prolonged hypo glycaemia. This is particularly evident 
in the elderly and patients with irregular eating habits, and can result in fatalities. Secondly, 
the danger of high dose glibenclamide (e.g., 20 mg/day usually given as 10 mg in the morning 
and 10 mg at night) is potentially a hypoglycaemic risk, especially in patients who consume 
small meals. To overcome the symptoms of hypo glycaemia, the patient increases his glucose 
intake which increases his postprandial blo.od glucose level, which in turn elicits an 
unnecessary further increase in the dose of glibenclamide. A vicious cycle is thus set in 
motion. Thirdly, Huizar et aL (2003) found that diabetic patients treated with sulphonylureas 
did not display the level of ST-segment changes on electrocardiogram that would make them 
candidates for thrombolytic therapy. In essence, SUs can mask the severity of a myocardial 
infarction. If this finding is confirmed by larger studies, then guidelines for the use of 
thrombolytics may need to be reconsidered in this group of patients. Indeed, the warning on 
the Daonil® package insert merely states "increased cardiovascular mortality", without 
further elaboration. 
Other studies reviewing dose-response effects of glibenclamide are presented in the literature 
reVIew. 
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3 Survey of the prescribing of glibenclamide at selected 
provincial institutions in KwaZulu-Natal 
3.1 Introduction 
The majority of South Africans (up to 80%) utilize the health services offered by the province. 
These institutions serve the population of the greater eThekwinilDurban area (approximately 
3 064 624, for 2002, projected from 1996 census, www.durban.gov.za). Hence, the medical 
systems at provincial institutions, with their captive diabetic population, offer a simple and 
effective way to evaluate prescription and usage patterns. These institutions purchase 
medications in bulk packs and prepack these according to the doses prescribed by the 
attending clinicians. For chronic care, patients usually return to the institution on a monthly 
basis for their medication. In the case of glibenclamide (5 mg dose unit) pack sizes of 14,28, 
42, 56, 70, 84 and 112 would correspond to daily doses of 2.5 to 20 mg/day based on a 28-day 
month. 
The objective of this survey was to evaluate the prescribing patterns and the extent of high 
dose (20mg/day) glibenclamide usage in state and provincial institutions. 
3.2 Methods 
Pharmacy managers of the 10 major institutions in the greater eThekwini area were contacted 
telephonically and asked to provide their records of the number of units per pack size of 
glibenclamide prepacked per annum for the years 2000, 2001 and 2002/3. Data (Appendix 1) 
from the individual institutions is anonymised. 
3.3 Results 
This evaluation will only focus on the extent of usage of high dose (20mg/day) glibenclamide 
at the institutions surveyed. Six of the 10 state institutions responded with the requested data. 
Only data for the year 2002/3 was complete and is presented in table 1 and figure 1. Twenty 
five percent of all dose unit packs dispensed, comprised the 20mg dose of glibenclamide. 
Although not presented here, a similar picture was noted for the years 2000 and 2001 from 
those centres that did supply data. 
At Centre A, which supplies chronic diabetic medication to geriatric homes and clinics, the 
usage was 25 %. 
At a major provincial hospital (Centre B), the usage was 44% for 2002 and for the years 2000 
and 2001 the figures were 47% and 46%, respectively. 
In the case of a community clinic (Centre C), the figure was 7% for the year 2002. 
At a provincial hospital (Centre D), the figure was 24% for 2002 and 17% and 8 % for 2000 
and 2001, respectively. 
Centre E, a provincial hospital situated in central eThekwini, the figures are 45% for the year 
June 2002 - June 2003. 
At center F, a provincial hospital also situated in central eThekwini, 7% of all glibenclamide 
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Figure 1: Number of units of various pack sizes of glibenclamide Smg tablets 
prepared as prepacks for out-patient dispensary use at 6 provincial 
health care institutions (A- F) in the greater eThekwini area. One-
month pack sizes of 14 - 112 correspond to dosage regimens of 
2.Smg/day to 20mg/day 
Table 1: Usage of 20mg dose as inferred from number of pre-packed units of 
112 glibenclamide tablets dispensed by provincial institutions in the 
greater eThekwini area in 200213 
Centre Number of20mg/day Total of all packs Percentage 
dose packs prepared prepared in 2002 
in 2002 
A 5694 23116 25 
B 28334 64743 44 
C 3083 44415 7 
D 3594 15230 24 
E 6590 14758 45 
F 2621 38750 7 
Total 49916 201012 25 
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Discussion 
This survey of glibenclamide supply in the public sector in the greater eThekwinilDurban area 
confirms that the drug is used in excess of the maximum recommended dose of 15 mg per 
day. This high dose usage is consistent over the previous 2 years for those centres that were 
able to supply this data. From this survey, it is not possible to determine whether these doses 
are associated with efficacy or safety issues. These prescribing patterns might reflect the 
status of the different dosage requirements in stabilised patients or the trends of titration of 
individual patients to their final dosage. It is particularly disconcerting that the high dosage 
appears to have been used by centres supplying medication to mainly geriatric patients. 
The short term and long term adverse effects of hypo glycaemia and cardiovascular events 
associated with glibenclamide use will be highlighted in this dissertation. Although the cost of 
glibenclamide to the province is low due to the nature of the present tender system of 
purchase, drug wastage is, nevertheless, an important consideration. It can become significant 
if the purchasing system for the province is changed (as has been legislated for the private 
sector) due to legislation advocating a single exit price for medicines from manufacturers. In 
such an event, the province may then be forced to pay higher prices or the same price as the 
private sector for all medications. Drug wastage might be due to use of doses that do not 
provide (additional) clinical benefit, or due to poor compliance as a result of adverse effects. 
This survey however, is not without its limitations e.g., not all the major institutions in the 
greater eThekwini area were surveyed. This is not a serious limitation since the areas serviced 
by the institutions that did provide data, are representative in terms of geography and 
population. A more relevant limitation however, is that it is not known whether the tendency 
towards use of high doses noted in this public sector survey are also applicable in the private 
sector due to the known discrepancy in the nature and quality of care. This extrapolation 
cannot be made and would require a similar survey in the private sector. 
Pack sizes are an indirect measure of dosage and by implication, usage. However, while 
compliance is not measured in this survey and is assumed to be total, this limitation must be 
borne in mind in extrapolations of dose usage. 
Pack size does not always mean one month supply. Patients could be making more than one 
visit per month for various reasons (dose adjustment, loss of medications). 
The number of diabetics served by the institutions surveyed is not known, but a crude 
approximation can be inferred from the number of units of medication packs dispensed. 
Prescribing patterns are best determined by examining individual prescriptions, reviewing 
data from private medical aid societies or health maintenance organizations, and reviewing 
pharmacoeconomic databases. These sources are reluctant to divulge this type of information 
often due to valid patient confidentiality concerns. Where this information is available it 
requires considerable time and effort to extract the data. Therefore, this public sector survey 
uses a simple method to provide macro trends on glibenclamide use and prescribing patterns. 
In spite of these reservations, this survey serves a useful purpose not only as motivation for 
this study, but also to concientise the relevant institutions on high dose glibenclamide use. 
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In conclusion, this survey of glibenclamide usage in the greater eThekwinilDurban area 
confirms that the maximum recommended dose of 15 mg per day is being exceeded in public 
institutions. An evaluation of the dose-exposure response relationship to identify the clinical 
benefit of these higher doses is therefore warranted. 
4 Aims and objectives 
To date, there is no clinical study relating glibenclamide dosage to its blood glucose lowering 
effect in a South African diabetic population. A study on the dose-exposure-response 
relationship of glibenclamide in type 2 diabetic patients might clarify the issue. The aim was 
therefore to investigate the effect of increasing doses of glibenclamide on blood glucose levels 
and blood insulin levels in type 2 diabetic patients, with the view to determining which dosage 
regimen best controlled blood glucose levels. 
This study was therefore designed to: 
• characterise the within-subject blood glucose response and insulin response to 
increasing doses of glibenclamide 
• characterize the pharmacokinetics of glibenclamide in type 2 diabetic patients 
• develop a pharmacokinetic/pharmacodynamic (PKPD) model for the relationship 
between glibenclamide and blood glucose levels 
• examine the relative contribution of pharmacokinetics to the overall variability in 
pharmacodynamic response to glibenclamide 
• establish the dose at which glibenclamide optimally controls blood glucose in type 2 
diabetics 
• make dosage recommendations based on PKPD principles to diabetes caregivers 
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1 Diabetes mellitus 
Diabetes mellitus (DM) is a term describing a metabolic disorder characterized by 
chronic hyperglycaemia with disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, insulin action, or both 
(Beers, 1999). 
DM spans a very broad clinical spectrum ranging from asymptomatic individuals (in 
whom the diagnosis is proven by biochemical investigation) at one extreme, to 
severely symptomatic, ill patients at the other extreme. The single defining feature 
common to this broad clinical spectrum is the diagnostic demonstration of 
hyperglycaemia. Symptoms of marked hyperglycaemia include polyuria, polydipsia, 
and unexplained weight loss. Other symptoms include pruritis, polyphagia, impaired 
vision and susceptibility to infections (Harris and Zimmet, 1992). 
The vast majority of cases ofDM fall into 2 broad categories. 
Type 1 Diabetes Mellitus 
In this category, the cause is an absolute deficiency of insulin secretion which leads 
to a variety of metabolic consequences. The clinical picture is of a severe 
hyperosmolar state due to severe hyperglycaemia, the symptoms of which are 
drastic, insatiable thirst, polyuria and rapid, severe weight loss. Poorly regulated 
lipolysis results in elevated concentrations of ketone bodies which, ifhigh enough in 
the blood, lead to metabolic acidosis which leads to coma and death if left untreated. 
Insulin treatment is essential to sustain life in patients with type 1 diabetes (Harris 
and Zimmet, 1992). 
Type 2 Diabetes Mellitus 
In this more prevalent category, the cause is a combination of resistance to insulin 
action and an inadequate insulin secretory response. In such subjects, 
hyperglycaemia without clinical symptoms may be present for a long period before 
DM is detected. The result is that complications of DM such as retinopathy, 
nephropathy, atherosclerotic coronary disease, stroke or neuropathy may be the first 
clinical indications of the disease (DECODE study, 1999). Despite the presence of 
hyperglycaemia, ketone bodies in the blood and urine are absent and insulin 
treatment is not necessary to sustain life, although insulin may be necessary to 
achieve and maintain glycaemic control. 
There are a few cases of diabetes, about 5%, that are secondary to identifiable 
causes. These include malnutrition-related diabetes, pancreatic disease, endocrine 
disease, gestational diabetes, drug-induced and toxin-mediated and some rare 
conditions. 
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1.1 Clinical characteristics 
The World Health Organisation (WHO) classification of DM provides a framework 
within which to identify and differentiate the various types and stages of DM. 
Various other classifications [National Diabetes Data Group, American Diabetes 
Association Classification (ADA), South African Medical Journal (SAMJ) 
Classification] are based in essence on the WHO classification. Table 2 tabulates 
the various components of the WHO classification ofDM 
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Table 2: WHO aetiological classification of DM (Alberti and Zimmet; 
1998) 
I . Type I diabetes ·(~-cell destruction usually leading to absolute insulin deficiency) 
A. immune-mediated 
B. idiopathic 
ii . Type 2 diabetes· (ranges from predominant insulin resistance with relative insulin deficiency to a predominant 
secretory defect with insulin resistance) 
Ill. Other specific types 
A. Genetic defects of ~-cell function 
I . Chromosome 12, HNF-I a (MODY 3) 4. 
2. Chromosome 7, glucokinase (MODY 2) 5. 
3. Chromosome 20, HNF ± a (MODY I) 








Type A insulin resistance 
Leprechaunism 
Rabson-Mendenhall syndrome 




4. Cystic fibrosis 
Endocrinopathies 
I . Acromegaly 


































G. Uncommon forms of immune-mediated diabetes 
I . Stiff-man syndrome 
2. Anti-insulin receptor antibodies 
3. Others 
H. Other genetic syndromes sometimes associated with diabetes 
I . Down's syndrome 7. 
2. Klinefelter's syndrome 8. 
3. Turner's syndrome 9. 
4. Wolfram's syndrome 10. 
5. Friedreich's ataxia II . 
6. Huntington's chorea 






















*Patients with any form of diabetes may require insulin at some stage of their diseases. Such use 
of insulin does not in itself, classify the patient. 
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Table 3 and 4 outline the differences between type 1 and type 2 diabetes according 
to the SAMJ classification [Society for Endocrinology, Metabolism and Diabetes of 
South Africa (SEMDSA) Guidelines, (2002) and Edwards et aI., (1995)]. 
Table 3: Characteristics of type 1 and type 2 diabetes based on 
SEMDSA Guidelines (SEMDSA, 2002) 
Characteristic Type 1 DM Type2DM 
Onset <40 years >40 years 
BMI Thin Fat 
Insulin Dependent Requiring 
DKA Very prone Less prone 
Symptoms Acute Gradual 
Key: BMI body mass index 
DKA diabetic ketoacidosis 
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Insulin deficiency Severe (C-peptide negative) 
Spontaneous ketosis Yes 
Need insulin to survive Yes 
Insulin insensitivity Mild, variable 
Aetiology 
Genetic susceptibility Moderate 
HLA markers Yes 
Autoimmune features Yes 
Environmental factors ? Viruses 
Clinical features at 
presentation 
Age (not very useful) Most <40 years 
(peak at 13 years) 
Body weight BMI mostly <25; recent loss 
common 
Microvascular complications Rare 
Signs and Symptoms Abrupt onset, 
weight loss, 
ketosis, polydypsia, polyuria, 
fatigue 
Prevalence 10-15 % of all diabetics 





human leucocyte antigen 
body mass index 










Most >40 years 
(peak at 70 years) 
BMI mostly >25 ; recent loss 
sometimes 
Sometimes present 
Polydypsia, polyuria. Weight 
gain, fatigue, blurred vision, 
susceptability to infection, 
impotence in men, pruritis, 
unusual sensations in the 
periphery, polyphagia 
85-90% of all diabetics 
Obesity 
Age >30 
Geographical and ethnic factors 






The revised criteria [American Diabetes Association (ADA) report, 2003] avoids the 
discrepancy between FBG and 2-hour postload glucose (PG) and facilitates and 
encourages the use of a simpler and equally accurate test viz., fasting blood glucose, 
for diagnosing diabetes. The cut off point for the 2-hour PG is justified because it is 
at approximately at this point that the prevalence of microvascular complications 
considered specific for diabetes viz., retinopathy and nephropathy, increases 
dramatically. The relationship between FBG, the 2-hour PG and the development of 
retinopathy was confirmed in the Pima Indians and Egyptians and in the NHANES 
III studies (Harris et aI., 1998). The relationship between macrovascular disease and 
FBG and 2-hour PG has been examined. In the Paris Prospective Study (Balkau et 
aI., 1999), coronary artery disease and all cause mortality were related to these two 
parameters. Therefore, both FBG and 2-hour PG provide important information 
regarding the risk for both microvascular and macrovascular disease. 
Diagnostic Criteria for Diabetes Mellitus 
The ADA Expert Committee (2003) has revised and set the following criteria for the 
diagnosis of diabetes. Diabetes can be diagnosed in three different ways and each 
must be confirmed on a subsequent day by one of the three recommended methods. 
The revised criteria for diagnosis of DM are still based on measures of 
hyperglycaemia. The metabolic defects underlying the hyperglycaemia are referred 
to independently i.e., in the classification of the disease. 
Blood glucose levels are distributed over a continuum but there is an approximate 
threshold separating subjects who are at increased risk for some complications of 
DM from those who are not. Based partly on estimates of the thresholds for 
microvascular disease, the previous WHO criteria defined DM by fasting blood 
glucose (FBG) 7.0 mmollL, 2 hour blood glucose (pG) 11.1 mmollL in the OGTT, 
or both (Alberti and Zimmet; 1998). 
However, almost all subjects with a raised FBG had an elevated 2 hour PG by 
OGTT, but only one-fourth with a raised 2-hour PG by OGTT had a raised FPG. It 
is this discrepancy, and the necessity to devise a simpler diagnostic test (the FBG) 
than the OGTT, that led to the revision of the criteria for the diagnosis of DM 
(Alberti and Zimmet; 1998). 
The revised criteria are for diagnosis and not for treatment or goals of therapy. The 
new diagnostic cut-off point (FPG 6.1 mmollL) is based on the observation that this 
degree of hyperglycaemia reflects a metabolic abnormality that has been shown to 
be associated with serious complications (Alberti and Zimmet; 1998). 
Diabetes mellitus is diagnosed according to various criteria. The revised criteria for 
the diagnosis of type 2 diabetes according to the ADA, SEMDSA, WHO, and SAMJ 
are listed in table 5 below. 
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Table 5: Criteria for diagnosis of diabetes (SEMDSA, 2002; Alberti and 
Zimmet, 1998; DECODE, 1999; ADA, 2004) 
Characteristic SEMDSA WHO ADA SAMJ 
FBG >7 >7 >7.0 >7.8 
2hrpp >11.1 >11.1 > 11.1 ---
RBG >11.1 >11.1 --- >11.1 
IGT --- >7.8-<11.1 * --- ---
IFG --- --- >5.6-<6.9* ---
Key: 
FBO Fasting blood glucose confirmed on the following day 
2hr pp 2 hour postprandial blood glucose 
RBO Random blood glucose 
!FO Impaired fasting glucose 
OOTT Oral glucose tolerance test (75 g glucose) 
lOT Impaired glucose tolerance 
All values in mmo]/L 
*- Value based on OOTT 
The ADA Expert Committee (2003) also recognises an intermediate group of 
subjects whose glucose levels are too high to be considered altogether normal. The 
criteria for defining this group of subjects are as shown in Table 6. 
Table 6: Catergories for defining OM 
Normal Intermediate Provisional diagnosis ofDM 
Fasting <6.1 6.1 <7.0* 7.0 
2-hour post- <7.8 7.8 <11.1 ** 11.1 
load (OGIT) 
Key. 
*IOT Impaired glucose tolerance 
**IFG Impaired fasting glucose 
OOTT Oral glucose tolerance test 
All units in mmo]/L 
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Diagnostic Tests for Type 2 Diabetes 
When symptoms suggest diabetes the diagnosis may be confirmed by the presence 
of glycosuria with or without ketonuria, and a random blood glucose concentration 
greater than 11.1 mmollL. 
It is now recommended that persons over the age of 45 years be tested regularly for 
the presence of DM (Alberti and Zimmet, 1998). In addition, younger adults 
presenting with the following, should also be tested: 
• A weight that is 20% more than ideal body weight 
• High blood pressure 
• Low HDL cholesterol levels (0.91 mmollL) and high triglyceride levels 
(2.82 mmollL) 
• A close relative with diabetes 
• A high-risk ethnic background 
• Delivered a baby weighing over 4.08kg 
• A history of gestational diabetes 
Some experts recommend that any asymptomatic child over age 10 years should be 
tested for type 2 diabetes if they are overweight and have at least two of the above 
mentioned risk factors. Children who have symptoms of diabetes are usually 
diagnosed as type 1. This is of particular concern given the rise in childhood type 2 
diabetes with some centers reporting a misdiagnosis in 25% of cases (Alberti and 
Zimmet, 1998). 
Pathogenesis 
Type 1 DM is an example of T cell-mediated autoimmune disease characterized by 
selective destruction of pancreatic ~-cells . Genetic and environmental factors playa 
role in pathogenesis. 
Type 2 DM is a polygenic disorder with environmental influences playing a major 
role in its onset and progression. It is a disorder with dual defects involving insulin 
resistance and ~-cell dysfunction. The progression of the disease is related to 
deterioration in ~-cell function and increased insulin resistance. 
Genetic factors: The clustering of type 2 DM in families, provides evidence for a 
genetic basis for DM. Studies on identical twins provide further confirmation for 
this theory. Later studies showed that concordant rates of type 2 diabetes in this 
population was as high as 33% (Lebovitz, 1998). Monogenic and polygenic 
disorders result in maturity onset diabetes in the young (MODY) and an altered 
metabolic state (obesity, insulin resistance, and impaired ~-cell secretory function) 
respectively (Lebovitz, 1998). 
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Environmental factors: It has been postulated that polygenic forms of type 2 
diabetes are the consequence of having evolved a "thrifty" genotype that had 
survival benefits in the past but is detrimental in our modem indulgent society. This 
thrifty genotype is a disadvantage and leads to obesity, insulin resistance and type 2 
diabetes (Neel, 1962). 
An alternate view is that individuals with a low birth weight have a higher 
prevalence of obesity, insulin resistance and type 2 diabetes in adult life than those 
who had normal birth weight. This is due to the exposure to the indulgences of 
modem day living in the face of a relatively small pancreatic ~-cell mass (Barker, 
1993). 
Studies have shown that rural (traditional-living) populations are experiencing a 
major increase in the burden of type 2 DM as they move to urban (non-traditional) 
situations, often with a 5- to 10-fold increase in the prevalence of type 2 DM 
(Harris, 1995). 
Biochemical defects: There is agreement that type 2 DM is closely associated with 
two features namely, insulin resistance and insufficient insulin secretion. The former 
suppresses hepatic glucose output and promotes peripheral glucose disposal, while 
the later attempts to overcome the degree of insulin resistance. As long as ~-cell 
function remains adequate to match or overcome insulin resistance in the prediabetic 
state, the chronic hyperglycaemia of type 2 DM does not appear (DeFronzo et aI., 
1992). 
Immunologic factors: These also contribute to the aetiology of DM by auto-
immune damage to the pancreatic ~-cells, acutely as in type 1 diabetes, or slowly 
evolving auto-immune damage, as in latent auto-immune diabetes in an adult 
(LADA). 
Metabolic factors: 
The "glucocentric" theory of metabolic derangement in type 2 DM: The traditional 
thinking in the pathogenesis of type 2 DM centres around impaired ~-cell function 
resulting in impaired secretion of insulin the consequence of which is 
hyperglycaemia. This is a necessary defect in all stages of abnormal glucose 
tolerance. This glucocentric theory forms the basis for pharmacotherapy of type 2 
DM, namely OHA's and insulin (DeFronzo et aI., 1992). 
The "lipocentric" theory for the metabolic derangement of type 2 DM shifts the 
basis for the pathogenesis of type 2 DM to abnormal lipid dynamics. This theory is 
based on evidence that insulin resistance in tissues such as liver and muscle might, 
at least in part, be a consequence of a genetically programmed abnormal 
accumulation of fat in these sites. It is also likely that lipotoxicity plays a role in ~_ 
cell demise in type 2 DM. 
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Prevalence 
The WHO estimates that between 120 and 140 million people suffer from DM 
worldwide and that this number could double by the year 2025. Most of the increase 
will occur in the developing countries and will be due to population aging, 
unhealthy diets, obesity and sedentary lifestyle (Alberti and Zimmet, 1998). 
In the UK, DM affects about 2% of the population, and 7.8% in the USA. Diabetes 
mellitus is approaching epidemic proportions in South Africa, the present estimated 
prevalence being between 4 and 5 % and is expected to increase to 8% by 2010 i.e., 
from 1.6 million to 3.5 million. In South Africa, it is estimated that 5-8% of blacks, 
8-10 % of coloureds, 13-18% South Africans of Indian origin and 3.5-4% of whites 
are diabetic (Naicker, 2002; Trutter, 1998). 
Diabetes is universal with widely varying prevalence rates between and within 
different populations. There is great variation in the frequency of type 2 diabetes in 
different countries, the highest being noted in the Pima Indians of America and the 
South Pacific islands. More than 50% of Pima Indians have type 2 diabetes. The 
Pima Indians once had an agricultural lifestyle, but, due to a rapid development of a 
westernised lifestyle, they are now overweight and inactive and thus prone to 
developing insulin resistance and type 2 diabetes (Unger, 1995). 
The risk of developing type 2 diabetes increases with age, obesity and lack of 
physical activity. Type 2 diabetes is more common in individuals with a family 
history of diabetes and in members of certain racial or ethnic groups (Edwards et al., 
1995). It occurs more frequently in individuals with hypertension or dyslipidaemia 
and women with prior gestational diabetes mellitus (GDM). 
The correlation of risk factors with development of diabetes is never 100%. 
However, the greater the number of risk factors present in an individual, the greater 
the chance of that individual developing or having diabetes (Edwards et al., 1995). 
Pathophysiology 
Impaired ~-cell function is a necessary defect in impaired glucose regulation (IGR). 
However, it manifests itself in a different manner in fasting and glucose-stimulated 
conditions. In the fasting state, the basal insulin secretory rate increases as a 
function of the progressive decline in insulin action. Thus, fasting insulin levels are 
taken as a marker of insulin sensitivity. A specific alteration of acute insulin release 
is an early and progressive defect after a glucose challenge. 
To understand the impact of ~-cell dysfunction in type 2 diabetes on metabolic 
homeostasis, the different phases of insulin secretion need to be considered 
separately. Insulin secretion can be divided into the basal (post absorptive) state and 
the stimulated (postprandial) state. The former plays a major role during the 
interprandial phases and the overnight fast. The latter regulates glucose metabolism 
when carbohydrate is abundant and needs to be disposed of. 
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Basal insulin secretion 
Adequate basal insulin secretion is important in glucose regulation both in the liver 
and the peripheral tissues viz. muscle and adipose tissue. Endogenous glucose 
production (EGP) is modulated and modified by basal insulin levels and is very 
sensitive to minor changes in portal insulin concentration. 
Skeletal muscle is the major peripheral site for glucose disposal while the liver is the 
prime site for gluconeogenesis. In the fasting state, blood glucose concentrations are 
maintained by a delicate balance between glucose production by the liver and 
glucose disposal by peripheral tissue. Glucose disposal is regulated by insulin and 
various non-insulin mechanisms. Hepatic glucose production is regulated by the 
combined effects of insulin and glucagon. 
Glucose stimulates release of insulin. Insulin response to a glucose stimulus is 
biphasic with a rapid early insulin peak followed by a second slow-rising peak. 
Figure 2 describes the biphasic secretion of insulin to a glucose stimulus. The first 
phase peak is due to the release of insulin from the ~-cells while the second phase 
peak represents newly synthesized insulin and is directly related to the level of 
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Biphasic insulin secretion in vivo (Pratley and Weyer, 2001) 
Type 2 DM is characterized by a blunting or loss of the first phase of insulin 
secretion as illustrated in figure 3 below. This phenomenon has also been observed 
in the Pima Indians and is not just a marker of type 2 DM but a pathophysiological 
mechanism (Del Prato et aI., 2002). 
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In type 2 diabetic patients, the combination of insulin resistance and inadequate 
basal insulin secretion to compensate for the defect in insulin action may well 
account for excessive hepatic glucose production. Basal level of insulin is important 
in modulating the intracellular fate of glucose uptake by peripheral tissues and a 
dysfunction in basal insulin secretion may contribute to the release of free fat~y 
acids (FF As) and lactate. The latter is a preferential substrate for gluconeogenesIs 
and the former provides the energy required for driving the gluconeogenesis, the 
result of which is enhanced EGP and fasting hyperglycaemia. Correction of this 
relative hypoinsulinaemia in type 2 diabetics is thus a rational therapeutic approach 
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Loss of first-phase insulin response (Pfeifer et al., 1981) 
In the early stages of type 2 DM, first-phase insulin release in invariably lost despite 
the enhancement of second-phase insulin secretion. The acute elevation of blood 
glucose concentration and the subsequent biphasic insulin release in hyperglycaemic 
clamp studies are associated with progressive suppression of hepatic glucose 
production and an increase in glucose disposal. Abolition of first-phase insulin 
release by somatostatin and insulin replacement is not associated with changes in 
glucose disposal. However, the impact on suppression of hepatic glucose production 
is dramatic with the liver releasing glucose at a greater rate despite the presence of 
hyperglycaemia and hyperinsulinaemia. These results are in agreement with the 
correlation between plasma concentration 30 minutes after an oral glucose load and 
the rate of glucose appearance in patients with IGT. Further, an inverse correlation 
between the rate of appearance of glucose and the insulin/glucagon ratio is found in 
patients with IGT. In the postprandial phase, plasma glucagon levels remain high 
despite normal or increased insulin levels while EGP is not suppressed (Flier et al., 
1979). 
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A significant improvement in postprandial glucose tolerance is apparent with early 
administration of insulin to restore or mimic first-phase insulin release (Bruce et aI., 
1988). This may be interpreted as a sparing effect on ~-cell function due to 
prevention of excessive rise in glucose concentrations. The lower plasma C-peptide 
values in the late phase are associated with lower glucose and insulin 
concentrations. This correlates directly with the 120-minute post-OGTT blood 
glucose and insulin levels. 
Postprandial byperglycaemia 
Prevention of postprandial hyperglycaemia is important as it is implicated in the 
development of macro: and microvascular complications associated with diabetes 
(Baron, 1998). Postprandial hyperglycaemia may be defined as elevated glucose 
concentrations following the ingestion of a meal. It is generated by a combination of 
impaired insulin secretion, unsuppressed hepatic glucose production and reduced 
glucose uptake into the periphery (Cozma et aI., 2002). In nonnal individuals, 
glucose levels rarely rise above 7.8 mmollL during the postprandial period. There is 
a progressive rise in postprandial glucose levels associated with increasing degrees 
of impainnent of glucose tolerance. Individuals with post-challenge glucose levels 
in excess of 11.lmmoVL have diabetes by definition. However, fasting glucose 
levels are often below the current glycaemic threshold of 7.0 mmollL for the 
diagnosis of diabetes. It has thus been concluded that fasting glucose level is not a 
good predictor of postprandial levels as it often underestimates post-challenge 
glucose levels (Baron, 1998). 
The risk of cardiovascular disease is related to the degree of postprandial 
hyperglycaemia rather than fasting blood glucose levels (Hanefield and Temelkova-
Kurktschier, 1997). Postprandial blood glucose, triglycerides and blood pressure are 
risk factors for myocardial infarction, whereas fasting blood glucose is not a risk 
factor. Thus prevention of postprandial hyperglycaemia could be important in the 
prevention of diabetic complications (Baron, 1998). It is also noted that individuals 
with impaired glucose tolerance (IGT) have elevated postprandial glucose levels and 
an increased risk of atherosclerosis (Pan et aI., 1993). 
The National Health and Examination Survey (NHANES) in the USA reported an 
association with post-load hyperglycaemia and increased all-cause and 
cardiovascular mortality (Saydah et aI., 2001). The incidence of retinopathy is 
higher in patients with postprandial glucose levels higher than 11.1 mmoVL (Bando 
et aI., 2001). Macrovascular disease is a major cause of death in type 2 diabetes and 
conventional treatments of diabetes have had minimal effect on diabetes-related 
cardiovascular mortality. 
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A study of patients with gestational diabetes showed that monitoring and targeting 
postprandial hyperglycaemia rather than fasting blood glucose, resulted in greater 
reduction of HbAle, significantly smaller babies and a reduction in the number of 
babies that were large for their gestational age (de Veciana et aI., 1995). A study 
conducted by Edward et al. (2000) showed that adding a second antihyperglycaemic 
agent lowers HbAle and glucose levels. However, when insulin lispro was used to 
focus on postprandial blood glucose, there was a greater impact on overall metabolic 
control. Insulin lispro and acarbose prevented postprandial blood glucose excursions 
in obese type 2 patients. Regulation of postprandial hyperglycaemia by agents such 
as acarbose has been shown to decrease Apo B and triglyceride levels. This may 
have a favourable effect on atherosclerosis and coronary artery disease (Reaven et 
aI., 1990). 
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1.2 Insulin Resistance (IR) 
A constellation of insulin resistance, reactive hyperinsulinaemia, increased 
triglycerides, decreased high- density lipoprotein cholesterol and hypertension was 
designated as 'syndrome X' by Reaven (1988). The close association of type 2 
diabetes and cardiovascular disease led to the hypothesis that the two arise from a 
common antecedent. This concept is termed the Metabolic Syndrome (Wilson et aI., 
1999). Table 7 lists the criteria for characterization/classification of metabolic 
syndrome. 
Table 7: Criteria for characterization/classification of the Metabolic 
Syndrome*(Ford et aI., 2002) 
Parameter Value 
Waist circumference >102 cm in men 
>88 cm in women 
Hypertriglyceridaemia 1.69 mmoVL 
Low HDL cholesterol < 1.04 mmollL in men 
< 1.29 mmoVL in women 
Blood pressure 130/85 mmHg 
Fasting blood glucose (FBG) > 6.1 mmoVL 
*The prescence of three or more of the above criteria are a pre-requisite for the classification of 
metabolic syndrome 
Type 2 DM represents an extreme of insulin resistance. Insulin resistance (IR) is the 
body's inability to correctly utilize its normal (endogenous) insulin supply, even 
though that insulin is present in sufficient amount. As a result of IR the pancreas 
produces more insulin than is required (hyperinsulinaemia). 
Insulin resistance reflects defective insulin action in skeletal muscle and the liver. 
The major causes of skeletal muscle insulin resistance in the prediabetic state may 
be grouped into genetic, obesity and physical inactivity. At present there is no clear 
understanding of the factors that define the genetic basis of insulin resistance. 
There is a close relationship between obesity and insulin resistance. While being 
overweight does not cause IR, losing weight reduces IR. Diabetics are obese and the 
risk of developing diabetes increases progressively in both men and women with the 
degree of obesity. This is due to increasing IR and decreasing insulin sensitivity (IS) 
as body mass increases. A diet high in fat, a sedentary lifestyle and a genetic 
predisposition all contribute to obesity. Central or truncal obesity, more typical of 
men, but often seen in female type 2 daibetics, offers the greatest risk for the 
development of diabetes. This distribution of fat is due to the deposition of adipose 
tissue both subcutaneously and intra-abdominally. 
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This visceral fat is metabolically active and releases non-esterified fatty acids 
(NEF As) that cause insulin resistance among other effects, thus contributing to the 
hyperinsulinaemia and reduced IS that is Syndrome X. The worldwide epidemic of 
type 2 DM is fuelled by a parallel epidemic of obesity and reduced physical activity, 
clearly pointing to the prevention of obesity as the most direct route to the 
prevention of the metabolic syndrome and its sequelae (Reaven, 1988). 
Insulin resistance and diabetes increase the atherosclerotic process. There is 
mounting evidence that insulin-resistant subjects have a defect in insulin-mediated 
nitric oxide production which parallels their defect in glucose transport (Radikova, 
2003). 
Measures of insulin resistance and acute insulin response 
Type 2 DM represents an extreme of insulin resistance. Insulin resistance is a 
condition in which the response to the hormone insulin, is muted and the body must 
produce excess insulin to maintain normal blood glucose concentrations. This 
condition is also called low insulin sensitivity. 
Insulin sensitivity is measured by the hyperinsulinaemic euglycaemic clamp 
technique, which is the gold standard, homeostatic model assessment (HOMA) and 
more recently, Quantitative Insulin Sensitivity Check Index (QUICK!). These 
measures have proven to be suitable surrogates for more complex gold standard 
technique. HOMA (Mathews et aI., 1985) and QUICKI (Katz et aI., 2000) utilise 
fasting blood glucose and fasting insulin levels in determining insulin sensitivity. 
Katz et ai. (2000) concluded that fasting glucose and insulin levels contain sufficient 
information to accurately assess insulin sensitivity in vivo over a wide range in a 
diverse popUlation. They observed that QUICKI is a novel, simple, accurate, and 
reproducible method for determining insulin sensitivity in humans. 
The formula for HOMA is: 
Equation 1: RHOMA= Fasting Glucose*Fasting Insulin 122.5 
The formula for QUICKI is, 
Equation 2: QUICKI is: 1/[log fasting insulin + log fasting glucose] 
When glucose is measured in mmollL, the factor 22.5 is used and when glucose is 
measured in mg/dl, the factor is 405. HOMA is an index of insulin resistance 
(RHoMA) which is the inverse of the corresponding index of sensitivity (SHOMA) i.e., 
(RHoMA=lI SHOMA). HOMA and QUICKI are related by the following equation: 
Equation 3: QUICKl= l /[log(HOMA) + log(22.5)] 
Indices of insulin sensitivity/resistance derived from fasting glucose and insulin 
concentrations reflect hepatic insulin sensitivity and basal hepatic glucose 
production. Lichnovska et ai. (2002) report a mean HOMA normal value ± SD of 
1.57 ± 0.87 and a mean QUICKI of 0.366 ± 0.029 in healthy subjects of both 
genders. 
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Numerous authors have shown good correlations between ROMA and clamp-
derived insulin sensitivity (Radziuk:, 2000). The basal hyperglycaemia of diabetes 
may be considered as a compensatory response (with a major role in maintaining 
sufficient insulin secretion from a reduced p-cell capacity) to control hepatic glucose 
efflux. It has also been stated that hyperglycaemia and hyperinsulinaemia are 
necessary in the insulin resistance state, to maintain near normal peripheral glucose 
uptake when metabolic glucose clearance at a specific insulin concentration is 
decreased, as a result of insulin resistance. 
In view of the direct relationship between basal hepatic glucose production and 
fasting blood glucose concentration, adequate overnight insulin secretion is needed 
to ensure euglycaemia in the post absorptive phase. In type 2 diabetic patients, the 
combination of insulin resistance and inadequate basal insulin secretion to 
compensate for the defect in insulin action may account for the excessive 
endogenous glucose production. It has been hypothesized that dysfunction in basal 
insulin secretion may contribute to an increase in free fatty acids (FF A) and lactate. 
Lactate is a preferential substrate for gluconeogenisis and FF As provide the energy 
required for driving this gluconeogenesis, the final result is enhanced endogenous 
glucose production and fasting hyperglycaemia (Avogaro et ai., 1998). Therefore 
correction of absolute or relative hypoinsulinaemia in type 2 DM is a rational 
therapeutic approach. 
Development of diabetes occurs more frequently in individuals with low 
insulinogenic values (Del Prato et ai., 2002). Impaired beta-cell function is a 
necessary defect in all conditions of impaired glucose regulation. In the fasting state, 
the basal insulin secretory rate increases as a function of the progressive decline in 
insulin action - therefore fasting blood insulin concentration is often used as a 
marker for insulin sensitivity. After a glucose challenge, the change in acute insulin 
release (AIR) is an early and progressive defect. While this may be an intrinsic 
defect its continuous decline is affected by glucose toxicity (Leahy et al., 1992) and 
lipotoxicity (Del Prato et ai., 2002). 
Del Prato et al. (1990) studied type 2 DM patients with secondary failure to ORAs 
before and after adding a preprandial subcutaneouos injection of long acting insulin 
while maintaining preprandial administration of a Su. There was improvement in 
the post-absorptive concentration of blood insulin associated with a reduction of 
basal hepatic glucose production, fasting blood glucose and FF As, in keeping with 
the hypothesis proposed above. The improvement of basal insulin levels, was 
associated with a positive influence on daily blood glucose profile, as indicated by 
decrease in fasting blood glucose and a reduction in 24 hour glucose levels. 
In summary, a high fasting insulin concentration is a surrogate marker for insulin 
resistance. An incremental 30 min insulin concentration is an indicator of early 
phase insulin response. The insulinogenic index (In which is a measure of the ratio 
of the increment of insulin to that of blood glucose 30 min after glucose load, 
provides a parameter of insulin response and a parameter of insulin release (Del 
Prato et al., 2002). 
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Insulin secretion and sensItlvity are highly interdependent phenomena. Any 
decrease in insulin sensitivity is immediately translated into minute increases in 
blood glucose concentration that will in turn produce a compensatory stimulus for 
insulin secretion. This prevents greater hyperglycaemia. When the ~-cell is unable 
to compensate for the prevalent insulin resistant state by further augmenting insulin 
secretion, hyperglycaemia continues to increase, producing impaired fasting glucose 
or diabetes. Therefore assessment of insulin secretion and sensitivity has clinical 
relevance. Equation 4 shows the insulinogenic index (Del Prato et aI., 2002) is 
calculated as the ratio of the increment of insulin to that of blood glucose 30 min 
after glucose load and provides a parameter of insulin response as represented 
below. 
Equation 4: 
II = Insulin(time = 30 min) - Insulin(time = 0) 
Glu cos e(time = 30) - Glu cos e(time = 0) 
Low values of insulinogenic index occur more frequently in diabetic individuals 
than in normal insulin responders. In the study by Jensen et aI. (2002) diabetic 
subjects and patients with impaired glucose tolerance had insulinogeic values of 
36% and 64% that of normal subjects, respectively. Suzuki et aI. (2003) in their 
study reported an insulinogenic index of approximately 64 for insulin measured in 
pmol (9.22 when insulin is measured in IlU/mL) and 34 for insulin measured in 
pmol (4.9 when insulin measured in IlU/mL) for subjects with normal glucose 
tolerance (NGT) and impaired glucose tolerance (IGT) respectively. 
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1.3 Complications 
While the chronic complications of DM are probably the single greatest cause of 
anxiety for most diabetic patients, it must be noted that over 40% of type 1 diabetics 
survive for over 40 years, half of them without developing significant complications 
(DCCT, 1993). Furthermore, with continuing advances in diabetic care as seen by 
the decreasing incidence of nephropathy, the damage due to diabetic complications 
is likely to decrease even further. 
Chronic diabetic complications can be classified as: 
Microvascular (small vessel/microangiopathic) disease 
The Diabetes Control and Complications Trial (DCCT, 1993) linked the severity of 
microvascular complications with the degree and duration of hyperglycaemia in 
type 1 DM while the United Kingdom Prospective Diabetes Study (UKPDS) 
produced analogous evidence in type 2 DM (UKPDS 33, 1998). 
Basement membrane thickening and abnormal leakiness in the microcirculation are 
common features and are essential components of retinopathy and nephropathy, and 
to a lesser extent in neuropathy. The lesions are identical in both type 1 and type 2 
diabetics, suggesting that hyperglycaemia or some other metabolic disturbance is 
responsible. These changes are very often found at diagnosis in type 2 diabetes, 
reflecting the long, unsuspected presence of the disease. 
Microangiopathy involving the capillaries and pre-capillary arterioles may occur in 
any tissue, but occurs especially in the kidneys, eyes and peripheral nerve endings in 
type 2 diabetic patients. This association of hyperglycaemia with microvascular 
complications has been recognized implicitly in type 2 diabetes. 
• Retinopathy 
Diabetic retinopathy is the commonest cause of blindness, but is easily detected and 
now often treatable. Background changes affect almost all cases after 20 years of 
diabetes~. Maculopathy is a common cause of blindness in type 1 DM and may be 
invisible on fundoscopy. Laser photocoagulation prevents blindness in 50% of cases 
with new vessel disease while vitreo-retinal surgery restores vision in 50% of cases 
with advanced eye disease (DCCT, 1993). 
The prevalence of non-proliferative diabetic retinopathy rises from 5% among 
patients with duration of diabetes of less than 5 years to 30%, 45%, and 62% among 
those with duration of 5-9 years, 10-14 years and 15years, respectively (Lebovitz 
for the Framingham Eye Study, 1980). Klein et ai. (1984) showed that the risk of 
retinopathy is lower in type 2 than in type 1 DM and that the level of 
hyperglycaemia at baseline examination has a significant impact on the 
development of retinal changes. In patients with initial early retinopathy, the 
average risk of progression was reduced by 50% in patients who received intensive 
therapy (DCCT, 1993). 
Proliferative retinopathy is uncommon in type 2 diabetes, the cumulative incidence 
being less than 4% (Klein et aI., 1984). 
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• Diabetic nephropathy 
Hyperglycaemia is necessary for the development of diabetic renal damage, as again 
shown by both the DCCT and UKPDS. Diabetic nephropathy affects mainly the 
glomerulus, but tubular lesions may occur and is the commonest cause of premature 
death in type 1 DM. In the UK alone, it accounts for 25% of patients with end-stage 
renal failure (DCCT, 1993; UKPDS 33, 1998; UKPDS 35, 2000). 
Nephropathy is rarer in type 2 DM. Hypertension is an important association with 
nephropathy which, if not treated, accelerates the decline in the rate of glomerular 
filtration (GFR). The main significance of micro albuminuria is the increased risk of 
developing overt proteinuria which is associated with a high mortality by way of 
renal failure (66% of proteinuric patients). Type 2 diabetic patients frequently have 
proteinuria at diagnosis which tends to be persistent with increasing age, yet the risk 
of progressing to renal failure is less than in patients with type 1 diabetes (Caterson 
et aI., 1997). 
Control of hypertension, cessation of smoking and improving glycaemic control 
significantly slow the deterioration in renal function. Hypoglycaemia is a common 
problem in patients with with compromised renal function. Insulin and 
sulphonylureas, that are excreted partly through the kidneys, may accumulate thus 
prolonging their duration of action. Insulin is preferred when creatinine levels rise. 
Metformin should not be given because of the very high risk of lactic acidosis. 
• Diabetic neuropathy 
Diabetic neuropathy involves the somato-sensory system, causing variable sensory 
and motor deficits. The autonomic outflow to various organs is also affected by 
diabetes. Epidemiological studies have associated severe nerve damage with poor 
diabetic control while tightening glycaemic control has produced short-term 
neurophysiological and clinical benefits (Harris and Zimmet, 1992). 
Hyperglycaemia could damage nerves through glycation of proteins and/or 
overactivity of the polyol pathway. Vascular damage through diffuse occlusion of 
capillaries supplying the nerves occurs and may occlude larger vessels causing 
localised infarction and demyelination. 
Macrovascular (Iarge-vessellmacroangiopalhic) disease 
The association between macrovascular disease and either the duration of diabetes 
or the level of glycaemia is weak. Factors such as insulin resistance, 
hyperinsulinaemia or the metabolic syndrome may be more important in the 
development of macrovascular disease. UKPDS 35 (2000) showed that at near 
normal levels of glycosylated haemoglobin (HbAle) the risk of myocardial 
infarction was 2-3 times the risk for a microvascular endpoint. The Kumomoto 
study (1995) showed a definite decrease in macrovascular disease with strict 
glycaemic control. This outcome is due to control of not only FBG, but also 
postprandial blood glucose levels. The atherosclerosis of diabetes is distinguished 
from that affecting non-diabetic people by its rapid and extensive development. 
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Atherosclerosis is very common in both types of diabetes and is a major cause of 
death in type 2 DM. Hyperglycaemia amplifies those predisposing factors which 
operate in the non-diabetic subject viz., 
• Hypertension is two to three times commoner in diabetics than in the general 
population and affects up to one third of diabetic patients. The association 
may be partly explained by sodium retention, altered vascular reactivity and 
insulin resistance (Caters on et aI., 1997). 
• Hyperlipidaemia is common, with an atherogenic pattern of increased VLDL 
and LDL-cholesterol and reduced HDL cholesterol, which is more 
pronounced in type 2 DM. Triglycerides are also increased in untreated 
diabetes (Lebovitz, 1998). 
• Smoking is another predisposing factor and the 10-year mortality in diabetic 
smokers is twice as high as in non-diabetic smokers and most premature 
deaths are from macro vascular deaths (Lebovitz, 1998). 
• The atheroma in diabetic patients is more extensive and multi focal and tends 
to involve the more distal arteries (Lebovitz, 1998). 
• Coronary heart disease 
Cardiovascular disease is the commonest cause of death in type 2 diabetes (Reaven, 
1988; UKPDS 35, 2000). Diabetic women are notably affected since they lose the 
protection from cardiovascular disease enjoyed by non-diabetic women and have a 
relatively greater risk of developing atherosclerosis than diabetic men. IGT lends 
itself to an increased frequency of cardiovascular disease (Taskinen, 1995). 
• Stroke and Peripheral vascular disease 
The prevalence of stroke and peripheral vascular disease is similar to that of cardiac 
macrovascular complications in diabetic patients, and their clinical presentation is 
no different from that of the non-diabetic population (Reaven, 1988; DIGAMI 
study, 1995). 
Management involves the treatment of risk factors. Active treatment of hypertension 
with drugs that do not worsen blood glucose or lipid levels, optimizing glycaemic 
control and treatment of hyperlipidaemia reduce the cardiovascular complications. 
Life-style modification, dietary control, reducing obesity and cessation of smoking 
are crucial in the management. 
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Other Complications 
• The Diabetic Foot 
Foot problems are one of the commonest causes of hospital admissions for diabetic 
patients and are usually the result of neuropathic and vascular changes that 
complicate DM. Proliferative retinopathy and neuropathy causing foot ulceration 
frequently co-exist (Edwards et aI., 1995). 
Diabetic Metabolic Emergencies 
Coma in diabetic patients is a medical emergency and is commonly due to the 
metabolic complications of the disease and/or its treatment, as well as other factors . 
• Diabetic ketoacidosis (DKA) 
DKA is uncontrolled diabetes with hyperglycaemia and metabolic acidosis due to 
high circulating ketone-body levels. DKA is a life-threatening condition that occurs 
secondary to insulin deficiency reSUlting in unrestrained lipolysis. It develops 
mostly in type 1 diabetic patients but can occur in type 2 diabetic patients due to a 
precipitating factor eg., infection or myocardial infarction (Edwards et aI., 1995). 
Treatment of DKA consists of insulin therapy, rehydration and correction of the 
metabolic acidosis and electrolyte imbalance as well as treatment of the 
precipitating cause (Edwards et aI., 1995). 
• Hyperosmolar non-ketotic coma (HONK) 
Patients with type 2 diabetes mellitus have partial insulin deficiency. The 
anticatabolic effect of insulin may be relatively well preserved whilst its anabolic 
effect is impaired. In this setting lipolysis is not markedly accelerated and ketone 
body concentrations remain relatively normal despite severe hyperglycaemia. 
Insulin therapy and fluid replacement form the basis for management of 
hyperosmolar non-ketotic coma (Edwards et aI., 1995). 
• Hypoglycaemia 
Hypoglycaemia is defined as an arterial blood glucose level less than 2.2 mmollL 
but in practice the diagnosis is made on the basis of venous blood glucose levels in 
association with symptoms of hypo glycaemia. 
Factors predisposing to hypoglycaemia are high insulin levels, deficiency of 
counter-regulatory hormones, hypothyroidism, liver damage, intense exercise, and 
prolonged starvation. Drugs and toxins which may cause hypo glycaemia include 
ethanol, pentamidine and salicylate overdosage especially in children. 
The management of hypo glycaemia involves an oral glucose load followed by a low 
glycaemic index (GJ) snack for mild episodes and intramuscular glucagon or 
intravenous dextrose for severe episodes (SEMDSA, 2002). 
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2 Pharmacology of agents used for the management of 
Diabetes Mellitus 
The pharmacological management of diabetes has undergone unprecedented 
expansion. The increasing number of anti-diabetic agents will ensure that a larger 
number of patients achieve glycaemic control, but the adverse effects, cost of 
therapy, ease of administration and urgency for blood glucose normalization will 
govern their use (Chehade and Mooradian, 2000). 
Table 8 provides a list of pharmacological agents for the management of type 2 
diabetes mellitus. 
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Table 8: Pharmacological agents used in the management of patients 








































Neutral protamine lispro (NPL) insulin 
Insulin aspart (Novorapid) 
Insulin glargine (Lantus) 
Amylin agonists 
Pramlintide 
Glucagon-like peptide I (7-36)-amide 
Glucagon antagonists (in early development phase) 
54 
Mechanism of Action of the Different Therapeutic Agents 
Table 9 provides the general mechanisms of action of various anti-diabetic agents 
(Chehade and Mooradian, 2000). 
Table 9: Mechanism of Action of the Different Therapeutic Agents 
Mechanism Drug groups 
Prolongation of glucose absorption a-Glucosidase inhibitors, glucagon-like peptide-I, 
amylin analogues 
Reduction of hepatic glucose output and Biguanides 
enhancement of insulin effect 
Enhancement of insulin sensitivity Thiazolidinediones 
Stimulation of insulin release Sulphonyureas, meglitinide analogues 
Insulin replacement Insulin formulations and analogues 
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2.1 Insulin and Insulin Analogues 
Several studies have shown that insulin therapy improves peripheral insulin 
sensitivity and decreases endogenous glucose production in subjects with type 1 as 
well as type 2 diabetes (Yki-Jarvinen and Koivisto, 1984; Lager et aI., 1983). Even 
short-term intensive insulin therapy for 2-3 weeks using large amounts of insulin 
per day to attain normoglycaemia, ameliorates both peripheral insulin resistance as 
well as endogenous glucose production quite substantially (Scarlet et aI., 1982; 
Garvey et aI., 1985). Interestingly, these beneficial effects were maintained after 
withdrawal of insulin therapy for at least 2 weeks (Andrews et aI., 1984). 
Furthermore, the study by Garvey et aI., (1985) suggests that second-phase insulin 
secretion is enhanced approximately 6-fold after restoration ofnormoglycemia using 
continuous subcutaneous insulin infusion, while first-phase insulin secretion was not 
significantly affected. These results indicate that short-term restoration of 
normoglycemia is able to reduce the detrimental effects of glucose toxicity on both 
peripheral glucose disposal and hepatic glucose production, as well as insulin-
secretory capacity. 
The Veterans Affairs Cooperative Study on Glycaemic Control and Complications 
in type 2 diabetes (VACSDM) showed that intense stepped insulin therapy is 
effective in maintaining near normal glycaemic control for greater than 2 years in 
type 2 diabetic patients whose glycaemia could not be controlled with oral 
hypoglycaemic agents (Abraira et aI., 1995). 
The Kumamoto Trial showed that intensive insulin therapy not only improved 
glycaemic control but also prevented the onset and progression of microvascular 
complications (Okhubo et aI., 1995). 
The UKPDS provided additional support for intensive therapy by demonstrating that 
macrovascular as well as microvascular complications could be minimized by such 
therapy (UKPDS 33, 1998). The findings of the UKPDS 33 (1998), regarding 
intensive therapy are: 
• Diet therapy alone inadequate in two thirds of patients 
• Pharmacologic therapy plus nutrition/exercise is necessary 
• No threshold for HbAle reduction in reducing complications 
• Insulin does not increase macro vascular disease 
The DCCT (1993) demonstrated that the use of a wide range of insulin preparations 
can be used for intensive insulin therapy. A summary of the findings of this study 
are presented below: 
• Insulin therapy which resulted in 62% reduction in retinopathy, 56% 
less progression of kidney disease and 60% less progression of 
neuropathy. 
• The need for tight glycaemic control was emphasised. 
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Insulin Preparations 
Table 10 below lists some of the commonly used insulin preparations and their 
pharmacokinetic profiles. 
Table 10: 










The various available insulin preparations (Adapted from 
FDA,2002) 
Examples Onset of Action Peak of Action Duration of Action 
Humalog® (lispro) 
15 minutes 30-90 minutes 3-5 hours 
(Eli Lilly) 
NovoRapid® 


















Humalog Mix® 25 
(Eli Lilly) The onset, peak, and duration of action of these mixtures would reflect 









none 24 hours 
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An insulin regimen must be tailored to the individual needs of the patient. 
Hypoglycaemia remains the most common adverse effect of insulin therapy and is 
due mainly to erratic meal timing, excessive insulin dosage or unplanned exercise 
(Buse, 1999). 
The currently available insulin preparations fail to reproduce insulin patterns that 
closely mimic physiological responses. 
Regular insulin is not fast - or short-acting enough, and the need for it to be injected 
30 or 60 minutes before a meal impacts on a patients lifestyle. 
Insulin lispro was developed to overcome some of the limitations of regular insulin. 
It acts within 10 to 20 minutes, peaks around 1 to 2 hours, and is cleared from the 
system within 4 to 5 hours. It has been shown to improve postprandial 
hyperglycaemia and to reduce hypoglycaemic episodes (Garg et al., 1996). The 
overall glycaemic control, as measured by HbAle levels, was not different when 
patients were taking lispro insulin as compared with regular insulin (Melki et aI., 
1998). 
Studies have shown that insulin aspart, another rapid acting insulin analogue, shows 
favourable effects on postprandial hyperglycaemia with the added advantage that 
the insulin can be administered at the beginning of the meal. This advantage, 
however, is offset by the 10-20% variability of action of insulin aspart (Home et al., 
1998). 
Insulin glargine, when injected once a day, demonstrates a constant 'peakless profile 
over a 24-hour time period (Linkeschowa, 1999). 
58 
2.2 Oral hypoglycaemic drugs 
2.2.1 Drugs that delay glucose absorption 
a-Glucosidase inhibitors 
Clinical effects 
This class of drugs primarily targets postprandial hyperglycaemia. It reversibly 
inhibits the brush border glucosidases and results in a redistribution of carbohydrate 
absorption from the upper portion of the gut to the extended surface area covering 
the whole length of the small intestine (Balfour and Mcavish, 1993). 
Clinical studies have shown a decrease of HbAlc of 0.5 to 1.0%, a decrease of 
fasting blood glucose of 10 to 20% and a decrease in postprandial glucose of 30 to 
50% (Holman et al. , 1999). 
Addition of acarbose to type 2 diabetic subjects pretreated with insulin, metformin, 
or sulphonylureas causes a reduction of HbA1c levels between 0.5 and 0.8%. This 
beneficial effect seems to last for at least 3 years as has been recently shown by 
UKPDS (UKPDS 33, 1998). During the last 3 years of this long-term trial, 379 
patients were additionally treated with acarbose in a placebo-controlled design. This 
resulted in a mean reduction of the HbAl c by 0.5% in the group of patients who still 
took acarbose after 3 years. This significant effect was sustained over the 3 year 
period. 
Adverse effects 
Acarbose is well tolerated at low doses (25mg), but at higher doses, symptoms of 
carbohydrate malabsorption and gastrointestinal discomfort are common (Chiasson 
et al., 1994). 
Major adverse effects associated with acarbose therapy are mainly gastrointestinal 
including flatulence and abdominal discomfort resulting from malabsorption with 
consequent increased fermentation of carbohydrates. Depending on the acarbose 
dosage used (300-900 mg/day), the frequency of gastrointestinal effects was as high 
as 56- 76% (placebo, 32- 37%) in early studies. When the new recommendations for 
the use of of a-glucosidase inhibitors were introduced viz., low starting dose of 50 
mg/day, slow increase of dosage over weeks to a maximum dose 100 mg three times 
daily, the incidence of gastrointestinal adverse effects were reported to be as low as 
7.5%. Furthermore, it has been shown that the incidence of gastrointestinal side 
effects decreased with long-term treatment (Chiasson et aI., 1994). 
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Metformin, the most commonly used biguanide, reduces hepatic gluconeogenesis, 
thereby reducing basal hepatic glucose output while enhancing glucose uptake by 
the peripheral tissue, mainly skeletal muscle. The precise cellular mechanism of 
action of metformin is still not entirely understood. While several cellular 
mechanisms have been described, no single unifying site of action has been 
identified. Nevertheless, it is generally undisputed that metformin has no effect on 
the pancreatic ~-cell or on stimulating insulin secretion. Mild increases in glucose-
stimulated insulin secretion after metformin treatment are thought to be the result of 
reduced glucose toxicity on the ~-cell secondary to improved glycaemic control 
(Katzung and Karam, 1998). 
Metformin has several potential advantages including a favourable effect on plasma 
lipid profile. There is a decrease in very low density lipoprotein (VLDL) and low 
density lipoprotein (LDL) cholesterol levels (Bailey, 1993). A slight increase in the 
high density lipoprotein (HDL) cholesterol level has been observed. Metformin is 
often associated with loss of body weight (UKPDS 34, 1998). 
UKPDS 34 (1998), showed that metformin is particularly effective in overweight 
type 2 diabetic subjects. In essentially all clinical studies, the improvement of 
hyperglycemia with metformin occurred in the presence of unaltered or reduced 
blood insulin concentrations indicating the potential of metformin as an insulin-
sensitizing or insulin-mimetic drug. 
Studies have consistently shown that metformin lowered fasting blood glucose 
levels by about 3.3 to 3.9 mmollL and HbAl e by about 1.5 to 2 percent (DeFronzo 
and Goodman, 1995) 
Metformin in combination 
Metformin is also used in combination with other antihyperglycemic agents. 
Because of metformin's unique mechanisms of action, a synergistic effect on 
glycaemic control has been observed in combination with sulphonylureas (Marena 
et aI., 1994), thioglitazones and insulin where a dose-sparing effect was consistently 
demonstrated (Schneider et aI., 1999). Interestingly, in patients in whom 
sulphonylurea therapy has failed to achieve satisfactory glycaemic control, the 
combination of bedtime NPH insulin with metformin was found to be most 
advantageous when compared with other regimens viz., insulin alone, sulphonylurea 
alone or a combination of insulin and sulphonylurea. A decrease in HbAle was 
achieved without significant weight gain in patients on a combination of metformin 
and insulin (Yki-Jarvinen et aI., 1999). 
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Adverse effects 
Mild gastrointestinal disturbances are the most common side effects. Lactic 
acidosis, although rare, is the most serious side effect of metformin treatment 
(Katzung., 1998). Selby et ai. (1999) showed that in 9,875 patients, only one case of 
probable lactic acidosis was observed in 20 treatment months. The incidence of 
lactic acidosis with metformin is 10 to 20 times lower than with phenformin. This is 
explained by the necessity to hydroxylate phenformin before renal excretion, a step 
that is genetically defective in 10% of Caucasians (Oates et aI., 1983). In contrast, 
metformin is excreted unmetabolized. In addition, metformin neither increases 
peripheral lactate production nor decreases lactate oxidation, making lactate 
accumulation unlikely (Selby et aI., 1999). 
Contraindications 
The contraindications of biguanides, as reviewed by Matthaei et aI. (2000) are: 
renal disease, hepatic disease, cardiac or respiratory insufficiency, severe infection, 




Examples of the above class of agents include the following: troglitazone 
(withdrawn), pioglitazone and rosiglitazone. 
Clinical effects 
These agents increase insulin sensitivity at skeletal muscles and adipose tissue. 
Their effects are believed to be mediated through selective activation of peroxisome 
proliferator activated receptor y (PPAR-y) [Saltiel and Olefsky, 1996]. 
TZD's alone 
The use of TZDs as monotherapy has been associated with a decrease of HbAle by 
0.5 to 0.8% and when combined with insulin therapy, the drop in HbAle ranges from 
0.7 to 1.4%. Between 20 to 50% of patients may not respond to this class of drugs 
especially patients with low insulin levels. However, type 2 diabetic patients who 
are obese and hyperinsulinaemic respond well to TZD therapy (Saltiel and Olefsky, 
1996). 
TZD in combination 
While thiazolidinedione monotherapy is less effective compared with 
sulphonylureas or metformin, combinations with other forms of pharmacological 
treatment appear to be more promising. 
The addition of various doses of troglitazone (200 - 600 mg) to the sulphonylurea 
compound Glynase® (glibenclamide) in patients with secondary sulphonylurea 
failure has been shown to reduce fasting blood glucose by 4.38 mmollL and HbAle 
by 2.65% (absolute numbers). This additive effect with sulphonylureas was also 
reported for pioglitazone (Schneider et aI., 1999). 
Reports showing a marked reduction in exogenous insulin requirements in insulin-
treated obese patients are in keeping with the concept that thiazolidinediones 
enhance insulin action. Troglitazone reduced HbA1c by 1.3% below placebo, while 
insulin dosage was reduced by 30% (Schwartz et aI., 1998). Similarly, addition of 
pioglitazone in insulin-pretreated patients with type 2 diabetes resulted in an 
improvement of glycaemic control compared to patients treated with insulin only 
(Rubin et aI., 1999). 
The combination of thiazolidinediones with metformin also showed significant 
additive effects (Fonseca et aI., 1999). One study suggested that troglitazone 
improved peripheral insulin sensitivity while metformin preferentially acted on the 
liver in an insulin-mimetic or insulin-sensitizing way (Inzucchi et aI., 1998). 
However, this study unexpectedly demonstrated that metformin had no effect on 
glucose production when added to troglitazone therapy. 
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Adverse effects 
Adverse effects of both rosiglitazone and pioglitazone are oedema and fluid 
retention (Beebe and Patel, 1999) 
The most commonly reported side effect with rosiglitazone is upper respiratory tract 
infection. Pioglitazone has been associated with significant, as yet unexplained, 
elevations of creatine kinase (Matthaei et aI., 2000). 
Although early studies showed that troglitazone was generally well tolerated, 
reversible increases in liver enzymes more than 3 times the upper limit of normal 
occurred in 1.9% of troglitazone-treated patients compared to 0.6% of placebo-
treated patients. At this point the treatment of 20 patients were discontinued 
because of liver function abnormalities (Watkins and Whitcomb, 1998). However, 
prescription on a larger scale has led to 43 known cases of severe liver damage 
associated with troglitazone resulting in 28 deaths (FDA, 1997). It is unclear the 
extent to which the liver damage in those patients resulted from the drug per se i.e., 
whether the hepatotoxicity was substance specific (PP AR-y-mediated) or 
idiosyncratic. Recently, cases of hepatocellular injuries were reported in patients 
taking rosiglitazone (Freid et aI., 2000). However, the causal relationship is open to 
question. In large cohorts, transaminases were not found to be significantly higher 
with rosiglitazone compared with placebo (Salzman and Patel, 1999). On the basis 
of the available data, there is currently no evidence of hepatotoxicity with 
pioglitazone. 
The use of a combination of thiazolidinedione and sulphonylurea is associated with 
an increase in body weight to as much as 5.9 kg after 12 months use (Inzucchi et 
al., 1998). 
The potential disadvantage of TZDs is the increased incidence of liver injury 
(Imura, 1998). Clinical trials suggest that rosiglitazone and pioglitazone may 
produce less hepatotoxicity than troglitazone, but liver function testing is still 
recommended. Rosiglitazone, in contrast to troglitazone, does not induce 
cytochrome P450 3A4 metabolism and is thus likely to have fewer drug-drug 
interactions (Balfour and Plosker, 1999). It is to be noted that troglitazone has been 
withdrawn from the market due to hepatotoxicity. 
Contraindications 
Contraindications to the use ofthiazolidinediones include hepatic disease and 
cardiac failure (Imura, 1998). 
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2.2.3 Insulin secretagogues 
Meglitinide analogues 
This is a new class of insulin secretagogue similar to SU's. Their actions are 
mediated through ATP-regulated potassium channels but via different binding sites 
on the ~-cells. Unlike SUs, they have a "quick-on, quick-off action" that 
theoretically offers improved postprandial control and reduces the occurrence of 
postprandial hyperglycaemia. 
The meglitinides decrease FBG by 3.3 mmollL and HbAle by 1.7-1.9 % compared 
with placebo. Body weight gain occurs with repaglinide treatment. The risk of 
inducing hypo glycaemia low, but further therapeutic trials are needed to evaluate 
their safety and efficacy and to determine their place in therapy (Mayerson and 
Inzucchi, 2002). 
D-phenylalan i ne derivatives 
Nateglinide (Starlix®) which is not a meglitinide, appears to have a faster onset and 
termination of action than repaglinide but with a reduced efficacy. It reduces 
postprandial hyperglycemia and it complements the action of metformin and 
thiazolidinediones in type 2 DM. It is safe and well-tolerated. Hypoglycaemia and 
related symptoms occur less frequently with nateglinide (0.3%) than with 
repaglinide (approximately 13%). Its pharmacokinetic profile, ~-cell specificity, 
targeting of postprandial glucose and efficacy, alone and in combination with other 
agents makes it an ideal agent for mealtime insulin replacement therapy (Kalbag et 
aI., 2001). 
Sulphonylureas 
. A comprehensive discussion on this group of oral hypoglycaemic agents follows 
later in this Chapter. 
Potential agents 
Potential drugs under investigation for the treatment of type 2 diabetes include the 
following: 
Glucagon-like peptide-l (GLP-l) 
GLP-1 increases meal-stimulated insulin secretion by binding to GLP-l receptors on 
the ~-cell membrane. It has insulinotropic effects, glucagon inhibitory effects and it 
delays gastric emptying. It primarily targets postprandial hyperglycaemia but fasting 
hyperglycaemia can also be reduced. These peptides should be given parentally or 
bucally due to their short plasma half-life of less than 5 minutes. More stable 
agonists are being developed for oral administration. Dipeptidyl peptidase IV 
(DDIV) inhibitors are also being investigated as potential antidiabetic agents. These 
agents inhibit the degradation of GLP-l by reducing its catalysis by DPPIV) 
(Wiedeman and Trevillyan, 2003). 
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Vanadium 
Vanadium has been shown to have antihyperglycaemic activity in type 2 diabetic 
patients. Vanadium compounds decrease endogenous glucose production, increase 
peripheral glucose disposal and reduce lipolysis, but the effect was found to be 
relatively mild in type 2 diabetic patients (Matthaei et aI., 2000). 
Etomoxir 
Etomoxir, an inhibitor of camitine palmitoyl transferase 1, has been shown to have 
antihyperglycaemic activity in type 2 diabetic patients by inhibiting hepatic 
gluconeogenesis and decreasing plasma triglyceride concentrations. The 
antigluconeogenic effect is slow to reverse, resulting in difficulties in reversing 
hypoglycaemia (Matthaei et aI., 2000). 
Amylin 
Amylin is a hormone secreted by the pancreatic ~-cells in response to 
hyperglycaemia. Serum amylin levels are very high in hyperinsulinaemic 
individuals and very low in individuals with low insulin secretory capacity, for 
example type 1 diabetic patients. Amylin inhibits gastric emptying and, to a lesser 
extent, suppresses glucagon secretion. Its short half life and its tendency to 
aggregate precludes it from being pharmacologically useful. Pramlintide, an amyl in 
agonist, circumvents some of these difficulties and ongoing clinical studies, both in 
patients with type 1 and type 2 diabetes, indicates that it significantly reduces 
postprandial hyperglycaemia (Matthaei et ai., 2000). 
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2.3 Treatment of Type 2 Diabetes Mellitus 
Four major studies (DCCT, VASCM, UKPDS, Kumamoto) have demonstrated that 
intensive therapy decreases both macro and microvascular complications. The goals 
of current management should therefore not only address glycaemic endpoints but 
also control risk factors i.e., hyperglycaemia and hyperinsulinaemia, for the 
prevention of complications. The challenge is to optimize glycaemic control with 
the minimum number of available agents at the least possible cost. 
2.3.1 Therapeutic Goals 
Various therapeutic goals have been developed for the management of type 2 DM. 
These are represented in the following tables. In South Africa, the therapeutic goals 
are similar to that of the American and European guidelines as listed in table 11, 12 
and 13 respectively. It is noted that the acceptable limits are set at a higher level for 
South Africa (SEMDSA guidelines, 2002). This will have consequences on the 
development of complications based on the major trials mentioned above and the 
study by Ousman and Sharma (2001). While aggressive and stringent glycaemic 
control is the ideal, economic and financial constraints are a barrier to this goal in 
developing countries like South Africa (SEMDSA guidelines, 2002). 
Table 11: Therapeutic goals for the management of diabetes in South 
Africa (SEMDSA guidelines, 2002) 
Parameter SEMDSAI SAMJ 
Optimal Acceptable 
FBG (mrno1!L) 4-6 6-8 
PPG (mrno1!L) 5-8 8-10 
BMI (kg/m2) male 20-25 25-27 
BMI (kg/m2) female 19-24 24-26 
Waist (em) male --- <94 
Waist (em) female --- <82 
HbAlc(%) Normal <2% above 
BP (mrnHg) <140/90 140/90-160/95 
Cholesterol (mrno1!L) <5.2 5.2-6.5 
HDL (mrno1!L) > 1.1 0.9-1.1 
Triglyeerides (mrnol/L) <1.7 1.7-2.2 
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Table 12: Therapeutic goals for the management of diabetes in the 
USA 
American Diabetic Association (ADA) 
HbA lc 7% 
LDL-cholesterol <2.6mmoVL 
BP <l30/80 
BMI <27 and ideally <25 
FBG <4.4-6.7 mmoVL 
Bedtime glucose 5-7.78 mmoVL 
Table 13: Therapeutic goals for the management of diabetes as 
proposed by the European Diabetes Policy Group (1999) 
Low risk Arterial risk 
Microvacsular risk 
HbAle (%) 6.5 >6.5 
>7.5 
Venous blood glucose 
F asting!preprandial 6.0 >6.0 
7.0 
Self monitored blood glucose 
Fasting! preprandial 5.5 >5.5 
>6.0 
Postprandial (peak) <7.5 7.5 
>9.0 
Lipids Low risk at risk 
high risk 
Total serum cholesterol <4.8 4.8-6.0 
>6.0 
LDL cholesterol <3.0 3.0-4.0 
>4.0 
HDL cholesterol >1.2 1.0-1.2 
<1.0 
Triglycirides <1.7 1.7-2.2 
>2.2 
* All values are in mmollL 
Blood pressure Low risk 
(mmHg) <140/85 
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Measures of Glycaemic Control 
• Blood glucose monitoring 
The development of test-strips suitable for self-monitoring of blood glucose levels 
has revolutionised diabetes management. Most test-strips contain glucose-oxidase 
and a dye which reacts with hydrogen peroxide generated by the oxidation of 
glucose in the blood sample. The colour generated can be read visually against a 
colour chart or electronically by a reflectance meter. Generally, blood glucose 
readings can be made at different time-points on different days so that a pattern is 
established. This is particularly helpful in optimizing insulin doses for type 1 DM. 
In type 2 DM, fasting values are useful but self- monitoring should also include 
postprandial and random blood glucose levels. Patients should always test whenever 
they feel unwell, and during the night if nocturnal hypoglycaemia is suspected. The 
accuracy of self blood glucose monitoring depends on accurate technique as well as 
the type of reflectance meter used. 
• Glycosylated (Glycated) haemoglobin and fructosamine 
Glucose reacts with the valine residue on the ~-chain of the adult haemoglobin 
(HbA) and the resulting glycosylated haemoglobin (HbAle) can be separated from 
native haemoglobin and measured by electrophoresis. HbAle is a 'stable, clinically 
useful subcomponent of HbA and is a measure of the average glycaemia during the 
life-span of the red blood cell viz., glycaemic control over the preceding 120 days. 
Non-diabetic HbAle values are about 5-6% of total HbA (SEMDSA 2002). HbAle 
measurements are a useful index of medium-term glycaemic control but are 
invalidated if red-cell turnover is disturbed or if abnormally migrating haemoglobin 
variants are present. 
Serum albumin is also glycosylated and can be measured by the 'fructosamine' 
reaction. Albumin turnover is faster than haemoglobin and therefore fructosamine 
indicates mean glycaemia during the preceeding 1-2 weeks. Current assays, while 
cheaper than those for glycosylated haemoglobin, are unreliable and less 
reproducible (Fluckiger et al., 1987). 
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The Impact of Glycaemic Control on Complications 
Ousman and Sharma (2001) demonstrated that the incidence of clinical 
complications of type 2 DM was significantly associated with glycaemia viz. that 
there is a direct relationship between the risk of complications ofDM and the degree 
of hyperglycaemia over time. These investigators also showed that there was no 
threshold of glycaemia above which the risk of complications no longer increased, 
nor was there a threshold below which the risk no longer decreased. The risk of each 
of the complications evaluated rose with increasing mean HbAle . In particular, at 
near-normal HbA le, the risk of myocardial infarction (MI) was 2-3 fold that of 
microvascular complications. 
Ousman and Sharma (2001) also showed the dramatic decrease in the risk of 
complications for every 1 % reduction in mean HbAle as follows: 
• 21% reduction in death related to DM 
• 21 % reduction in all-cause mortality 
• 37% reduction in microvascular complications 
• 43% reduction in amputations 
• 43% reduction in death from peripheral vascular disease 
2.3.2 Management of diabetes mellitus 
Non-pharmacological Management 
Theoretically, diet, exercise and lifestyle modification can prevent the progression 
to, and of, type 2 DM if the decline in insulin secretion can be prevented. If these 
measures are insufficient to prevent the early emergence of postprandial 
hyperglycaemia then therapy should be initiated as described in the text below. 
Pharmacological Management 
Type 1 diabetes is characterized by an absolute deficiency of insulin. 
Pharmacotherapy is thus aimed at replacing this deficiency with exogenous insulin. 
This thesis will concentrate on the management of type 2 diabetes mellitus. 
Type 2 diabetes is characterized by a relative deficiency of insulin and insulin 
resistance. Pharmacotherapy is aimed at increasing secretion of insulin from ~-cells, 
improving insulin sensitivity and delaying the absorption of carbohydrates. In the 
evolution of type 2 diabetes there is a progressive rise and a subsequent decline in 
insulin secretion. With these changes in insulin secretion, there is an initial increase 
in postprandial hyperglycaemia followed by fasting hyperlycaemia. 
There are many pharmacological approaches to the management of DM, each based 
on mechanism of drug action, patient characteristics and glycaemic targets. 
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Monotherapy 
The relative efficacy of the oral hypoglycaemic agents used as monotherpy are 
presented in table 14. The sulphonylureas and metformin appear to produce the 
greatest benefit in terms of HbAle reduction and decrease in fasting blood glucose. 
Other oral agents tend not to differ markedly in their individual efficacies. Since 
there is little to choose between them, the selection of any individual OHA would 
depend on cost, patient profile and side effects. 
Table 14: Relative efficacies of oral Monotherapy Agents (Medical 
Association Communications, 2001) 
Monotherapy Reduction of HbA1c Reduction of Fasting Blood Glucose 
(%) (FBG) 
(mmol/L) 
Sulphonylurea 1.5-2 3.3-3.85 
Metformin 1-2 3.3-4.29 
Pioglitazone 0.6-1 .9 3.02-3.3 
Rosiglitazone 0.7-1.8 3.02-3.3 
Repaglinide 0.8-1.7 1.65-2.2 
Acarbose 0.5-1 1.1-1.65 
The UKPDS 34 (1998) described a 7% secondary failure rate with monotherapy. 
Primary and secondary failure with sulphonyureas have been discussed. Patients 
who do not reach the goal of normoglycaemia on monotherapy should be introduced 
to combination therapy to achieve target control. 
From a practical point of view, fasting and postprandial blood glucose values can be 
used as a guide to management. Table 15 lists factors predisposing patients to 
secondary failure to monotherapy. 
Table 15: A summary, based on the literature, of predisposing factors 
to secondary failure to Monotherapy 
• Decreasing ~-cell function 
• Obesity 
• Non-adherence to treatment 
• Lack of exercise 
• Intercurrent illness 
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Combination Therapy 
• Combination of Oral Hypoglycaemic Agents 
One of the main conclusions from UKPDS 49 (1999) is that combinations of 
treatments will routinely be needed for type 2 diabetes (Holman et aI., 1999). The 
advantages of combination therapy is that better glycaemic control can be achieved 
with a combination of two drugs that work at different sites. In addition, there are 
fewer side effects with lower doses of two different drugs than with a large dose of 
one drug. Furthermore, if these two drugs are combined in one form, e.g., 
Glucovance®, a combination of glibenclamide and metformin, then compliance 
may be improved. Glycaemic outcomes need to be considered when embarking on 
combination therapy. The potential benefits of combination therapy is presented in 
table 16 below. 
Table 16: Glycaemic outcomes of combination therapy (De Fronzo et 
al.,1999) 
Regimen Reduction in HbAtc Reduction in 
(%) Fasting Blood 
Glucose (mmol/L) 
Sulphonylurea and 1.7 3.60 
metformin 
Sulphonyurea and 0.9-1.8 2.78-3.33 
troglitazone 
Sulphonyurea and 1.2 2.78 
pioglitazone 
Sulphonylurea and 1.3 2.22 
acarbose 
Repaglinide and 1.4 2.22 
metformin 
Pioglitazone and 0.7 2.22 
metformin 
Rosiglitazone and 0.8 2.78 
metformin 
Insulin and oral Open to target Open to target 
agents 
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Bell and Ovalle (2000) demonstrated that patients who did not achieve glycaemic 
control on SU monotherapy and had been initiated on insulin therapy, could be 
transferred back to oral combination therapy with metformin and a SUo The 
successfully converted patients were better controlled on a combination regimen 
than on insulin alone. On the basis of this study, it was concluded that adequate 
glycaemic control can be maintained for an average of 7.8 years on combination 
therapy following failure using SU monotherapy. 
The success of glibenclamide-metformin combinations has been confIrmed by other 
clinical studies. ErIe et al. (1999) studied 40 type 2 diabetics who received 
combined glibenclamide (5mg, 7.5mg or 10 mg/day) plus metformin (800mg, 
1200mg or 1600 mg/day) as preconstituted, fIxed combinations, or glibenclamide 
alone (5mg, 10mg or 15 mg/day). Metabolic control was achieved with fIxed 
combinations of low-dose glibenclamide plus metformin, compared to higher doses 
of glibenclamide alone. The FDA~ in the USA, and the Medicines Control Council 
(MCC) in South Africa approved the use of Glucovance®, a combination of 
glibenclamide and metformin (1.25 mg/250 mg; 2.5 mg/500 mg; 5mg/500 mg) for 
use in type 2 DM. Xixing et al. (2001) who added rosiglitazone to SU in Chinese 
type 2 diabetics previously not controlled by SU alone, demonstrated a decrease in 
HbAle levels (-1.4% to -1.9%). 
Combination of rosiglitazone and metformin (Avandamet®) has also received 
approval by the FDA for the treatment of type 2 diabetes. However, long term, 
extensive clinical usage will determine its effIcacy. 
It has been shown that the addition of a TZD after failure of a combination of 
metformin and a SU reduced HbAle levels to within therapeutic range (Ovalle and 
Bell, 1998). This effect is thought to be due to the rejuvenating effect of the 
thiazolidinediones on the pancreatic ~-cells rather than the insulin-sensitizing effect 
of the thiazolidinediones. The decision to implement a triple regimen must be based 
on sound pharmacological principles and must be economically viable as an 
alternative to introducing insulin therapy. 
• Combination Insulin and Oral Hypoglycaemic Agents 
Patients who persistently present with a HbAle greater than 8% and a fasting blood 
glucose greater than 7.77 mmollL should be considered to be in secondary failure. 
Table 17 tabulates the causes and signs of secondary failure from the literature. 
Table 17: Causes and signs of Secondary Failure 
Signs FBG> 7.77 mmoVL (>6.66 mmoVL? 
HbAle > 8% (>7%?) 
Causes Decreasing ~-cell function 





In a multi centre study (eight centres) 826 patients with type 2 diabetes were 
randomized shortly after diagnosis to initiate treatment with diet alone, insulin 
alone, or a sulphonylurea alone. Insulin was added when fasting blood glucose was 
persistently >108 mgldLl5.99 mmollL (Riddle et aI., 1992). The sulphonylureas 
used were glipizide or chlorpropamide, possibly because earlier in the trial, 
glibenclamide was associated with more hypoglycaemic episodes. Insulin was given 
first as ultralente alone, with mealtime regular insulin added as needed. Both 
pharmacotherapeutic regimens out performed diet alone. However, the regimen 
mandating the timely addition of insulin to a sulphonylurea proved superior to 
insulin alone. The median HbAlc over 6 years was 0.5% lower with the progressive 
regimen and was associated with similar weight gain but less hypo glycaemia 
compared with insulin alone. The advantage in glycaemic control was quantitatively 
very similar to that seen in smaller and shorter studies which also compared 
sulphonylurealinsulin therapy with aggressively titrated insulin monotherapy 
(Riddle et aI., 1992). 
Oral hypoglycaemic agent-insulin combinations are still not very widely used 
because such combinations have been hindered by lack of a clear physiologic 
rationale. It has been proposed that injected long-acting insulin can improve 
overnight glucose control sufficiently to reduce glucose toxicity and lipotoxicity, 
thereby allowing a sulphonylurea to maximize its effect of potentiating mealtime 
insulin secretion. A second proposal is that chronic use of sulphonylureas increases 
the contribution of endogenous insulin secretion to regulation of basal glucose 
production, leading to greater glycaemic stability. This effect can reduce the 
exogenous insulin requirements by 20-50% but cannot be adapted to varying needs 
especially during exercise, when mobilization of insulin from subcutaneous depots 
can increase inappropriately (Riddle et aI., 1992). 
These mechanisms might apply not only to sulphonylureas, but also to metformin 
and thiazolidinediones, when they are combined with insulin therapy. A recent 
physiologic study by Yu et ai. (1999) of concurrent use of metformin or troglitazone 
with very intensive, continuous subcutaneous insulin infusion, showed that the 
insulin dosage declined by 30% with metformin and 50% with the 
thiazolidinedione, whereas C-peptide levels were unchanged. In these conditions of 
increased tissue responsiveness to insulin, appropriate modulations of endogenous 
insulin secretion is more effective in attenuating both increases and decreases of 
blood glucose. With metformin, there is less risk of hypo glycaemia, while with 
thiazolidinediones, which act mainly at muscle and fat, a reduction of postprandial 
hyperglycemia is as important. The ability of metformin to improve the 
effectiveness of multiple injections of insulin for type 2 diabetes was shown in a 
small 6-month clinical study by Ales-Santa et ai. (1999). In this study, optimized 
treatment achieved HbAlc levels of 6.5% with metformin plus insulin but only 7.5% 
with placebo plus insulin. Another advantage of using metformin with insulin is the 
limitation of the weight gain usually seen with intensive insulin therapy. 
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One study compared the ability of bedtime NPH insulin versus bedtime glargine to 
re-establish optimal glycaemic control while one or two oral agents were continued. 
A preliminary report by Rosenstock et al. (2001) included data from more than 300 
patients and pooled data from the two randomized treatment groups. This report 
concluded that remarkably good control is possible using an oral agent plus basal 
insulin strategy. Mean HbAle was reduced from 8.6% at baseline to 6.9% after 18 
weeks of titration of insulin dosage. 
Therefore in summary, the management of type 2 DM should start with dietary 
change, exercise and lifestyle modification. Initial and subsequent therapy must 
consider patient weight, blood glucose levels, symptoms, level of activity, co-
morbid illnesses and concommitant medication. Initial monotherapy for the 
overweight patient may be metformin or a thiazolidinedione. In the case of the lean 
patient, SUs would be the first choice. Failure of monotherapy would necessitate 
combination therapies as discussed above. The addition of a third drug should be 
based not only on benefits in glycaemic control but also on patient acceptance and 
costs. 
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3 A review of the pharmacology of the sulphonylureas 
with particular emphasis on glibenclamide 
The potential of the sulphonylamides, the forerunners to the sulphonylureas as 
hypoglycaemic agents, began with a serendipitous observation by Marcel Janbon. 
He noticed that patients treated with a sulphonamide for typhoid fever developed 
symptomatic hypo glycaemia (Feldman, 1985). Further investigations on dogs 
confirmed that the compound produced hypogylcaemia in fasted normal dogs but 
not in pancreatectomised dogs. It was therefore concluded that the agent probably 
stimulated insulin release from islets of the normal fasted dogs and that this insulin 
was responsible for the development of hypo glycaemia. 
The first effective hypoglycaemic sulphonylurea, carbutamide, was introduced into 
clinical study in Germany in 1955 and later in the United States of America. 
However, because of the high frequency of toxic effects, particularly on the bone 
marrow, it was withdrawn in the United States. Thereafter, the first safe and 
effective sulphonylurea, tolbutamide, was introduced into clinical practice in 1956. 
Three other sulphonylureas viz., chlorpropamide, acetohexamide and tolazamide 
were introduced in the next decade as treatment of DM. These four agents are 
known as the first-generation sulphonylureas [Marble et aI., (1897); White and 
Cambell., (1980); Lebowitz and Melander., (1997)]. 
Glibenclamide (glyburide) and glipizide, classed as the second-generation 
sulphonylureas, were introduced into clinical practice in Europe in 1969 and 1973, 
respectively. Others that make up this group include gliclazide, glimepiride, and 
gliquidone (see Table 18). 
The second-generation sulphonylureas have much greater potency per milligram 
than their first-generation counterparts. Glibenclamide, which has the generic name 
glyburide in the United States, became the most widely prescribed sulphonylurea in 
Europe and worldwide. Extensive studies both in Europe and the United States 
demonstrated that glibenclamide is an effective and safe medication for the 
treatment of certain patients with DM (Feldman, 1985). The name glibomuride has 
frequently, but erroneously, been applied to glibenclamide. In this dissertation the 
name glibenclamide will be used. 
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3.1 Chemistry 
The sulphonylureas are chemically related more closely to the sulphonamide 
antibiotics and to a lesser extent to the thiazide diuretics as all three groups are para-
substituted arylsulphonamides (Feldman, 1985). 
Structural modification of the second-generation sulphonylureas has resulted in a 
marked increase in hypoglycaemic potency as compared to the first-generation 
agents. Thus, 5 mg of glibenclamide is equivalent to 1000 mg of tolbutamide, 500 
mg of acetohexamide, 250 mg of chlorpropamide and 250 mg of tolazamide 
(Feldman, 1985). This increased potency is not due to a pharmacokinetic effect of 
slow metabolic inactivation or renal excretion, but is an intrinsic property of the 
molecule. Whilst SU's appear to have similar principle pharmacodynamic 
properties, their clinical effects may differ due to variations in chemical structure 
causing dissimilarities in selective fJ-cell binding and thus potency. The 1000: 1 
potency ratio between the least and the most potent SU parallels the difference in 
selective binding to j3-cells. However, this diversity in potency does not signify a 
corresponding difference in clinical efficacy (Feldman, 1985). Figure 4 illustrates 






The chemical structure of glibenclamide (Feldman, 1985) 
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3.2 Pharmacodynamics 
Mechanism of hypoglycaemic action 
The mechanisms of SU-induced hypo glycaemia remain to be fully elucidated. 
Probable changes in pancreatic insulin and glucagon secretion and peripheral insulin 
receptor populations are involved. Post-receptor aspects of tissue response to insulin 
remain to be elucidated and may contribute considerably to the debate. In addition, 
the regulators of insulin receptor populations and the mediators of insulin 
responsiveness at the cellular level remain to be clarified. 
At present there are currently 3 postulated mechanisms of action for sulphonylureas: 
• release of insulin from pancreatic ~-cells 
• reduction of serum glucagon concentration 
• an extrapancreatic effect to potentiate the action of insulin on its target 
tissues 
Insulin release from the ~-cells: 
Sulphonylureas bind to a specific receptor that is associated with a potassium 
channel in the ~-cell membrane. This binding inhibits the efflux of potassium ion 
through the channel and results in depolarization. This depolarization opens a 
voltage-gated calcium channel and results in calcium influx and the release of pre-
formed insulin. It must be noted that insulin synthesis is not stimulated and may 
even be reduced by sulphonylureas. Insulin secretion is only stimulated by 
sulphonylureas if there is a sufficient mass of ~-cells. Thus, a reduction of ~-cells 
may result in inadequate insulin release on stimulation (Katzung et aI., 1998). 
Reduction of serum glucagon concentration 
Chronic administration of sulphonylureas to type 2 diabetic patients reduces serum 
glucagon concentrations and this may contribute to the hypoglycaemic effect of 
these drugs. The mechanism of this inhibitory effect on glucagon has not been 
elucidated (Katzung et aI., 1998). 
Potentiation of insulin action on target tissues 
Evidence suggests that increased binding of insulin to tissue receptors occurs during 
sulphonylurea administration, but this is a secondary beneficial metabolic effect 
resulting from reduced glycaemia or low fatty acid levels (Katzung et aI., 1998). 
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Additional effects of Sulphonylureas 
• Increased Insulin Action 
SU therapy is associated with increased tissue sensitivity to insulin action. This may 
be a primary effect but also a consequence of the increased access to insulin and the 
ensuing reduction of hyper glycaemia following increased exposure to insulin (Sartor 
etal., 1987). 
• Reduced Hepatic Extraction of Insulin 
Early studies suggest that reduced hepatic extraction of insulin secreted from the 
pancreas may promote an increased systemic availability of insulin. This has been 
demonstrated for glipizide and glibenclamide (Groop et al., 1987). This could be a 
primary or secondary effect as effective diet regulation seems to reduce hepatic 
insulin extraction. Thus, the effect may be a consequence of glucose reduction and 
improved insulin action in the liver. 
• Effects on Platelets and Fibrinolysis 
While several reports suggest that SUs may reduce platelet adhesion and platelet 
aggregation, it is likely that the anti-platelet effects are secondary to blood glucose 
reduction produced by such drugs. Glipizide and gliclazide may be able to increase 
fibrinolytic activity, while chlorpropamide is associated with low fibrinolytic 
activity (Sartor et al., 1987). 
• Effect on Basement Membranes 
In subjects with impaired glucose tolerance, glipizide reportedly reversed the 
increase in membrane thickness that may be a sign of diabetic microangiopathy 
(Sartor et al., 1987). 
• Effect on Insulin Receptor Population 
A primary defect in type 2 DM is peripheral insulin resistance (Flier et al., 1979) 
which is associated with a decreased number of high-affinity insulin binding sites or 
insulin receptors in peripheral tissues viz., monocytes, adipocytes and erythrocytes. 
Beck-Nielsen. (1979) studied 9 patients over a one year period of continuous 
treatment, 5 with diet alone and 4 with diet plus glibenclamide. The drug treated 
group showed a significantly greater increase in the number of insulin receptors but 
this was not dose-related when the dosage was changed at 3-month intervals. 
Beck-Nielsen et al. (1979) showed that the short term change in receptor number 
was similar in both diet- and drug-treated groups, while the responsiveness to 
insulin increased much more in the drug-treated group. Similarly, blood glucose 
control appeared to be equally as good following one year of treatment with either 
drug plus diet or with diet alone, despite significantly higher numbers of monocyte 
insulin receptors in the drug-treated group. 
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Summary of mode of action of SUs 
SU's bind to receptors in the plasma membrane of insulin-secreting ~-cells of the 
pancreas causing closure of K+-ATP channels. This gives rise to voltage changes, 
calcium influx and subsequently, the release of insulin. SU receptors are also found 
in blood vessels, the heart and brain. While the clinical relevance of these receptors 
is unclear, there is evidence to suggest that their activation may increase peripheral 
vascular resistance and exacerbate myocardial ischaemia. Glimepiride seems to be 
more ~-cell selective than glibenclamide and the first generation SUs. In humans, 
glibenclamide, not glimepiride, attenuates diazoxide-induced vasodilatation 
(Melander et aI., 1998). 
The precise mechanism of the long-term pancreatic and extra-pancreatic effect of 
SUs is uncertain. 
Effect of sulphonylureas on glycaemia and microvascular end points 
This class of drugs is effective in reducing blood glucose levels in patients with type 
2 diabetes and are generally used when exercise and dietary therapy fail to control 
hyperglycaemia. Research conducted by the UKPDS group revealed that the 
sulphonylureas, chlorpropamide and glibenclamide, were both more effective than 
dietary treatment alone, in reducing HbAlc levels in patients with type 2 diabetes 
mellitus. The median HbAlc levels over 10 years were 6.7%, 6.7%, 7.1% and 7.9% 
for chlorpropamide, glibenclamide, insulin and dietary therapy, respectively. In 
addition, the UKPDS group found that intensive treatment with chlorpropamide, 
glibenclamide or insulin produced a 25% reduction in the risk of microvascular end-
points as compared to dietary therapy. There was no observed difference in the 
effect produced by these 3 agents (UKPDS 33, 1998). 
Adverse effects of sulphonyureas 
Hypoglycaemia 
Sulphonylureas carry the risk of causing severe hypo glycaemia which in tum is 
associated with the risk of death or serious neurological defect. In the UKPDS 
(1998), the percentage of patients experiencing major hypoglycaemic episodes per 
year were 0.7%, 1.0%, 1.4% and 1.8% with dietary treatment, chlorpropamide, 
glibenclamide and insulin, respectively. The corresponding percentage of patients 
experiencing any hypoglycaemic episode in these treatment groups were 10%, 16%, 
21 % and 28%, respectively (UKPDS 33, 1998). Chlorpropamide and glibenclamide 
carry the greatest risk of severe prolonged hypoglycaemia due to their relatively 
long duration of action. A decrease in drug elimination that may be due to renal 
impairment further increases the risk of severe hypoglycaemia (Krentz, 1994). 
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Hypoglycaemia is an exaggeration of the SUs desired pharmacologic effect. Seltzer, 
(1972) in a review of drug-induced hypoglycaemia, found that the agents 
responsible for hypo glycaemia were sulphonylureas (47%), alcohol (37%) and 
salicylates (3%). Of the 212 cases involving SU therapy, there were 120 for 
chlorpropamide, 49 for tolbutamide, 21 for carbutamide, 9 for acetohexamide, 7 for 
glibenclamide and 6 for tolazamide. Hypoglycaemia induced by chlorpropamide 
required the longest period of glucose infusion before it resolved because of its long 
half life. The small number of cases of glibenclamide-induced hypoglycaemia 
probably reflects the caution following the experience with chlorpropamide 
Two other studies by Lewis et al. (1975) showed that 1.6% of 5033 patients and 
3.1 % of 3209 patients receiving glibenclamide experienced hypo glycaemia. In a 
multi centre study in the United Kingdom, the percentage of patients who developed 
mild hypo glycaemia were 62% on insulin, 31 % on glibenclamide and 7% on 
chlorpropamide (Multi-center study, 1983). Seltzer (1972) reported hypoglycaemia 
with glibenclamide use in 6% of 285 patients. In this study, the initial daily doses 
were 5-15 mg of glibenclamide which were increased to a maximum of 30 mg daily. 
A study done in Sweden from 1972 to 1981 showed that of 57 cases of 
glibenclamide-induced hypoglycaemia that were reported, there were 10 deaths and 
22 protracted hypoglycaemic episodes (12-72 hours). Factors identified as 
contributing to the hypoglycaemia were age greater than 75 years (21 % were over 
80 years old), and hepatic and renal impairment. The median dose of glibenclamide 
in the hypoglycaemic patients and a random sample of non_hypoglycaemic patients 
was comparable viz.,10 mg (Seltzer, 1972). 
Cardiac effects 
There are concerns regarding the cardiovascular safety of sulphonylureas. Animal 
experiments have highlighted these concerns. SUs block the ATP-sensitive K+ 
channels in the ~-cells of the pancreas, but also block the opening of these channels 
in other tissues, including the myocardium. Glibenclamide is taken up into cells 
readily and this may give rise to an increased risk of cardiac complications. In 
addition, glibenclamide has a longer lasting and irreversible effect on membrane 
potential. Glimepiride is a more selective K+ channel blocker but its effect on the 
cardiovascular system remains to be elucidated (O'Keefe et al., 1999) 
While the University Group Diabetes Programme (UGDP, 1970) found tolbutamide 
to produce a cardiovascular mortality rate 2.5 times that of patients treated with diet 
alone, the UKPDS 33 (1998) group did not show any increase in cardiovascular 
events with intensive glycaemic control. Berger et al. (1999) concluded that 
sulphonylureas may exert adverse cardiovascular effects in patients with ischaemic 
heart disease and hence, did not advocate their general use in this group of patients. 
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Other adverse effects (O'Keefe et al., 1999) 
The first generation sulphonylureas have a low frequency of side effects. These side 
effects include gastrointestinal discomfort (nausea, anorexia), psoriasis and skin 
eruptions. Chlorpromide has the highest reported frequency of side-effects (6.2 and 
8.5%), followed by glibenclamide (1.5 and 3.6%) and glipizide (1.6%) 
The more serious side effects that have been reported with first-generation 
sulphonylureas include: 
• cholestatic jaundice and hepatocellular disease. Liver disease decreases the 
metabolism of glibenclamide and the recommendation is that the dose of 
glibenclamide should be reduced (not> 20mg/day). 
• red cell aplasia and haemolytic anaemia. Chlorpropamide is implicated more 
than other first generation sulphonylureas. Serious toxicity associated with 
glibenclamide has been extremely uncommon. 
• Since glibenclamide is chemically related to sulphonamides, cross 
allergenicity is a possibility. 
• Occasionally patients receiving sulphonylureas develop symptomatic 
dilutional hyponatraemia. This is a drug-induced syndrome of inappropriate 
antidiuretic hormone seen in 4 -6.3% of patients receiving chlorpropamide, 
0.9% receIVmg tolbutamide and 1.9% receIVmg glibenclamide. 
Hyponatraemia is more likely to develop in elderly patients taking 
chlorpropamide together with a thiazide diuretic. 
Hepatic and Renal Disease 
Liver disease not only inhibits the metabolism of glibenclamide but also impairs 
hepatic gluconeogenesis which makes diabetics with cirrhosis more susceptible to 
glibenclamide-induced hypo glycaemia. Since the literature is sparse on the 
evaluation of the pharmacokinetics of glibenclamide in patients with liver disease, it 
is therefore prudent to avoid treating diabetic patients who have significant liver 
disease with glibenclamide. 
The kidneys play an important role in the elimination of several first-generation 
sulphonylureas, 30% in the case of chlorpropamide (Pettplerre et aI., 1972). In the 
case of glibenclamide which undergoes both hepatic and renal excretion, it is less 
likely to accumulate in patients with moderate renal impairment. In studies using 
14C-Iabelled glibenclamide or radioimmunoassay (Kuhnie et aI., 1982), 
glibenclamide elimination was found to be unaffected in patients with moderately 
impaired and normal renal function. This finding was confirmed by Jonsson et ai. 
(1998) who demonstrated that neither glibenclamide nor its two major metabolites, 
4-trans-hydroxyglibenclamide and 3-cis-hydroxyglibenclamide accumulated in 
diabetic patients with impaired renal function. The metabolites of glibenclamide, 4-
trans-hydroxyglibenclamide and 3-cis-hydroxyglibenclamide (Feldman, 1985) have 
minimal hypoglycaemic activity (0.25% and 2.5%), respectively, after oral 
administration in the rabbit. The hypoglycaemic activity of these metabolites has not 
been established in humans. 
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Neither glibenclamide nor its two metabolites accumulated in DM subjects with 
impaired renal function (Jonsson et aI., 1998). Animal studies of the effect of renal 
impairment on the pharmacokinetics and pharmacodynamics of glibenclamide do 
not clarify the picture. 
In view of the above evidence, glibenclamide should be used with caution in 
patients with moderate renal compromise and not at all in patients with severe renal 
impairment. 
Drug Interactions (Marble et aI., 1987) 
Alcohol 
Flushing reactions (disulfiram reaction) with the ingestion of alcohol occur almost 
exclusively in patients taking chlorpropamide (34%). This phenomenon has not 
been described in patients on glibenclamide. Possible explanations for this is that 
glibenclamide does not inhibit aldehyde dehydrogenase or that its plasma 
concentration is not high enough to inhibit this enzyme. 
Alcohol and tolbutamide are both metabolised by hepatic microsomal enzyme 
systems. Since there is a decrease in plasma half-life of tolbutamide after the 
ingestion of alcohol, it is more difficult to maintain therapeutic plasma 
concentrations of tolbutamide in this state. Interactions between alcohol and 
tolbutamide are not well documented (Feldman, 1984). 
Agents that antagonize the hypoglycaemic action 
Drugs that may antagonise the action of first generation sulphonylureas, such as 
thiazide diuretics, glucocorticoids, oestrogens and phenytoin, will probably also 
antagonise the actions of second-generation sulphonylureas. 
Agents that potentiate the hypoglycaemic action (Marble et aI., 1987) 
Some mechanisms by which drugs potentiate the action of sulphonylureas include: 
• displacement of the sulphonylurea from albumin binding sites 
• alterations of renal excretion 
• hepatic metabolism of sulphonylureas 
• insulin-like action on glucose transport into tissues 
• stimulation of pancreatic insulin secretion 
Drugs that are highly protein bound such as salicylates, warfarin and 
phenybutazone, will displace sulphonylureas from albumin binding sites. This will 
result in a higher plasma concentration of the free drug thereby exerting a greater 
hypoglycaemic effect. The large, non-polar chemical group of glibenclamide 
prevents it from being displaced from its albumin binding site by ionic agents such 
as aspirin, dicumarol and phenylbutazone. Caution however needs to be exercised 
when using these drugs in clinical situations to establish if in fact this interaction 
does not occur. 
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Phenylbutazone may potentiate the action of glibenclamide by decreasing the renal 
excretion of its metabolites without altering its metabolism. 
Primary and Secondary Failure 
The following patient characteristics are sometimes predictive of a positive clinical 
response to sulphonylureas: 
• The patient is not diagnosed with diabetes until after the age of 40 
• Duration of diabetes is less than 5 years 
• Patient is close to, or above, his or her ideal body weight 
• There has been no prior insulin treatment or insulin requirement for 
glycaemic control is less than 40 units per day 
• The fasting blood glucose is less than 10 mmollL 
Failure of SU therapy can be either primary or secondary. 
Primary failure of therapy is defined as treatment failure that occurs in patients 
who did not ever achieve good control of diabetes with a sulphonylurea. The causes 
of primary failure include inappropriate patient selection, poor dietary compliance, 
poor compliance in taking medication and unresponsiveness to the drug (Davidson 
et aI., 1970; Camerini-Davalos et aI., 1962). 
Secondary failure occurs in those patients who achieve good control of diabetes 
initially and later lapse into poor control. The causes of secondary failure include 
those indicated for primary failure as well as temporary metabolic stress. It has been 
shown that between 25-50% of patients with primary or secondary failure to a first-
generation sulphonylurea achieved satisfactory glycaemic control with 
glibenclamide therapy (Davidson et aI., 1970). Some patients on glibenclamide also 
experience primary or secondary failure. 
In a study by Camerini-Davalos et ai. (1962) an 18% primary failure rate and a 22% 
secondary failure rate was noted in patients treated with tolbutamide. It was found 
that only 3.7% of the patients had true secondary failure after causes such as 
disregard for diet, poor drug compliance and temporary metabolic stress were 
eliminated. In another study by Gunderson (1975), of 3500 patients, 8.4% and 4.8% 
were found to have primary and secondary failure, respectively. Of these, 42% were 
treated with first-generation sulphonylureas, 9% received phenformin and 49% 
required insulin therapy. It was therefore concluded that primary and secondary 
failure rates with glibenclamide are comparable with other sulphonylureas. Overall, 
between 20-30% of patients treated with SUs may present with primary or 
secondary failure. 
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Indications for Sulphonylureas (Marble et aI., 1987; Katzung et aI., 1998) 
SU's, including glibenclamide, are only effective in those diabetic patients who still 
possess some capacity for endogenous insulin production. SU's should be used in 
type 2 DM patients when non-pharmacological treatment modalities and the use of 
non-insulinotropic anti-diabetic agents (acarbose, metformin and thiazolidinediones) 
are insufficient to achieve therapeutic goals. Insulinotropic agents are not first line 
drugs in overweight or obese type 2 diabetic patients because they cause further 
weight gain. Sulphonylureas represent first line drugs in non-obese type 2 diabetic 
patients whose main pathophysiological problem is impaired insulin secretion. 
Success is more likely in those type 2 diabetics with little or no tendency to 
ketoacidosis and who, if they are receiving insulin, would have a requirement of no 
more than 20, or at most, 30 units of insulin daily (UKPDS 34, 1998). 
Contraindications (Marble et aI. , 1987; Katzung et aI., 1998) 
SU's are contraindicated in patients with: 
• type 1 diabetes 
• during acute infections, particularly with fever 
• those undergoing major surgery 
Clinical comparisons between SUs 
The second generation SUs such as glibenclamide, have an increased 
hypoglycaemic activity, 50 to 100 times more potent on a weight to weight basis 
than the 1 st generation agents. They also offer the advantage of fewer drug 
interactions. 
In a placebo controlled crossover study by Groop et al. (1987) the clinical efficacy 
of glibenclamide and glipizide were compared over two 6-month periods. While 
there were great inter individual differences in the final daily dose, the mean final 
doses were similar (about 15mg for both drugs). Most patients took the medication 
3 times daily. This is contrary to the once a day dosing recommended for 
glibenclamide. 
Draeger et al. (1996) compared the efficacy of glibenclamide and glimepiride in the 
treatment of type 2 diabetic patients. They concluded that both drugs were well 
tolerated and that glimepiride once daily provided equivalent metabolic control at a 
lower dosage (1-8mg) as compared to glibenclamide (2.S-20.0mg). 
When dosage is individualised as governed by the effect on fasting blood glucose, 
there is little or no difference in clinical efficacy between sUlphonylureas i.e., the 
SU's are qualitatively similar but quantitatively different. 
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3.3 Pharmacokinetics 
Sulphonylureas differ in intrinsic activity, potency and pharmacokinetics (Lebovitz 
and Melander, 1997) and are primarily metabolized by the liver and excreted in the 
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Pharmacokinetic properties of oral hypoglycaemic drugs 
(Marble et aI., 1987; White and Cambell, 1986) 
Duration Dose Protein Plasma Volume of Elimination' 
(hr) range binding' half-life distribution (Ukg) 
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2-24 250- metabolism to 
1500 hydroxyhexamid 












drug (6 to 60%) 
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320 metabolism. 
12-20 Renal excretion 
30- of unchanged 
120 drug « 20%) and 
metabolites 
Contribution of 
metabolites to activity 
Hydroxyhexamide 
more potent than 
parent drug but only 
very small amounts 















Glipzide' 16-24 40- 97-99 3-7 0.2 Hepatic Probably nil 




Glisoxepide' 5-10 2-16 93 1.4-5.3 0.07 Hepatic ? 
metabolism and 




Tolazamide 12-24 100- 94 ",,7 Hepatic Small (6 major 
1000 metabolism. metabolites are 
Renal excretion formed, but only 3 
ofless active are hypoglycaemic, 
metabolites. and mildly so) 
Tolbutamide 6-12 500- 95-97 4-10 0.15 Hepatic Nil 
3000 metabolism. (hydroxytolbutamide 
Renal excretion active but formed in 
ofless active small amounts) . 
metabolites . 
Sulphonamidop 89 2.6-5.6 Hepatic About 15 to 30% 
yrimidines metabolism excreted as 
Glymidine (active demethyolated 
(glycodiazine) metabolite). metabolite (as active 
.' Second generations' drug. 
ER*- Extended release 
MR*- Modified release 
M* -Micronised 
Absorption 
Renal excretion as parent drug) 
of active 
metabolite 
While early formulations of glibenc1amide showed bioavailabilities of 45%, current 
formulations are virtually 100% bioavailable. Peak plasma concentrations are 
reached within 2 to 6 hours after ingestion in the fasting state. Dietary fibre was 
shown to decrease the plasma concentration of glibenc1amide by 50%. The rate of, 
or completeness of absorption is not affected by food (Jackson and Bressler, 1981). 
Kaiser and Forist (1975) suggested that absorption from one formulation follows 
zero-order kinetics at least in normal subjects. After a single dose, peak serum 
concentrations in volunteers occurs at about 1.5 hours after oral administration of a 
tablet (Adams et aI., 1982; Groop et aI., 1985) and 0.5 to 2 hours after a solution 
(Pearson et aI., 1986). Table 19 summarises the pharmacokinetics of glibenc1amide 
following oral dosage. 
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Chlorpropamide is the slowest and the longest acting SU, while glipizide is one of 
the fastest- and shortest acting. Glibenclamide is slower in onset than glipizide 
because it is more slowly and incompletely absorbed in the non-micronised form. 
This slower onset is demonstrated when glibenclamide and glipizide are infused at 
equal rates and at similar plasma concentrations (Groop et aI., 1987). 
Optimal reduction of postprandial hyperglycaemia occurs if glibenclamide is 
ingested 30 minutes prior to a meal because of the time required for gastrointestinal 
absorption. However, the potential danger of hypoglycaemia necessitates that the 
drug be given immediately before or with meals so as not to compromise 
compliance. Sartor et a1. (1982) reported that the addition of glibenclamide to a 
standardized breakfast, lunch and dinner would enhance plasma immunoreactive 
insulin (IRl) concentrations and reduce blood glucose concentrations as compared to 
meals taken without the drug. 
Distribution 
The SU's are highly protein bound, mainly to albumin, varying from about 75% for 
acetohexamide to 99.5% for glimepiride. There are also differences in the volume of 
distribution (Vd) ranging from 0.07 L/kg for glisoxepide to 0.25-0.3 L/kg for 
gliclazide 0.13 L/kg for glimepiride and 0.2 L/kg for glibenclamide. Glibenclamide 
produces fewer protein-binding related drug interactions than the first generation 
SUs. This is due to lower plasma concentrations and non-ionic binding capacity 
[Marble et aI., (1987); White and Cambell., (1986)]. 
Metabolism and elimination 
All SU's undergo varying degrees of hepatic metabolism and biliary and renal 
excretion. Tolbutamide, glibenclamide, glipizide and gliclazide are eliminated by 
hepatic metabolism. Although they can be used with caution in patients with 
impaired renal function, insulin therapy is preferred to prevent severe 
hypoglycaemic episodes that have been reported in such patients treated with SU's 
(Katzung, 1998). 
Characteristics of elimination of SUs influence their use in patients with impaired 
renal function or liver disease. Compounds that are eliminated mainly by hepatic 
metabolism (tolazamide, tolbutamide, glibenclamide), carry the increased risk of 
symptomatic hypoglycaemia if significant liver disease is present, particularly if 
other drugs which inhibit their metabolism are given at the same time. In the case of 
highly albumin-bound drugs such as tolbutamide, clearance of unbound drug may 
not change in liver disease and alteration of dosage may not be necessary. Enzyme-
inducers on the other hand, can accelerate the metabolism of SUs such as 
tolbutamide and thus interfere with diabetes control. 
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Glibenclamide is metabolised almost completely in the liver to two hydroxy 
derivatives and one unidentified metabolite. The cyclohexyl ring is hydroxylated by 
the liver to form 4-trans-hydroxyglibenclamide and 3-cis-hydroxyglibenclamide. 
These compounds possesed only 0.25% and 2.5% the hypoglycaemic potency of 
glibenclamide, respectively, when evaluated after oral administration in rabbits 
(Feldman, 1985). 
The excretion of these hydroxy metabolites appear to be the same in humans as in 
rabbits with equal amounts being excreted in the urine and bile. This pattern of 
excretion (dual route) is unusual as almost all the metabolites of the first-generation 
SU's are excreted in the urine only. 
The elimination half-life varies from 3-5 hrs for glibenclamide to 35 hours for 
chlorpropamide. The time to steady state varies from 5 to 9 days and therefore 
dosage adjustment should not be made before this time. Approximately 50% of a 
dose of glibenclamide is excreted in the urine as metabolites and the remainder in 
the faeces (Feldman, 1985). The elimination half-life varies from 1.4 to 2.3 hours in 
healthy subjects (Ings et aI., 1981; Matsuda et aI., 1983) while the half-life increased 
to 2.7 hours at a dose of 2.5 mg daily and 2.9 hours at 5 mg daily during long term 
treatment (Matsuda et aI., 1983). 
A 'third phase' of elimination of glibenclamide with a half-life of 10 hours in 6 
healthy subjects has been reported (Ferner and Chaplin, 1987). They suggested that 
this may reflect either the elimination of metabolites measured by a nonspecific 
assay, or the elimination of glibenclamide from the 'deep' compartment. Severe 
renal impairment (creatinine clearance = 5 mllminll.7m2) in one subject delayed the 
elimination of glibenclamide, increasing its half-life to 11 hours (Pearson et aI., 
1986). However, in other subjects with creatinine clearances ranging from 29 to l31 
mllminl1.7m2, the half-life varied from 2.0 to 5.0 hours. 
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3.3.1 Summary of Glibenclamide pharmacokinetics 
The phannacokinetic parameters of glibenclamide following oral administration are 
summarised in table 19 below. 
Table 19: Glibenclamide pharmacokinetics following oral 
administration 
Drug Reference Subjects Condition 
micronised (Neuvonen and Kistot, healthy fasting 
1991) (Kivisto et aI., 
1993) 
micronised (Sartor et aI. , 1982), healthy fasting 
(Ayanoglu et aI., 
1983) 
non-micronised (Sartor et aI., 1982), healthy fasting 
(Ayanoglu et aI., 
1983) 
Gilemid® healthy fasting 
Daonil® (Ayanog1u et aI., healthy food 
1983), (Yamato et aI., 
1969) 
non-micronised [Neuvonen and Kistot, healthy fasting 
I 991j,(Fleishaker and 
Phillips, 1991) 
micronised (Fleishaker and Type 2 fasting 
Phillips, 1991), (Sartor 
et aI., 1982) 
suspension (Coppack., 1990), healthy fasting 
(Fleishaker and 
Phillips, 1991) 
Daoni1® (Ings et aI., 1981), healthy fasting 
(Kivisto, 1993) 
Daoni1® (ings et aI., 1981), healthy food 
(Ki~isto et aI., 1993) 
Daonil® (Sartor et aI., 1982) healthy fasting 
solution healthy food 
Daoni1® (Compendium, 1994), healthy food 
( (Sartor et aI., 1982) 
Gn® (Compendium, 1994), healthy food 
(Sartor et aI., 1982) 
Gt® (Compendium, 1994), healthy food 
(Sartor et aI., 1982) 
Euglucon® (Yamato, 1969) healthy food 
G1ibenclamide BP Coppack, 1990 Type 2 fasting 
Glibenclamide BP Coppack, 1990 Type 2 Food 
Glibenclamide BP Coppack, 1990 Type 2 Fasting 
Glibenclamide BP Coppack, 1990 Type 2 Food 
Key: 
Cmax- Maximum concentration 
T max- time to reach maximum concentration 
T 112- half-life 
Dose Cm .. nglmL ± SD 
(m2) 
1.75 117 ± 32 
2 138 ± 44.3 
2.5 93 ±60 
2.5 27.9 ± 3.2 
2.5 66.2 ± 32.4 
2.5 34± II 
5 179 ± 82.8 
5 398 ± 40.9 
5 292 ±168.5 
5 292 ± 64 
5 143 ± 33 
5 308 ± 120 
5 189.6±42.9 
5 85.5 ± 27 .9 
5 50.3 ± 29.7 
5 176 ± 34.8 
10 241 ± 154 
10 262 ± 152 
20 354 ± 93 
20 360 ± 139 
T .... h±SD 
1.8 ± 1.2 
1.84 ± 0.44 
2.77 ±0.51 
3.8 ± 1.7 
3.8 ± 1.1 
3.8 ± 2.1 
4.9 ± 2.5 
0.75 ± 0.42 
3.4 ± \.3 
2.6±0.8 
2.35 ± 1.22 
2.2 ± 1.1 
3.0± 0.9 
3.6 ± 0.7 
4.0 ± 1.1 
3.94 ± 1.18 
2.1 ±0.7 
2.7 ± 0.9 
3.2 ± 2.4 
3.5 ± \.3 
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Tl/zh ±SD 
0.78 ± 0.45 
1.35 ± 0.54 
1.97± 0.98 
-
2.4 ± 0.8 
2.4 ± 5.1 
8.3 ± 3.9 
3.3 ± 2.7 
1.8 ± 0.8 
1.6 ± 0.3 
1.59 ± 0.41 
1.5 ± 1.1 
1.8 ± 0.7 
1.8 ± 0.9 





Synopsis of selected pharmacokinetic studies of glibenclamide 
Studies on the pharmacokinetics and pharmacodynamics of glibenclamide have 
increased our understanding of its clinical use in diabetes mellitus. These studies 
have focused on the use of the drug in different age groups, different ethnic groups 
and different disease states. A synopsis of some of these studies is presented here. 
Jaber et a1. (1994) compared the effect of acute dosing with chronic dosing of 
glibenclamide on pharmacokinetic parameters. They administered 2.5mg 
glibenclamide as an oral solution to 20 type 2 DM patients aged between 40-70 
years. The results are presented in table 20 below. 
Table 20: Glibenclamide pharmacokinetic parameters (mean ±SD) at 0, 
6 and 12 weeks (Jaber et aI., 1994) 
Cmax 
Week Tmax (h) (ng/ml) ke (h-I ) tl/2 (h) CI (Llhr) Vd (L) 
0 1.9 ±1.5 
6 1.1 ±O.9 
12 1.7±1.3 
Key: 
Tmax- time to maximum concentration 
Cmax- maximum concentration 
Ke- elimination rate constant 
t llr half life 
Cl- clearance 
Vd- volume of distribution 
177±75 O.209±O.O95 4.0±1.9 3.8±1.3 
268 ±240 O.O77±O.O47 13.7±10.5 2.6±1.3 
278±146 O.O8±O.O47 12.2±8.2 3.2±2.1 
Significant prolongation in the elimination half-life (4 to 13 hours) and an increased 
Vd (from 20 to 51L), with a relatively constant CL was observed with chronic 
dosing. Thus the pharmacokinetics of glibenclamide differs with acute and chronic 
administration. These changes suggest the possibility of glibenclamide accumulation 
during chronic dosing with no apparent increase in the incidence of adverse effects. 
The insulinotropic effect of glibenclamide was maintained during long term therapy, 
which would exclude the possibility of exhaustion or glibenclamide-induced 
desensitization of pancreatic p-ce1ls. The authors conclude that these findings 
support the initiation of glibenclamide at the lowest possible doses. Although this 
study, published in 1994, reported the merits of initiating glibenclamide at low dose, 
subsequent studies did not follow through the recommendation. However, a major 
limitation of this study and hence its conclusion was that it was a single dose study 
with no dose escalation. The dose escalation study (in this dissertation), attempts to 





Niemi et al. (2002) studied the role of genetic variability on the pharmacokinetics of 
glibenclamide in healthy volunteers (Table 21). The pharmacokinetic parameters of 
glibenclamide were not significantly changed in healthy volunteers with the 
CYP2C9* 112* genotype. But in those individuals with CYP2C9*3 allele, the total 
AUC was 280% that of subjects with the CYP2C9*1 genotype. It can be concluded 
from the above results that genetic polymorphisms of CYP2C9 markedly affect the 
pharmacokinetics (AUC and Cmax) of glibenclamide. This could result in a 
prolonged and more intense hypoglycaemic activity or action which could result in 
hypoglycaemia in susceptable individuals. 
This study was conducted in a very small number of healthy volunteers and 
examines the affect of genetic polymorphism/differences on the metabolism of 
glibenclamide. Extreme differences in pharmacokinetics in patient populations 
might translate into pharmacodynamic differences. Therefore the individual 
pharmacokinetic parameters of patients should be examined in relation to 
pharmacodynamic variability. Generalisation of the results of this study is restricted 
by the small sample size. 
Table 21: Mean (range) pharmacokinetic variables for glibenclamide in 
healthy volunteers with CYP2C9*1J*1, CYP2C9*1J*2, 
CYP2C9*1/**3 or CYP2C9*2J*3 (Niemi et aI., 2002) 
CYP2C9*1/*1 
(0=2) 
Cmax (ng/mL) 80.4 (54.7-109.4) 
Tmax (h) \.0 (\.0- \.5) 
TI/2 \,7 (\.5- \.9) 
AUC (0-12) (ng.hlmL) 221.6 (206.3-284.2) 
AUC (0-8) (ng.h/mL) 223.9 (208.1-287.9) 
Key: 
Cmax- maximum concentration 
Tmax- time to maximum concentration 
T 1/2- half life 
AUC- area under the curve 
CYP2C9*1/*2 CYP2C9*1/*3 or CVP2C9*2/*3 
(0=3) (0=2) 
64.0 (46.8-123.0) 136.0 (135 .6-136.4) 
\.5 (\.0- \.5) 2.5 (2.0-3.0) 
2.0 (1 .6-3 .0) 2.6 (2.3-2.8) 
221.1 (154.0-410.8) 594.4 (558.0-630.8) 
225.3 (155.7-434.8) 626.9 (579.6-674.1) 
Jonsonn et al. (2000a; 2000b) studied the pharmacokinetics of glibenclamide in 
Caucasians and Chinese type 2 diabetic patients after oral (2000a) and intravenous 
administration (2000b) respectively. The aim was to evaluate the role of ethnicity on 
pharmacokinetics of glibenclamide. The results are presented in table 22 and 23 
below. 
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Table 22: Pharmacokinetic variables of 2.5mg glibenclamide given 







Cmax: maximum concentration 
Tmax- time to maximum concentration 
T 1/2. half life 
AUC- Area under the curve 
Caucasians (n=10) Chinese (n=10) 
Mean (Range) Mean (Range) 
69 (21-153) 82 (41-146) 
2.0 (1.0-4.5) 4.5 (1.5-6.5) 
7.09 (2.14-27.8) 4.63 (2.77-11.24) 
440 (200-684) 513 (392-661) 
Table 23: Pharmacokinetics after 1.25 mg IV glibenclamide in 







Cmax: maximum concentration 
Tmax- time to maximum concentration 
Cl- clearance 
AUC- area under the curve 
Vss- volume of distribution at steady state 
Caucasians (n=10) Chinese (n=10) 
Mean (RanKe) Mean (RanKe) 
376 (309-420) 368 (220-443) 
2.0 (1.0-4.5) 4.5 (1.5-6.5) 
4.41(3.38-8.11) 4.10 (2.91-5.18) 
283 (154-370) 305 (241-430) 
6.31 (4.68-7.68) 5.49 (4.04-9.55) 
There were no significant inter-ethnic differences in the pharmacokinetics of 
glibenclamide whether given orally or intravenously and the authors concluded that 
it would be appropriate to employ the same dosage regimens in these two population 
groups. 
In the two studies cited above (Jonsonn et aI., 2000a and 2000b), the tmax of 
glibenclamide was identical in spite of the different routes of administration, 
namely, oral and intravenous. A comparison of the AUe's (283/440= 0.643; 
305/513= 0.594) quoted in these studies provides an estimate of the absolute 
bioavailabilty of approximately 78%, which is consistant with the literature. 
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Courtois et al. (1999) investigated the effect of age on the pharmacokinetics of 5 
mg single dose glibenclamide (table 24 below) (single 5mg dose) whilst insulin 
therapy was continued as normal. There was no significant difference in the 
pharmacokinetics of glibenclamide between the young and the aged group. The 
half-life of glibenclamide (2.63 ± 0.75 vs 2.78 ± 0.55 hr) between the groups was 
comparable. The authors concluded that age does not affect the pharmacokinetics of 
glibenclamide after a single dose. 
Table 24: Pharmacokinetic variables for glibenclamide (Courtois et aI., 
1999) 
I Control subjects (42-59 years) 
emax (microg/rnL) 
T 112 (h) 
Key: 
Cmax- maximum concentration 
Tmax- time to maximum concentration 




2.58 ± 0.37 
2.63 ± 0.75 




2.20 ± 0.34 
2.78 ± 0.55 
The pharmacokinetic of glibenclamide in diabetic patients with impaired (IRF) and 
normal (NRF) renal function was compared by Jonsson et al. (1998) and is 
presented in table 25 below. 
In this study, a single dose of 7 mg of glibenclamide was administered to 11 diabetic 
patients with impaired renal function and 11 diabetic patients with normal renal 
function. It was found that neither glibenclamide nor its two major metabolites, 4-
trans-hydroxyglibenclamide and 3-cis-hydroxyglibenclamide accumulated in 
diabetic patients with impaired renal function. AVC and Cmax of glibenclamide were 
lower in the IRF group but CUf and ke and ka were higher (table 25). The significant 
difference between AVC, Cmax and CUf for glibenclamide between the groups may 
be an indication of higher free fraction of glibenclamide in the IRF group. This 
would result in an increased metabolic clearance of glibenclamide, resulting in 
lower Cmax and AVC values in the IRF group. While serum albumin levels were 
significantly lower in the IRF group, this cannot fully explain the above findings 
since only one patient had a serum albumin level below 30glL, a concentration 
above which minimal alterations in glibenclamide binding occurs. The most 
probable elimination route for glibenclamide and its metabolites is biliary secretion. 
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Table 25: Mean (SO) pharmacokinetic variables of glibenclamide in 
diabetic patients with impaired (IRF) and normal (NRF) renal 
function after 7 mg orally (Jonsson et aI., 1998) 
t lag (h) 
ka (h· l ) 
Tmax (h) 
Cmax (ng/mL) 





t lag- lag time 
ka- absorption rate constant 
Tmax- time to maximum concentration 
Cm.x- maximum concentration 
Ke- elimination rate constant 
V If- apparent volume of distribution 
CIIf- apparent clearance 
AUC- area under the curve 
IRF 
0.46 (0.16) 
















Two studies (Rydberg, et aI., 1997; Tracewell et aI., 1998) estimated the 
pharmacokinetic parameters of glibenclamide using non-linear mixed effects model 
(NONMEM). The study by Rydberg et ai. (1997) comprised 8 healthy Caucasians. 
The aim of the study was to describe the relationship between the serum 
concentrations of glibenclamide (3.5 mg IVI and oral after 3 months) and its two 
major metabolites (3.5 mg IVI) and its effects on blood glucose levels. The 
pharmacokinetic parameters estimated by using NONMEM are presented in table 
26. 
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Table 26: Population pharmacokinetics parameters of glibenclamide in 
8 healthy volunteers estimated by NONMEM (Rydberg et aI., 
1997) 
Parameter Mean (CV%) 
KIO (h- I ) 1.30 (16%) 
KI2 (h- I ) 0.447 (15%) 
K21 (h- I ) 0.916 (3%) 
VI (L) 3.63 (17%) 
F 0.82 (29%) 
Ka (h-I ) 0.756 (60%) 
T lag (h) 0.40 (13%) 
EC 20 (ng/mL) 87 (Parent and metabolites) 
ECss 50 (ng/mL) 233 (Parent and metabolites) 
Key: 
KIO_elimination rate constant from compartment 1 to 0 
K' 2- elimination rate constant from compartment 1 to 2 
K2,_ elimination rate constant from compartment 2 to 1 
V ,_ volume of distribution of first compartment 
F- bioavailabilty 
Ka- absorption rate constant 
T lag- lag time 
EC 2o-concentration producing 20% of maximal effect 
This study shows that there is no direct relationship between sulphonylurea 
concentrations and blood glucose lowering effect (Rydberg et aI., 1997). NONMEM 
analysis demonstrated that the longer half life, the lag time effect and the bioactive 
metabolites of glibenc1amide reinforced the once daily dosing with the drug. 
Tracewell et aI. (1998) investigated the pharmacokinetics of glyburide 
(glibenclamide) in 51 well controlled type 2 DM patients in the daily dose range of 
1.25 to 20 mg (table 27). The objective of the study was to test the hypothesis that 
inter-subject variability in the dose of the drug is due to patient differences in 
pharmacokinetics. A one-compartment model with first-order absorption and first-
order elimination was used. The data were analysed using NONMEM. The 
parameters of concern were oral clearance (CIIf), apparent volume of distribution 
(Vdlf) and absorption rate constant (ka). The Vd (43.7L) was larger than reported for 
most studies. The oral CI for a 75 kg individual was 3.9 Land 2.9 L, for the older 
and younger patients, respectively. These values are comparable to those reported 
elsewhere in this discussion (see above). There were no significant differences in the 
pharmacokinetics of glibenclamide between obese and non-obese patients. 
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Table 27: Population Pharmacokinetics of Glyburide in Patients With 







Ka- absorption rate constant 
V-volume of distribution 
CI- clearance 
Std Error 
ka (h-I ) 0.957 
V(L) 43.7 
Cl (LlhrlKg) <60 yrs 0.0387 
Cl (L/hr/kg) >60yrs 0.0525 
The majority of pharmacokinetic analyses yielding PK parameters quoted above 
were obtained from non-compartmental analysis. The major difficulty with this type 
of analysis is noted when one attempts to compare results across studies and 
populations. In only a small number of studies was an integrated data analysis 
approach utilized [Rydberg et aI., (1997); Tracewell et aI., (1998)]. These latter 
types of analyses lend themselves to improved interpretation and the ability to 
interpolate and sometimes extrapolate to doses that have not been formally tested. 
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3.3.2 Dose-exposure response relationship investigations for 
sulphonylureas 
There is inadequate information on sulphonylurea dosage and its stimulatory effect 
on insulin secretion in human studies. There is even less information on the 
relationship between dose and response i.e., blood glucose lowering effect of SU's. 
In the USA, the dose of glibenclamide was increased to up to 20 mg/day if treatment 
goals were not met. In South Africa it is not uncommon to see doses of 20 mg/day 
and sometimes greater prescribed. While this practice has little scientific support, it 
is practised on the assumption of a linear dose-response relationship in the case of 
glibenclamide. 
The usual daily doses range from 2.5 to 20 mg/day. Most patients require between 5 
to 10 mg/day with few benefiting from doses greater than 15 mg/day. A dose-related 
increase in duration of action was seen over the range 1.25 to 5 .0 mg. Once daily 
dosing equally controls blood glucose as twice daily dosing (Jackson and Bressler, 
1981). Since the drug accumulates, dose adjustments should be made not sooner 
than at two week intervals. 
Sartor et al. (1982) noted that ambulatory diabetic patients receiving glibenclamide 
therapy had a wide variation in serum drug concentrations that was not related to 
their daily dose or to the degree of control of the patients' hyperglycaemia. Similar 
observations have been made in ambulatory patients receiving tolbutamide or 
chlorpropamide (Bergman et al., 1980; Melander et al., 1978). Hospitalised patients 
receiving glibenclamide and chlorpropamide also have a wide range of serum SU 
concentration suggesting that poor compliance alone cannot explain this occurrence. 
It is possible that individual differences in the rate of metabolism may explain this 
phenomenon. Early studies have found no direct relationship between serum 
concentration of glibenclamide and its ability to reduce hyperglycaemia (Matsuda et 
al., 1983). 
The maximum effect of glibenclamide does not appear to be different from that 
achieved with other sulphonylureas (Feldman, 1985). With long term dosing, Sartor 
et al. (1980) found no correlation between serum glibenclamide levels and fasting 
blood glucose levels among 37 diabetics. However Balant et al., (1977) noted a 
statistically insignificant trend towards lower postprandial blood glucose levels after 
15 days of glibenclamide treatment than after the first dose of the drug in 6 
diabetics. 
A long-term study comparing glibenclamide and glipizide showed little or no 
improvement in blood glucose control at doses greater than 10 mg/day (Groop et al., 
1987). In the case of glipizide, dose increases from 15 to 25 mg/day resulted in 
increased, rather than decreased, blood glucose levels (Wahlin-Boll et al., 1982). 
The authors concluded that there may be a narrow range of plasma concentrations 
below which SUs are ineffective and above which there is little additional beneficial 
effect. 
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It has been reported that the insulin-releasing effect of glipizide is more rapid than 
that of glibenclamide when the drugs are infused at the same rate. This suggests that 
there may be differences in the rates of tissue distribution and/or differences in the 
rates of binding of these two drugs to SU receptors on the ~-cells. This may be 
clinically relevant because delayed release of insulin following a glucose load is an 
important factor in the pathogenesis of type 2 DM (Melander et aI, 1998). 
Groop et al. (1991) examined the relationship between plasma glibenclamide 
concentrations (after primed continuous intravenous infusion of glibenclamide) and 
insulin response and glucose metabolism in 9 healthy subjects. They found that 
glibenclamide increased insulin secretion and glucose disposal during both 
euglycaemia and hyperglycaemia. This effect was achieved at drug levels of 100-
200 nM (0.0494-0.0998 mglL) corresponding to an oral dose of less than 10 mg of 
glibenclamide. 
Under hyperglycaemic conditions, plasma glibenclamide levels greater than 200 nM 
did not evoke any additional stimulation of insulin secretion or increase glucose 
disposal rate. In clinical practice, drug levels of 200 nM (0.0998 mglL) is usually 
exceeded in many type 2 DM patients who do not become euglycaemic on low 
doses of glibenclamide. 
Groop et al. (1991) concluded that this concentration of 200 nM corresponded to a 
maximum effective dose of less than or equal to 5mg glibenclamide. For oral 
administration, if the bioavailability is assumed to be 50%, then the maximum oral 
dose would be less than or equal to 10 mg. The bioavailability of the US 
formulation used in this study is incomplete, probably greater than 50%. 
Under euglycaemic conditions, plasma glibenclamide had to be raised from 100 nM 
to 800 nM to achieve the same insulin response that was achieved by 100 nM 
glibenclamide under hyperglycaemic conditions. This was an experimental study in 
healthy subjects which may be difficult to extrapolate to chronic treatment in type 2 
DM patients. However, this study demonstrates that the maximum acute effect of 
glibenclamide is achieved at lower doses than previously thought, due to its narrow 
range of operation. 
Herman et al. (1994) assessed the antihyperglycaemic efficacy of glibenclamide (G) 
metformin (M) and their combination MG in 165 type 2 diabetic patients. Doses 
were titrated to a FBG of less than 6.7 mmoliL as the target. Success rates were 
higher on the MG low dose combination than on monotherapy. When M and G 
were combined FBG declined with increasing doses of M whereas G exerted most 
of its effect at low dose. This study lends weight to the effectiveness of low dose 
glibenclamide in the treatment of type 2 DM. 
Jaber et al. (1994) in their investigations with 2.5 mg of glibenclamide, found that, 
since the insulinotropic effect of glibenclamide was maintained during long-term 
therapy, exhaustion of the ~-cells or glibenclamide-induced desensitization does 
not occur. The authors conclude that these findings support the initiation of 
glibenclamide at the lowest possible dose. 
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In contrast, in a study by Peters et al. (1996) markedly symptomatic patients under 
65 years of age were given 10 mg glibenclamide twice daily with a good clinical 
response. Their mean blood glucose levels fell from 25.4 to 11.2 mmolll after one 
week of treatment while HbAle dropped from 18.1 to 8.1 % after 4 months of 
therapy. It is suggested that the reason for this high dose in these severely 
hyperglycaemic patients might be due to the blunted absorption caused by 
pronounced hyperglycaemia. 
Rydberg et al. (1997) in their study of the kinetic-dynamic relations after a single 
dose of glibenclamide in healthy volunteers, derived a parameter that represented 
the steady-state drug concentration associated with 50% maximal hypoglycaemic 
effect (CEss50). The derived CEss50 for glibenclamide was 108 Ilg (0.108 mg). 
Rydberg et al. (1997) defined a minimum effective glibenclamide metabolite level 
at 30-50 ng/ml. They also found a significant decrease in glucose levels down to the 
6 ng/ml level for patients given 1.25 mg of glibenclamide. These data suggest that 
glibenclamide and its metabolites are active at low concentrations. 
Jonsson et al. (2001) in their study of glibenclamide in type 2 DM patients, found 
that during chronic therapy, the glibenclamide-stimulated release of insulin and 
proinsulin was more pronounced in patients on a low dose (less than 7.0 mg) than 
those on high dose (10.5 mg or more). They suggested that this was due to less 
impaired ~-cells in those receiving low doses, or a reduced SU sensitivity (down-
regulation) in those on high dosage. 
To date, the package insert for DiaBeta® (glyburide USP, February 2003) states that 
the usual maintenance dose is in the range 1.25 to 20 mg daily. The maximum dose, 
it cautions, should not exceed 20 mg. The package insert for Daonil® 
(glibenclamide) limits the maximum daily dose to 15 mg. 
The preceeding review of the literature illustrates the contrasting views of 
researchers and the clinical application of glibenclamide dosage. It is this 
discrepancy which forms the basis of this study. 
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Patients and Methods 
1 Clinical study methods 
1 .1 Patients 
This study was conducted at the Diabetes Unit at Addington Hospital, a tertiary referral 
diabetes clinic situated in eThekwinilDurban, KwaZulu-Natal, South Africa. With the advent 
of democracy in 1994 and the abolition of segregated health care facilities, this predominantly 
white clinic began to mimick the demographics of the region in racial composition. Hence, it 
was chosen as a study site. In addition, the clinic has a captive diabetic population. For this 
dissertation the terminology to describe ethnicity is both colloquail and based on the censors 
document (2002) where individuals catergorised themselves as black referring to South 
Africans of African origin, coloured referring to those of mixed ethnicity, Indians referring to 
those of Indian origin and whites referring to Caucasians (www.info.gov.za/yearbookl2004). 
1.2 Study design and study procedure 
In this prospective, within subject, dose-escalation, pharmacokinetic-pharmacodynamic study, 
a minimum of twenty patients was needed to ensure a sample size that would result in an 
accurate representation of the pharmacokinetic-pharmacodynamic parameters of the study 
population. From the diabetic population attending the outpatients clinic, 33 after being 
briefed on the study, voluntarily consented to participate. All participants signed a consent 
(Appendix 2) and indemnity form (Appendix 3). Subjects were selected and withdrawn on the 
basis of the criteria listed below. A zero-dose study was performed for each patient. 
Inclusion criteria 
• Entry level: >20 years of age 
• Fasting blood glucose level: > 9 mmollL 
• Signed informed consent 
Exclusion Criteria 
• Patients on insulin therapy. 
• Allergy to sulpha drugs. 
• Any contra-indications to multiple blood sampling e.g., poor venous access 
Withdrawal Criteria 
• Withdrawal of consent. 
• Intolerance to glibenclamide e.g., allergy to sulphonamides during study 
• Blood glucose level less than 3.5 mmollL or signs and symptoms of hypoglycaemia 
during dosage escalation 
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Study Procedure 
This study comprised 6 components: 
• VO baseline determinations 
• VI zero-dose 
• V2 2S00*llg glibenclamide 
• V3 SOOOllg glibenclamide 
• V4 10000llg glibenclamide 
• VS 20000llg glibenclamide 
*Glibenclarnide doses are expressed in rug or Ilg 
Visit O/Day O. Enrolment and washout period (V 0) 
Baseline biochemistry including lipid profile, FBG, fructosamine, insulin levels, HbAle, full 
blood count (FBC), urea and electrolytes (UE) and liver function tests (LFTs) were 
performed. All oral hypoglycaemic drug therapy was stopped for 14 days viz. the two-week 
washout period between Vo and V I. 
Visit 1/Day 14 (VI) 
This zero dose study was necessary to profile insulin and glucose in the absence of 
glibenclamide. A standardised breakfast to be consumed over a period of 10 minutes was 
administered. Blood samples (S mls) were taken to measure the blood glucose and insulin 
response to this meal at 30 minute intervals for up to 120 minutes post-breakfast. A 
standardised lunch was administered four hours post-breakfast and blood samples were taken 
to measure the glucose and insulin response at 30 minute intervals for up to 120 minutes. No 
drug was administered during this part of the study. 
After this zero-dose phase, the subject began the dose escalation component of the study. The 
starting dose of glibenclamide was 2.S mg daily for 14 days (commencing on day IS) with 
escalating doses of S mg; 10 mg and 20mg per day at 14 day intervals thereafter. 
Visit 2/Day 28 (V2) 
On day 28 the subject presented to the Clinic at 7 am after an overnight fast and without 
having taken glibenclamide. Blood (S ml) was drawn for FBG, insulin and fructosamine 
determinations. Glibenclamide 2.Smg was administered with 240 mL of water. This was 
followed 10 minutes later with a standardised breakfast, to be consumed over 10 minutes. 
Blood samples (Smls) were taken at the same time intervals as for the zero-dose phase, for 
insulin, glucose and glibenc1amide measurements. 
Four hours post-dose, a standardised lunch was administered and consumed over 10 minutes 
and blood sampling was repeated as for the post-breakfast phase. Thereafter the dose of 
glibenclamide was increased to S mg before breakfast to be commenced the following day 
(Day 29) for the next 14 days. 
119 
Visits 3, 4 and 5 (V3, V4, Vs respectively) 
The procedure for visit 2 was repeated with subsequent escalation of glibenclamide doses as 
indicted below: 
Days 29-42: 5 mg/day (V3) with repeat ofPKlPD procedures as performed on day 28. 
Days 43-56:10 mg/day (V4) with repeat ofPKlPD procedures as performed on day 42. 
Days 57-70 dose 20 mg/day (Vs) with repeat ofPKlPD procedures as performed day on 56. 
In summary, blood sampling times were: 0, 30, 60, 90, 120 minutes (post-breakfast sampling) 
and 240, 270, 300, 330, 360 and 420 minutes (post-lunch sampling) on days 14, 28, 42, 56 
and 70 for doses 0, 2.5, 5.0,10 and 20 mg, respectively. A synopsis of the dose-dependent 
study is presented in table 28 and figure 7. 
On completion of study all subjects were re-introduced into the pool of patients attending 
Addington Diabetes clinic for further follow up and continued treatment. 
NB: Glibenclamide doses are represented in /lg units for purposes of analysis and 
calculations. 
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Table 28: Synopsis of study procedures 
Visitooe Visit two Visit tbree Visit foor Visit five 
(V,) (V2) (VJ ) (V,) (V,) 
Zero (O)-phase Dose of Dose of Dose ofGlibenclamide= Dose of 
Glibenclamide= Glibenclamide= 10oo0",g Glibenclamide= 
Dose ofGlibenclamide= 0 25OO",g 5OOO",g 20000pg 
Drug therapy stopped for previous 2 Overnight fast Repeat method as for Repeat method as for Repeat method as 
weeks (washout period) visit two but with visit three but with for visit three but 
5000pg of IOOOOpg of with 20000pg of 
glibenclamide glibenclamide glibenclamide 
Baseline measurements for lipids, Bloods for FBG, Bloods for FBG, Bloods for FBG, insulin Bloods for FBG, 
FBG', fructosamine, insulin, LFT2, insulin and insulin and and fructosamine insulin and 
Haematology, HbAI/ fructosamine fructosamine fructosamine 
Administration of standardised Administration of drug Administration of drug Administration of drug Administration of 
breakfast 
Administration of Administration of Administration of 
drug 
standard ised breakfast standardised breakfast standard ised breakfast Administartion of 
standardised 
breakfast 
Blood sampling for insulin and Blood sampling for Blood sampling for Blood sampling for Blood sampling 
glucose at 30 minute intervals for 2 insulin, glucose and insulin, glucose and insulin, glucose and for insul in, 
hours glibenclamide at 30 glibencIamide at 30 glibenclamide at 30 glucose and 
minute intervals for 2 minute intervals for 2 minute intervals for 2 glibenclamide at 
hours hours hours 30 minute 
intervals for 2 
hours 
Administration of standardized Administration of Admin of standardized Administartion of Administration of 
lunch standard ized lunch lunch standardized lunch standardized 
lunch 
Blood sampling for insulin and Blood sampling for Blood sampling for Blood sampling for Blood sampling 
glucose at 30 minute intervals for 2 insulin, glucose and insulin, glucose and insulin, glucose and for insul in, 
hours glibenclamide at 30 glibencIamide at 30 glibenclamide at 30 glucose and 
minute intervals for 2 minute intervals for 2 minute intervals for 2 glibencIamide at 
hours hours hours 30 minute 
intervals for 2 
hours 
Subjects leave clinic with 2 week Subjects leave clinic Subjects leave clinic Subject leave clinic with Subjects 
supply of 2500",g of glibenc1amide with 2 week supply of with 2 week supply of 2 week supply of reincorporated 
5000pg of IOOOOpgof 20000pgof into Diabetes Unit 
gJibenclamide glibenc1amide glibenc1amide and treated 
accordingly 
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SCREENING AND BASELINE MEASUREMENTS 
WASHOUT PERIOD 
VISIT 1 (Zero phase study) 
l 
VISIT 2 (2500,ug of gUbenclaOIide) 
l 
VISIT 3 (5000,ug of gUbenclaOIide) 
VISIT 4 (lOOOO,ug of gUbenclamide) 
VISIT 5 (20000,ug of gUbenclaOIide) 
1 
SUBJECTS REINTERGRA TED INTO DIABETES CLINIC 
*NB: 2 week interval between visits 
Figure 5: Flow diagram of study* 
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Procedural and subject safety considerations 
• Subjects were trained to perform daily pre-dose home glucose monitoring using the 
Haemoglucotest® strips by Roche® diagnostics, and record this in a diary. 
• The 20 mg dose was administered as 10 mg in the morning and 10mg in the evening, 
10 minutes before meals during the 14 day period between visits. 
• Concomitant medication was continued throughout the study period and were itemized 
for each subj ect 
• Post-meal blood sampling occurred at consistent times for all study subjects. 
• All subjects were provided with 24 hour contact telephone numbers of the researcher 
as well as that of the clinician in charge of the Diabetes Unit. 
Compliance 
Compliance was assessed by pill counts, examination of diary entries and subject interview. 
Subjects were contacted telephonically to reinforce compliance and check on progress. 
Diet 
All subjects were counselled on appropriate diet by the dietician assigned to the Addington 
Diabetes Unit. Subjects were requested to record and report any major changes in dietary or 
exercise patterns during the study period. 
During the study a standardised breakfast and standardised lunch was provided. The 
composition of each is presented below: 
Standardised breakfast 
2 Wheat biscuits (37.5 g Bokomo Weetbix®) 
200 mls of 2% low fat milk 
250 mls tea fcoffee with/without 50 mls of 2% low fat milk 
Standardised Lunch 
2 slices brown bread with 18 g sweetmilk cheese (Melrose®) per slice with fresh lettuce 
250 mls tea fcoffee with/without 50 mls of2% low fat milk 
Drugs 
Glibenclamide 5 mg tablets - Glycomin ® (Lennon Meds) 
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1.3 Ethics and confidentiality 
Approval to conduct this study was obtained from the Ethics committee of the University of 
Durban-Westville. Permission to conduct this study was obtained from the Secretary for 
Health, KwaZulu-Natal Provincial Administration (Appendix 4). 
The rights of subjects were honoured and all subject information was treated with the strictest 
degree of confidentiality. Subjects were identified by their initials only for record purposes. 
Refusal or withdrawal from the study did not jeopardize the management of the patient. At the 
end of the study all subjects were incorporated into the patient population of the Diabetic Unit 
for continued management. 
All participants were briefed about the study in English or Zulu. They were given the 
opportunity to ask questions prior to signing consent forms 
2 Bioanalytics 
2.1 Glycated Haemoglobin 
In vitro tests for the evaluation of glycaemic control over a 90-120 day period is made 
possible by measuring glycated haemoglobin, a stable minor haemoglobin (HbAle). It 
correlates well with blood glucose concentration over this period and hence is used as an 
objective mesasure of glycaemic control. All HbAle measurements were performed at the 
Chemical Pathology Laboratory at Addington Hospital using the Cob as Integra method 
(Roche Diagnostics). Glycated haemoglobin was performed only on entry to determine patient 
suitability for entry into the study. It was not used as a measure of glycaemic control and 
therefore not performed at the end of the 70 day study period. 
Normal range: HbAle forms approximately 4-6% of total haemoglobin with a lifespan 
mirroring that of red blood cells (90-120 days). 
2.2 Fructosamine 
Glycated serum proteins have a shorter half life (19 days) than glycated haemoglobin and 
therefore provide a measure of short term glycaemic control. Fructosamine was measured in 
this study because dose adjustments were made every 14 days. Fructosamine is l-amino-
deoxyfructose. It was assayed at the Chemical Pathology Laboratory at Addington Hospital. 
Normal range: 5-285 /-lmollL. A change in fructosamine level can be used as a short term 
measure of glycaemic control. 
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2.3 Glibenclamide assay 
After blood samples were collected, they were left to stand for 1 hour prior to centrifugation 
for 10 minutes at 5000 rpm. They were stored temporarily in an ice-box in a fridge for the 
duration of the specific study (approximately 10 hours) and then stored at -80°C until 
transportation by airfreight for assay at the Department of Pharmacology, University of Cape 
Town. 
Glibenclamide was determined using a rapid high-performance liquid chromatography 
(HPLC). The assay is based on the procedure of Hamid et al. (1989). The process is described 
briefly. The serum samples were treated with acetonitrile to precipitate proteins. Flufenamic 
acid was added as an internal standard. After centrifugation, separation and reconstitution, the 
residue was dissolved and eluted from 51lm Spherisorb C-8 reverse phase column at ambient 
temperature. The mobile phase consisted of acetonitrile:water (45:55 v/v) at pH 3.7-3.8 and 
pumped at a flow rate of 2 mllmin. The effluent was monitored at 230 nm. The analysis time 
did not exceed 12 min. A peak height ratio (glibenclamide/flufenamic acid) and concentration 
displayed a linear relationship in the range 20-400 ng/ml. A regression equation ofy=0.0035x 
+ 0.015 (r2=0.9999) was obtained for a typical calibration curve. The detection limit of 
glibenclamide in serum was 20 ng/ml and the mean recovery of drug from serum samples 
spiked with known amounts of glibenclamide was 96.77%. Coefficients of variation ranged 
from 1.6-4.0% (within-day) and 1.4-3.5% (between-day). 
2.4 Glucose determination 
The finger prick sampling for blood glucose evaluation was used. Blood glucose was 
measured with an Accutrend Alpha® glucometer. The glucometer was calibrated according to 
manufacturer's guidelines and the accuracy of the measure of blood glucose was evaluated by 
the Pathology Laboratory at Addington Hospital. The finger prick method was used because 
any deleterious decrease in blood glucose levels would be detected early and remedial 
measures instituted. With laboratory blood glucose assays there was a delay of approximately 
2 hours. The accuracy of the Accutrend Alpha® glucose test was confirmed daily against the 
standard procedure used by the hospital laboratory. 
2.5 Insulin assay 
Insulin was quantitatively determined in serum at the Chemical Pathology Laboratory of the 
King Edward VIn Hospital, eThekwini. Serum insulin concentrations were measured with 
radio-immuno-assay (Pharmacia & Upjohn, Uppsala, Sweden). 
The radioimmunoassay was based on a double antibody solid phase technique. The insulin 
sample was allowed to compete with a fixed amount of an 1251 labelled insulin for the binding 
sites on highly specific antibodies. The concentration of insulin was then determined by 
comparing its competitive capacity to that of insulin standards of known concentration. 
A summary of the procedure as per the manual is described. Serum samples, Insulin 1251 
solution and anti-insulin solution were incubated at room temperature. A double antibody 
suspension was added to separate bound and free insulin, followed by incubation at room 
temperature, centrifugation and decanting. The resulting solid phase pellet was then measured 
for radioactivity in a gamma counter. The amount of bound radioactivity is inversely 
proportional to the amount of insulin in the sample. 
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2.6 Biochemical and other tests 
Liver function tests (LFT), urea and elecytrolytes and lipograms were performed at the 
Chemical Pathology Laboratory at Addington Hospital. 
Liver function tests and urea and electrolytes assays were performed on a Synchron CX3 
instrument using the Beckman kits and the lipograms were performed on the Synchron 
CX4/SI7 /9 using Beckman kits. 
3 Statistical methodologies 
3.1 Data Collection and management 
All data were recorded on a data capture form and then subsequently captured onto a 
spreadsheet. All data collected and computed during the course of this study was captured on 
Microsoft Excel® 2000 for Windows® 98. Entries on the spread sheet were checked for 
accuracy of data capture. 
3.2 Descriptive statistics and statistical comparisons 
SPSS® for Windows® was used for computation of descriptive statistics and statistical 
analyses. 
Area under the curve (AVC) and Cmax data were log transformed to obtain normally 
distributed data. The transformed end points were then compared across groups, using 
ANOY A for a cross over design accounting for sequence of treatment subject (within a 
treatment sequence visit period and treatment). 
Statistical tests used in this analysis included analysis of variance (ANaYA), independent 
samples t-test and Pearson correlation. Statistical significance was assumed at the p<O.OS 
level. 
3.2.1 Evaluation of clinical benefit due to glibenclamide 
Both FBG and PPG determinations were used to evaluate glycaemic control. FBG at time 
zero for all dose levels was recorded, PPG was determined as the maximum glucose 
concentration between the time windows 1.8 to 2.S h (for the post breakfast PPG) and S.S to 
6.S h (for the post lunch PPG). These values were compared against the SEMDSA criteria for 
optimal and acceptable blood glucose concentrations. 
126 
3.2.2 Measures of insulin resistance 
Indices of insulin sensitivity/resistance derived from fasting glucose and insulin 
concentrations reflect hepatic insulin sensitivity and basal hepatic glucose production. 
The formula for HOMA and QUICKI are: 
RHOMA= Fasting Glucose*Fasting Insulin /22.5 
and, QUICKI is: 1/[log fasting insulin + log fasting glucose] 
When glucose is measured in mmoVL, the factor 22.5 is used and 405 when glucose is 
measured in mg/dl. HOMA is an index of insulin resistance (RHOMA) which is the inverse of 
the corresponding index of sensitivity (SHOMA) i.e., (RHOMA=1/ SHOMA). HOMA and QUICKI 
are related by the following equation: 
QUICKI= 1/[log(HOMA) + log(22.5)] 
The insulinogenic index is calculated as the ratio of the increment of insulin to that of blood 
glucose 30 min after glucose load and it provides a parameter of insulin response (Del Prato et 
aI., 2002). 
II = A Insulin (30-0 min) 
___ A Glucose (30-0 min) 
= [30 min insulin level- fasting insulin level (JlUlml)] 
[30 min blood glucose - fasting blood glucose (mg/dL)] 
Del Prato et al. (2002) 
A modified II was used in this study, where the AUCO-30min insulin and AUC 0-30min glucose 
(after breakfast) were used in place of the change in blood insulin and blood glucose between 
o and 30 minutes. This modified method (which requires confirmation and validation) was 
used because a precise 30 minute insulin glucose measurement was not always possible. In 
addition the standardised breakfast served in place of the glucose load. Therefore the modified 
II formula is: 
AUCO-30min insulin btU/mL] 
II' 
AUC 0-30min glucose [mmol/L] 
In this dissertation the term II' will be used to represent the modified insulinogenic index as 
calculated above, unless otherwise indicated. 
This is a modified II, because it is a measure of the change in insulin from 0 to 30 min divided 
by the change in glucose from 0-30 min after a standardised meal. All subjects received the 
same meals and all subjects are there own controls and therefore this modified II can be used 
as a measure of insulin response. 
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3.3 Pharmacokinetic and pharmacodynamic methods 
Glibenclamide concentration versus time data was analysed using non-compartmental 
methods as well as compartmental methods. 
The non-compartmental analysis (NCA) was performed using WinNonlin® Professional 
Version 4.01, 2002 (Pharsight Corporation, California, USA). The computed PK measures 
and their definitions are listed in Table 29. 
Table 29 Non-compartmental pharmacokinetic measures and their definitions 
Abbreviation Definition 
AUCINF AUC from the time of dosing extrapolated to infinity 
AUClast 
Area under the curve from the time of dosing to the last measurable 
concentration 
Cl/f 
Total body clearance for extravascular administration =Dosel AUCINF 
Clast Concentration corre~ondil!& to Tlast. 
Cmax Maximum observed concentration, occurring at Tmax. 
t-half Terminal half-life 
Tlast Time of last measurable (non-zero) concentration. 
Tmax Time of maximum observed concentration 
Vz/f Volume of distribution based on the terminal phase 
Area under the curve (AUC) was calculated using the linear trapezoidal rule. In view of the 
short sampling period (approximately 8 hours), any non-zero pre-dose sample was substituted 
as the final 24-hour sample. During graphical exploration of the data, multiple peaks were 
noted. In view of this, data points for calculation of the terminal slope were manually selected 
rather than using the default WinNonlin algorithm. 
Pharmacokinetic and pharmacodynamic (PKPD) analyses and modeling were performed 
using nonlinear mixed effects modelling as implemented in the software NONMEM 
(Globomax LLC, USA and NONMEM Project Group, University of California, San 
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Results and Discussion 
1 Demographics 
1.1 Introduction 
Patients attending the Diabetes Unit at Addington Hospital are mainly African, Coloured and 
Indian in the age group characteristic of type 2 dabetics. 
1.2 Results 
Thirty three patients between 39 and 73 years of age, who met the inclusion criteria were 
screened prior to participation in this study. Of these, 24 consented to participate in this study. 
The remaining 9 comprised of 2 who declined entry into the study, 5 who did not return for 
baseline measurements after being screened and 2 who presented histories indicative of poor 
compliance. 
Two subjects did not complete all the dose escalation steps. Subject 16 could not proceed to a 
dose escalation beyond 5 mg/day due to the presence of symptoms of hypoglycaemia and 
subject 24 was lost to follow up after the 2.5 mg dose of glibenclamide. Data from these 2 
subjects was excluded from the non-compartmental analyses. There were no further 
withdrawals and no adverse effects were reported. 
All 22 subjects who completed the full dose escalation steps were thereafter incorporated into 
the regular pool of diabetic patients attending the Diabetes Unit. The study population 
described above is represented in Table 30, Table 31 and in Figure 6 below. 
Table 30 Patients screened and enrolled into the study 
Male Female Total 
Screened 4 29 33 
Emolled 2 22 24 
Lost to follow up 1 0 1 
Withdrawal 0 1 1 
Completed all dose 













1 absconded after zero dose 
1 withdrawn after 5mg dose 
due to hypoglycaemia 
symptoms 












Males (n 2) 


















Duration of DM 
(years) 
Mean Duration of 
DM (±SD) years 
Demographic profile of study population (n22) and cohort 
characteristics at entry into the study 
Mean ±SD Minimum 
54.1 9.2 39 
71.1 14.1 42.0 
156.4 8.6 145.0 
26.48 5.64 22.49 
29.93 6.71 19.05 
15.39 3.83 9.90 
13.92 6.87 3.0 
12.18 3.83 8.1 
466.86 92.49 310.0 
5.8 1.2 4.0 
3.9 0.95 2.2 
1.1 0.26 0.8 
1.6 0.89 0.5 
25 12.6 10.0 
64.1 10.4 48.0 
African 6 (27.3%) Coloured 2 (9.1%) Indian 14 (63.6%) 





















The demographics of the study popUlation is shown in Table 31. The age range of the final 
study cohort was 39-73 years with a mean (± SD) of 54.1 (± 9.2) years, with the majority (20) 
being female. The race distribution was African 27.3 % (n = 6), Coloured 9.1 % (n = 2) and 
Indian 63.6% (n = 14). The average duration of diabetes in this population was 8.95 (±1.45) 
years. 
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The mean (±SD) mass and HbAle of the study population were 71 (±14.1) kg and 15.39 
(±3.83) %, respectively. Based on body mass index, 30 % of subjects were of normal weight, 
21 % were overweight and 49% were obese. The mean baseline (±SD) serum creatinine was 
64.1 (±10) /!mollL. The total cholesterol, triglycerides, low density lipoproteins, high density 
lipoproteins was 5.8 (±1.2), 1.6 (±0.89), 3.9 (±.95) and 1.1 (±0.26) mmollL, respectively. The 
mean baseline (±SD) ALT was 25 (±12.6) U/L and the mean baseline glucose (±SD) on entry 
was 15.39 (±3.8) mmollL. The mean baseline insulin (±SD) was 13.92 (±6.87) /!UJmL. 
Concomitant disease distribution 
Hypertension was present in 50% of the subjects in the study. Of these, 3 subjects had 
concomitant angina. All other concomitant diseases are outlined in Table 32 below. 
Table 32 Concomitant diseases in subjects included in the study 
Disease Number 
Hypertension 8 
Hypertension with angina 3 
Postmenopausal syndrome (PMS) 2 
Rhinitis 1 
H yperlipidaemia 1 





The following medications as outlined in Table 33 were used concurrently by the subjects 
during the study period. 
Table 33 Concomitant medications used by subjects in this study 
Medication Number 
Aspirin 3 
Isosorbide dinitrate 3 
Indapamide 4 
Diltiazem 1 




Calcium gluconate 2 
Conjugated oestrogen 2 











Dic10fenac injection 1 
Thyroxine 1 
Captopril 1 
Hydrochlorthiazide was used by 5 subjects (alone or in combination with other therapy) in 
doses ranging between 12.5 and 25 mg per day. Non-steroidal anti-inflammatory drugs 
(NSAID's) were used in 7 subjects and one subject was on a lipid lowering drug, fluvastatin. 
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1.3 Discussion 
This prospective dose escalation study was conducted in type 2 diabetic subjects. Each 
subject in the study received the whole spectrum of doses. This within subject dose escalation 
design has the advantage over a parallel study design in that each subject is characterized at 
each dose level. In parallel design studies average dose responses are used to characterize 
individual subjects. Therefore parallel study designs do not account for intraindividual 
differences in dose responses leading to extreme variation in doses. 
The endpoints in this study were FBG, FBI, PPG, PPI, serial glucose and insulin 
evaluations. Serial insulin and glucose evaluations were performed to obtain a fuller picture of 
variations and exposure throughout the study period i.e., 8 hours. Ideally, characterization of 
these variations should be evaluated over a 24 hour period. Additionally, earlier and more 
frequent sampling for insulin and glucose would have allowed measurements of acute insulin 
response (AIR). It is recommended that future studies should include this in the study design. 
Fructosamine is a measure of glycaemic control in the preceeding 2 weeks and thus served as 
a measure of glycaemic control with each dose during the two week dosing interval. 
Therefore, fructosamine serves as a useful barometer when changes need to be considered 
over a short term i.e., 2-3 weeks. In the case of HbA1c, which is the gold standard of 
glycaemic control, a duration of2-3 months is needed. 
FBG and PPG are relevant measures not only for the study but because they are both 
appropriate and clinically relevant measures in the management of diabetic patients. 
Blood insulin measurements, although expensive, are useful in determining the insulin 
resistance status of the study population. Insulin resistance dictates and guides the rational 
pharmacological treatment of diabetes mellitus. It may thus be prudent to include insulin 
measurements in selected patients to guide pharmacotherapy. 
Blood sampling was adequate to profile changes in blood glucose, blood insulin and blood 
glibenclamide concentrations, simultaneously. The sampling process was adequate to describe 
both fasting and postprandial glucose and insulin profiles. However, the terminal phase of 
glibenclamide elimination was largely estimated because an inadequate number of samples 
were taken in the terminal phase. A 24 hour sample may have overcome this limitation. This 
was not possible as subjects saw this as an inconvenience. 
Type 2 diabetes mellitus is one of the most common chronic diseases in the world, affecting 
12% of the adult popUlation aged 40-74 years in the United States of America (ADA, 2003). 
The prevalence of type 2 DM in South Africans rises sharply from age 35-40 years and 
incre~ses with advancing age, with a 3-fold prevalence by age 60 years (Motala et aI., 2001). 
In thIS study the ages ranged from 39-73 years, which correlates with both national and 
international studies and shows that type 2 diabetes is mainly a disease of the older patient. 
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Courtois et al. (1999) investigated the effect of age on the pharmacokinetics of glibenclamide 
and concluded that age does not affect the pharmacokinetics of glibenclamide after a single 5 
mg dose. Therefore it may be concluded that population age in this study is not a contributory 
factor for pharmacokinetic variation. 
The sample population (who completed the dose escalation study) comprised of 91 % (n20) 
females and 9 % (n = 2) males. Mayet (2003), Robertson (1998) and Omar et al. (1988) in 
their studies of diabetes in South African type 2 diabetics, reported that females comprised 
approximately 76 % of their study populations. As with both local and international studies, 
females formed the majority (91 %) of the final study cohort in this trial. 
This study cohort comprised 27% African (n6), 9% Coloured (n2) and 64% South Africans 
of Indian origin (nI4) patients. In South Africa, it is estimated that 5-8% of Africans, 8-10 % 
of Coloureds, 13-18% of South Africans of Indian origin and 3.5-4% of whites are diabetic 
(Naicker, 2002; Trutter 1998). The high incidence of diabetes in South Africans of Indian 
descent has been reported by Motala et al. (2003). In the past few years there has been an 
increase in the reporting of type 2 DM in Africans due mainly to urbanisation, increasing 
obesity, and the removal of restrictive apartheid legislation thus allowing African patients the 
freedom to be treated at previously whites-only state hospitals. The high incidence of type 2 
DM in Asians has been well documented by Omar et al. (1988). However, this study 
population is not truly representative of South African demographics, but closely mirrors the 
incidence of type 2 DM in the greater eThekwinilDurban area which has the largest 
popUlation of Indians in South Africa. 
The mean duration of diabetes (±SD) in this population was 8.95 (± 4.5) years. This is a 
referral diabetes clinic and therefore de novo diabetics are not likely to present. Most patients 
attending this clinic are established diabetics who require specialized care in the management 
of their diabetes. 
According to studies of BMI in South African type 2 diabetics, Kalk (2001) found that 45 % 
of females and 15 % of males had BMIs greater than 30 kglm2, and 44 % of males and 70 % 
of females had BMIs between 25 and 29 kglm2 respectively. Based on these findings, 
approximately 70% of this study population were overweight and 50% obese. 
Reaven (1998) estimated that approximately 80% of type 2 diabetic patients are obese. In the 
study by Jaber et al. (1994) comparing the pharmacokinetics and pharmacodynamics of short 
and long term glibenclamide therapy in type 2 diabetes (NIDDM) , the mean BMI of the 
sample popUlation was 31.5 ± 9.2 kg/m2, similar to this study popUlation (29.1 ± 6.0 kg/m2). 
These findings compare favourably with studies by Motala et al. (2001) and are thus a 
reasonable reflection of the diabetic population in terms of body mass. With increasing BMI, 
adiposity and age, insulin resistance-related metabolic syndrome increases (Ford et aI., 2002). 
The mean BMI of this study cohort strongly suggests a tendency for patients to present with 
insulin resistance and has been confirmed by measuring this insulin resistance using the 
HOMA and QUICKI techniques. 
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Concomitant disease: hypertension is approximately twice as common in diabetic patients as 
in the non-diabetic population. Hypertension was present in 50% (n = 11) of the sample 
population while angina was present in 3 of these hypertensive patients. The high incidence of 
hypertension as reported by the ADA (1999b) [between 30 and 60 %], is reflected by this 
study sample. Mayet (2003) in her study of type 2 diabetic patients found that 42 % of type 2 
diabetic patients were hypertensive. Hypertension in combination with dyslipidaemia, and 
obesity has been labelled the 'Metabolic syndrome' or 'Syndrome X', a cluster of clinical 
conditions due to insulin resistance. Each of these conditions conveys significant 
cardiovascular risk which becomes substantial when present as such a cluster. This study 
population is characterised by the whole spectrum of insulin resistance viz., hypertension, 
dyslipidaemia and obesity, all of which are the metabolic abnormalities associated with type 2 
diabetes. 
Concomitant medications were used concurrently by the patients throughout the study 
period. Of these, 8 have been documented to affect blood glucose levels. 
Non-steroidal anti inflammatory drugs (NSAID's) were used in 7 subjects. Only one subject 
was on a lipid lowering drug, fluvastatin, probably due to the fact that the prescription of 
statins is restricted to patients attending the Ischaemic Heart Disease (IHD) clinic at this study 
site (Addington Hospital). 
The following diuretics were used by the study population: triamterene 50 mg in combination 
with hydrochlorthiazide 25 mg (Dyazide®), hydrochlorthiazide 25 mg and indapamide 2.5 
mg. Hydrochlorthiazide was used alone, or in combination, in 5 subjects in doses ranging 
between 12.5 and 25 mg per day. Thiazide diuretics have been implicated in inducing glucose 
intolerance in diabetic patients with an incidence of up to 30 %. High doses (greater than 12.5 
mg) are more likely to induce hypokalaemia which has been implicated in decreasing insulin 
secretion and thereby aggravating the glucose intolerance (Pandit et aI., 1993; Luna and 
Feinglos, 2001). These diuretics are one of the cheapest group of drugs used in the 
management of hypertension and it is recommended as first line antihypertensive therapy in 
the African patient (JNC 6, 1997). However, half or quarter of the dose would be more 
beneficial because, while the antihypertensive effect can be maintained, there would be a 
decrease in metabolic side-effects (glucose intolerance and hyperlipidaemia) [McNeil and 
Sloman, 1987] 
Although indapamide has been reported to be less likely to induce glucose intolerance, recent 
reports have suggested that this may not be the case. The substitution of indapamide for 
thiazides (for the reasons stated above), may not be totally safe as there are reports of 
metabolic side-effects due to indapamide (Osei et aI., 1986). 
Atenolol, a beta blocker, may inhibit insulin release leading to glucose intolerance. However, 
marked hyperglycaemia is not common with beta blockers, although they may inhibit 
glycogenolysis and cause hypoglycaemia. Added to these conflicting effects, ~-blockers mask 
the symptoms of hypo glycaemia, in particular, tachycardia (Pandit et aI., 1993). 
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The calcium channel blockers (isradipine, amlodipine, diltiazem) generally do not produce 
severe hyperglycaemia, although the potential does exist (Pandit et aI., 1993). These drugs 
were used for the treatment of concomitant diseases such as hypertension and ischaemic heart 
disease (lliD) in this study cohort. 
Angiotensin converting enzyme (ACE) inhibitors (captopril, perindopril), individually and as 
a group, have neutral effect on blood glucose in diabetic patients (Pandit et aI., 1993). ACE 
inhibitors are preferred in diabetic patients because of their beneficial effect on renal function 
and the cardiovascular system (O'Brien and Bulpitt, 1997). 
Low dose aspirin, as used by subjects in this study, rarely produces hypo glycaemia. 
Salicylates in daily doses of 4-6 grams are potent inducers of hypoglycaemia (Pandit et aI., 
1993). 
In animal studies, indomethacin and ibuprofen did not significantly affect glibenclamide 
induced hypo glycaemia (Sharma et aI., 1981). However, in some patients, these NSAIDs were 
co-administered with thiazide diuretics. This is a pharmacodynamic interaction, where the 
antihypertensive effect of thiazides can be blocked by NSAIDs due to the inhibition of 
vasodilatory prostaglandins (Brater, 1985). 
The effects of glucocorticoids on carbohydrate metabolism in susceptable patients are dose 
related and are most often seen with the systemic use of these drugs (Pandit et aI., 1993). The 
use of low dose nasal beclomethasone is less likely to produce this effect because of its low 
systemic bioavailabilty. 
Thyroxine has been reported to increase blood glucose. It may be the result of depletion of 
insulin reserves and increase in hepatic glucose production (Pandit et aI., 1993). 
Calcium gluconate, carbimazole, benzbromarone, chlorpheniramine, nitrates, and lofepramine 
and imipramine, have neutral or no clinical effects on glucose profiles. There are no reports of 
fluvastatin affecting blood glucose. The role of lipid lowering drugs in a diabetic population 
has been discussed in the section on lipids above. 
The effect of sex hormones on carbohydrate metabolism remain complex and controversial. 
Natural oestrogens, like conjugated oestrogen (Premarin®), can improve glucose tolerance 
and insulin action. Oestrogen increases insulin binding in adipocytes, hepatocytes and other 
plasma membranes (Pandit et aI., 1993). 
Type 2 diabetes is associated with a cluster of conditions viz., hypertension, insulin resistance, 
obesity and dyslipidaemia. The pharmacotherapy of these co-morbid diseases in this study 
shows that each disease was treated independently and to the exclusion of diabetes. A number 
of the antihypertensive drugs use in this study population are known to affect blood glucose 
levels, however, the pharmacodynamic interactions of these drugs are not an absolute 
contraindication for use in DM patients. Fluctuations in blood glucose, although not ascribed 
to these drugs, are usually treated by adjustment of the dose of the OHAs. This practice may 
have contributed to the use of high doses of glibenclamide in type 2 diabetic patients in the 
KZN area. 
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HbA1c was measured at entry as an inclusion criterion and was not used as a measure of 
glycaemic control in this pharmacokinetic/pharmacodynamic study of glibenclamide. The 
mean HbAle (±SD) in this study population was 12.18 % (±3.83). This is appreciably higher 
than the recommended acceptable value of 7 % (ADA, 1999). High HbAle levels are a 
reflection of poor glycaemic control and has been shown to be a marker for microvascular 
complications and macrovascular complications which begin at HbAle of 5% (UKPDS 35, 
2000). The risk of complications increases for each percentage increase of HbAle (UKPDS 
35, 2000). A 0.9% reduction in HbAle significantly reduces long term complications (UKPDS 
33, 1998). The major studies (DCCT, UKPDS) target HbAle to less than 7%. However, this 
study population was poorly controlled as reflected by the high mean HbAle levels. 
Fructosamine levels are a measure of glucose control over a 2-3 week period, as opposed to 
HbAle, which is a measure of glycaemic control over a 2-3 month period. Fructosamine levels 
are potentially useful when changes in treatment plan need to be evaluated over a short term 
(2-3 week). Fructosamine levels indicate, in a more timely fashion than a HbAle, how well 
changes to a treatment plan are working and whether other changes should be considered. 
Fructosamine levels do not detect wide swings in blood glucose levels or reflect postprandial 
glucose excursions (Kennedy and Merimee, 1981). 
There was a statistically significant decrease (p = 0.01) in fructosamine levels as the dose of 
glibenclamide increased from 0 to 20000 )lg i.e., all doses reduced fructosamine (2.72% and 
9.36%) but only the 20000 )lg dose produced a significant reduction (p=0.01; 9.36%) when 
compared to 0 dose. 
In a comparative study of HbAle and fructosamine in the diagnosis of glucose tolerance 
abnormalities, Guillausseau et al. (1990) found that neither were suitable for diagnosis of mild 
abnormalities of glucose tolerance. Results of this study indicate a statistically significant 
decrease in fructosamine levels with increasing doses of glibenclamide. However, the 
decrease of fructosamine from zero dose ranged from 12.72 (2.72 %) to 43.67 (9.36%) 
)lmoI/L, which translates to a difference from 0.56 to 1.94 mmollL of glucose (Bartol, 2000). 
As the mean fasting blood glucose at entry was 15.39mmollL in this study cohort, the clinical 
impact of this change would be negligible. 
This study indicates that changes in fructosamine are not robust enough to replace daily 
monitoring of fasting and postprandial blood glucose for changes in dose adjustment and/or 
treatment plan. 
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Type 2 DM is associated with micro- and macrovascular diseases, hypertension, insulin 
resistance and dyslipidaemias, which are a part of the cluster of conditions of the metabolic 
syndrome. This study population presented with hypercholesterolaemia, 
hypertriglyceridaemia, high LDL and low HDL, all of which are risk factors for 
cardiovascular diseases. Macrovascular complications due to atherosclerosis are the major 
cause of mortality in diabetic patients (Taskinen, 1995). Despite the fairly high prevalence of 
hyperlipidaemia in this study cohort, only one subject was on lipid lowering therapy. This is 
due to the very high cost of lipid lowering drugs (statins in particular). In addition, 
prescription of these drugs is limited to patients attending the lliD clinic at this study site. 
While this practice may not be uniform in all state institutions, it does indicate a conservative 
approach to the management of a major co-morbid condition in type 2 diabetics at this 
hospital. 
In a recent study comparing the effectiveness of Humulin L ® and Monotard HM® on 
glycaemic control, ' the mean (± SD) cholesterol was 5.98 (±0.48) and 5.72 (±0.18), 
respectively (Mayet, 2003). The present study population, with a mean cholesterol of 
5.8mmoVI, was representative of the diabetic population as reported by Mayet. However, this 
value is higher than the recommended 5.2 mmoVL optimum by SEMDSA (2002) «5.2), and 
within the 'at risk' range (4.8-6.0 mmoVL) as reported by the European Diabetes Policy 
Group (1999). 
The mean HDL of 1.1 mmol/L for the study population was less than the acceptable range of 
>1.7 mmoVL (SEMDSA, 2002) but within the 'at risk' group of 1.0-1.2 mmoVL. (European 
Diabetes Policy Group, 1999). South African norms are less stringent than their European 
counterparts. In this study sample, only one subject was on lipid lowering therapy 
(fluvastatin). 
The mean fasting triglycerides (1.6 mmoVL) for the study population was above the optimal 
«1 mmoVL) but below the below the acceptable range of 1.7-2.2 mmoVL recommended by 
SEMDSA (2002) and the European Diabetes Policy Group (1999), respectively. Mayet (2003) 
in her study of type 2 diabetes, the mean (± SEM) triglycerides was 4.57 (±1.30) and 2.12 
(±0.18) respectively. Mayet's study population was obese (BMI 31.3) as compared to this 
study population, BMI of26.48 (males) and 29.93 (females). 
The mean LDL of 3.9 mmoVL was greater than the acceptable value of < 2.6 mmoVL (ADA 
and Canadian) but within the 'at risk' level of 3.0-4.0mmoVL (European Diabetes Policy 
Group, 1999). 
At entry all subjects fulfilled the inclusion criteria for normal hepatic and renal function . 
The mean ALT (± SD) was 25 (±12.6) U/L and was within the normal range of 10-60 U/L. 
The mean (± SD) creatinine clearance of the study population was 64.1 (± 10.4) ~moVL and 
was within the normal range of 46-98 IlmoVL. 
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Glibenclamide undergoes hepatic metabolism and renal and biliary excretion [Feldman, 
(1985); Ings et aI. , (1981); Matsuda et aI., (1983)]. Since all subjects in this study presented 
with normal hepatic and renal function at entry, it can be concluded that changes in 
pharmacokinetics and pharmacodynamics will not be due to dysfunction of these 
aforementioned organs. 
141 
2 Insulin Resistance and Acute Insulin Release 
2.1 Introduction 
Insulin resistance is a core metabolic defect in type 2 diabetics and its determination may help 
in identifying individuals at high risk of both diabetes and cardiovascular diseases. Insulin 
resistance is determined by HOMA-IR and QUICKI. 
The insulinogenic index (II) is a mesure of acute insulin response which is a primary defect in 
type 2 diabetics. 
2.2 Results 
The modified II (II') is calculated using change in mean AUC (insulin 0-30min) divided by change 
in mean AUC glucose 0-30min. These values are presented in Table 34 and 35 below. 
Table 34: Change in mean AUC (insulin 0-30min) (Acute Insulin Response-AIR) 
Glibenclamide (pg) Mean A UC L1 0-30 insulin ± SD 
(pUlmL.h) p-value 
0 9.1579 4.21533 
2500 12.5641 6.38248 0.043 
5000 14.9279 9.76992 0.348 
10000 12.0409 7.49357 0.278 
20000 13.2852 7.24603 0.579 
The change in mean AUC insulin 0-30min between dose 0 and 250011g was statistically significant 
(p=0.043). The change between all other doses was not significant (p= 0.348,0.278 and 0.579 
between doses 2500-500011g, 5000-1000011g and 10000-2000011g respectively). 
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Table 35: Change in mean AUC glucose 0-30min 
Glibenclamide Mean Ao-30 21ucose ±SD p-value 
(flg) (mmoIIL. b) 
0 8.1327 1.97371 
2500 6.9152 1.62823 0.031 
5000 6.9154 1.82522 1.00 
10000 5.8799 2.08042 0.087 
20000 6.0773 2.08932 0.755 
The change in mean AVC glucose 0-30min between dose 0 and 2500 was statistically significant 
(p=0.031). The change between all other doses was not significant (p = 1.00,0.087 and 0.755 
between doses 2500-5000, 5000-10000 and 10000-20000 respectively). These AVC's were 
used to calculate the modified insulinogenic index (II'). 
The response of measures of insulin resistance (Modified Insulinogenic Index, HOMA-IR and 
QUICKl) to increasing doses of glibenclamide are presented in table 36 and graphical 
representations in figures 7,8,9 and 10 below. 
Table 36: Indices of insulin sensitivity and insulin resistance 
Dose II' HOMA-IR QUICK! 
SD SD 
0 \,24 0.73 3.17 \,44 
2500 \.98 \,17 3.76 2.1 
5000 2.33 \.57 4.5 3.2 
10000 2.46 1.9 3.9 4.27 
20000 2.49 \.53 3.46 2.12 
Key II': Modified Insulmogemc mdex 
HOMA-IR: Homeostatic Model Assessment of insulin resistance 














The Insulinogenic Index (II') is significantly different between doses if dose 0 is included. 
However, there is no statistically significant difference between doses if zero is excluded from 
the analysis. 
In this study the II' is lower than the 9.22 reported by Suzuki et al. (2003) for subjects with 
normal glucose tolerance (NGT). All doses of glibenclamide improve the II' value (p= 0.026) 
when compared to baseline (0 Jlg of glibenclamide) but there is no significant difference in 
effect between the various doses i.e., 2500-5000,5000-10000, 10000-20000 Jlg (see results). 
In this study population, the mean HOMA (refer to table) ranged from 3.17-4.5 which is 
higher than the normal value of 1.57 ± 0.87 reported by Lichnovska et al. (2002). 
At dose 0 Jlg, the mean QUICKI (± SD) is 0.24 ± 0.03 (refer to table 36) and at dose 20000 
Jlg it is 0.25 ± 0.04. Lichnovska et al. (2002) reported a mean value of QUICKI of 0.366 ± 
0.029 in healthy subjects of both genders. Using this as a normal value, the QUICKI, in this 
study is approximately 70% below normal. The very low mean QUICKI (0.24 ± 0.03) on 
entry in this study population indicates the high level of insulin resistance present. This 
reduced QUICKI value was seen across the dose range as there was no statistically significant 
difference in QUICKI as the dose of glibenclamide was increased from 0 to 20000 Jlg. 
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Figure 7: Dose vs HOMA-IR 
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Boxplots of Insulin sensitivity indices and responder status. The 
clear horizontal bar in the centre of the box shows the median; the 
box encloses the inter-quartile range i.e., 50% of the data. The 
whiskers show the interval of values outside the box and values far 
outside are represented by horizontal dashes 
146 
2.3 Discussion 
Assessment of insulin sensitivity is of paramount importance because it is widely accepted to 
be a core metabolic defect in subjects with type 2 diabetes mellitus. Glucose tolerance is an 
expression of the efficiency with which homeostatic mechanisms restore glycaemia to basal 
levels. The homeostatic response includes an increase in the insulin levels and also insulin 
dependent processes. Therefore an estimate of insulin sensitivity is possible if glucose and 
insulin concentrations are measured. 
The hyperinsulinaemic euglycaemic glucose clamp is the gold standard in the measurement of 
insulin sensitivity, but it is invasive and technically complex. QUICK! and HOMA are much 
simpler and require less technical skills i.e., they require only fasting blood insulin and fasting 
blood glucose levels. Insulin sensitivity is less accurate in cases of greatly deteriorated p-cell 
function and/or marked hyperglycaemia (Anderson et aI., 1995; Radziuk, 2000). QUICK! is 
said to provide a reproducible and robust estimate of insulin sensitivity that shows excellent 
linear correlation with the gold standard clamp measurement and has similar variability and 
discriminant power (Katz et aI., 2000). 
Type 2 DM represents an extreme of insulin resistance. Insulin resistance is a condition in 
which the response to the hormone is muted and the body must then produce excess insulin to 
maintain healthy blood glucose concentrations. This condition is also called low insulin 
sensitivity. 
The study evaluates the effect of increasing doses of glibenclamide on insulin sensitivity by 
using two different measures namely, HOMA and QUICK!. 
In this study, the mean HOMA ranged from 3.17 to 4.5 which is higher than the normal value 
of 1.57 ± 0.87 reported by Lichnovska et ai. (2002). This indicates that the insulin resistance 
of the study population is pronounced. The effect of increasing doses of glibenclamide on 
HOMA, shows no statistically significant change (p=0.785). The implications of this finding 
is that glibenclamide in increasing doses (from 0 to 20000 /lg) in this short term study, does 
not decrease insulin resistance. If this finding is confirmed in long term studies, then 
glibenclamide and possibly all other SUs would not protect patients against the co-morbid 
diseases (the triad) associated with insulin resistance and hence DM. 
The HOMA-IR model performs well in comparison with the hyperglycaemic clamp and the 
frequently sampled IVGTT (intravenous glucose tolerance test) or the oral glucose tolerance 
test (OGTT). However, HOMA-IR scores obtained in different studies cannot be compared 
unless the insulin assay is standardised. Furthermore, insulin sensitivity evaluated by HOMA-
IR is less accurate in cases of greatly deteriorated beta cell function and/or hyperglycaemia 
(Radziuk et aI., 2000). 
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In this study population at dose 0 flg the mean (± SD) QUICKI was calculated to be 0.24 ± 
0.03 and at dose 20000 flg it was 0.25 ± 0.04. Lichnovska et al. (2002) reported a mean 
QUICKI of 0.366 ± 0.029 in healthy subjects of both genders. Using this as a normal value, 
the QUICKI, in this study was approximately 70% that of the normal value. The very low 
mean QUICKI (0.24 ± 0.03) on entry in this study population reflects the high level of insulin 
resistance. This reduced QUICKI value was seen across the dose range as there was no 
statistically significant difference in QUICKI as the dose of glibenclamide was increased from 
o to 20000 flg. This lack of change in QUICKI indicates that increasing doses of 
glibenclamide do not favourably influence insulin resistance as measured in this study 
population. 
QUICKI provides a reproducible and robust estimate of insulin sensitivity which shows 
excellent correlation with the gold standard clamp measurement. This method works best in 
persons without diabetes, and caution must be used when interpreting results in type 2 
diabetes (Katz et al., 2000). 
Although the derivation of QUICKI is more empirical, similar considerations apply as for 
HOMA-IR: it is more accurate when glycaemia is near normal and f3 cell function has not 
deteriorated greatly (Radziuk, 2000). ' 
Insulin resistance determination by the HOMA and QUICKI methods work well in non-
diabetic patients but caveats in diabetic patients exist. Katz et al. (2000) in introducing the 
QUICKI method, did not select a cut off point defining insulin resistance but rather presented 
a continuum of insulin sensitivity with their data suggesting an arbitrary cut-off of 0.3. Our 
data supports this cut-off of 0.3 for insulin resistance since all our diabetics presented with 
mean (± SD) QUICKI values of 0.24 ± 0.03 at dose O. 
HOMA and QUICKI are calculated on FBI and FBG. Hence, IR can be easily determined at 
diabetic outpatient clinics. However, the reliability and sensitivity of these indices are 
dependent on the duration of diabetes and the degree of hyperglycaemia. This study 
population had a mean FBG and FBI on entry of 15.39 mmoVL and 13.92flU/mL respectively 
with an average duration of diabetes of 8.9 years. Therefore, these measures of IR may have 
limited application in this study population. 
Low insnlinogenic index and low acute insulin release (AIR) are two defects that may playa 
pathogenic role in impaired glucose regulation and hence in the pathology ofDM (Jensen et 
al., 2002). Insulinogenic index provides a parameter of insulin response and insulin release. 
Development of diabetes occurs more frequently in individuals with low values of 
insulinogenic index than in normal responders (Del Prato et al., 2002). 
In this study the II' was low in all SUbjects. All doses of glibenclamide improve the II' value 
(p= 0.026) but there is no difference in effect with increasing doses. This implies that all doses 
of glibenclamide increase the early phase insulin secretion or AIR (0-30 mins) , however 
increasing doses of glibenclamide, when compared to each other, do not significantly increase 
the II. While the maximum effect on II occurs at a dose of 20000 J.lg (11'= 2.49), this increase 
is not statistically significant from 2500 J.lg (11'=1.98) of gibenclamide. 
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The change in mean AUC insulin 0-30min between dose 0 and 2500 Ilg was statistically significant 
(p=0.043). The change between all other doses was not significant (p= 0.348, 0.278 and 0.579 
between doses 2500-5000, 5000-10000 and 10000-20000 Ilg respectively). Mean AUCinsulin 0-
30min is an indirect measure of acute insulin release (AIR) and beta cell function. Therefore 
doses of glibenclamide greater than 2500llg provide little further benefit on acute insulin 
release (AIR) and beta-cell function. It can be conclude that doses greater than 2500llg are not 
likely to improve AIR. 
In the study by Jensen et a1. (2002) diabetic subjects with a reduced insulinogenic index 
(36%) were compared to patients with normal glucose tolerance (NGT) (100%) and impaired 
glucose tolerance (IGT) (64%). The decreased II' in the present study is indicative of 
decreasing glucose tolerance and hence decreasing beta cell function as shown by Jensen et a1. 
(2002). The modified II adopted in this study is in agreement with the methodology adopted 
by Del Prato et a1. (2002) and may be used when precise 30 minute insulin plasma levels are 
not available and a standardised meal is used instead of a oral glucose tolerance test (OGTT). 
Although the euglycaemic hyperinsulinaemic clamp is the gold standard in measuring II, the 
indices used in this study underline a correlation which may be used as a guide to quantifying 
insulin secretion. However, reproducibility of this II' (modified methodology) needs further 
investigation for confirmation. 
The significance of the above findings are that the secretagogue glibenclamide, does not 
change insulin resistance, and that other agents alone, or in combination, may need to be used. 
Drug therapy targeting insulin resistance is discussed below. 
Type 2 diabetes is a heterogenous disorder due to prevalent insulin resistance associated with 
deficient insulin secretion, or to a prevalent defect of insulin secretion associated with 
impaired insulin action (Del Prato et aI., 2002). Insulin resistance is accepted to be a major 
risk factor in the aetiology of type 2 diabetes mellitus, hypertension, dyslipidaemias, 
atherosclerotic valvular disease and maybe a risk factor for coronary heart disease (Radikova, 
2003). In this study popUlation of type 2 diabetic patients, all subjects were insulin resistant 
based on the HOMA and QUICKI evaluations (albeit with their limitations). 
In the treatment of diabetes, drug therapy must target the pathophysiological hallmarks of 
type 2 diabetes mellitus viz., insulin resistance, pancreatic ~-cell dysfunction and endogenous 
glucose production. 
The findings of this study show that increasing doses of glibenclamide do not significantly 
decrease or alter insulin resistance. This was determined by the HOMA and QUICKI 
methods. SUs, when used as monotherapy in the hyperinsulinaemic phase of type 2 diabetes 
promote further weight gain and results in the vicious cycle of insulin resistance, 
hyperinsulinaemia, hyperphagia, further weight gain and worsening of the already present 
insulin resistance. Thus, insulinotropic agents are not recommended as first line drugs in 
overweight or obese type 2 DM patients, as has been shown by UKPDS 34 (1998). Such 
patients may benefit by the use of a-glucosidase inhibitors which decrease postprandial 
hyperglycaemia when used as monotherapy. In type 2 DM patients with fasting 
hyperglycaemia, a-glucosidase inhibitors are less effective but may be used in combination 
with other agents such as SUs or metformin or insulin (Holman et aI., 1999). 
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Metformin is the drug of choice as monotherapy in insulin resistant, overweight type 2 
diabetic patients (Matthaei et aI., 2000). The addition of meformin to SUs has a synergistic 
effect on glycaemic control and may be an ideal combination with glibenc1amide in this study 
population because it reduces insulin resistance. Metformin is indicated in insulin resistant 
states in type 2 DM. Thiazolidinediones (TZDs) are also indicated in patients where insulin 
resistance, rather than insulin deficiency, is the leading pathogenic mechanism (Matthaei et 
aI.,2000). 
These agents i.e., a-glucosidase inhibitors, metformin or thiazolidinediones, utilise 
endogenous hyperinsulinaemia to improve insulin action and do not impede the goal of 
weight reduction by further increasing hyperinsulinaemia and insulin resistance which is seen 
with the insulinotropic agents such as SUs e.g., glibenc1amide. 
Insulin resistance as shown in this study is a common finding in type 2 diabetes mellitus. 
Glibenc1amide is ineffective in decreasing insulin resistance in this diabetic population. This 
popUlation is more likely to benefit from the addition of insulin sensitizers e.g., 
thiazolidinediones and metformin which target insulin resistance. 
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3 Dose exposure response relationships evaluated using 
conventional methodologies 
3.1 Data used for dose-exposure-response relationship 
There were twenty two subjects in the data set who contributed a total of 3005 observations 
(1100 glucose, 1088 insulin and 817 glibenclamide) 
Blood samples were taken at 10 time points for each subject at each dose. Sample times were 
categorized into 10 groups as follows in table 37 below: 
Table 37: Time points for blood sampling 












3.1.1 Graphical exploration of glibenclamide concentration versus time data 
The spaghetti plots presented in figure 11 below represent the individual profiles of the twenty 
two subjects for each dose. There is an increase in glibenclamide concentrations with dose. 
There is linearity between dose and plasma glibenclamide concentration. 
Figure 11: Graph of glibenclamide concentration versus time profiles for all 
subjects by dose group. Each line within a panel represents one 
subject 
Glibenelamide Cone (II giL) vs Time (h) 
Time (h) 
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Table 38 demonstrates the effect of increasing glibenclimide doses on mean plasma 
glibenclamide concentration 
Table 38: Glibenclamide levels 
DAMT* Mean plasma concentration ±SD 
of drug 
(JIg) (ng/mL) 
0 0.00 0.00 
2500 95.76 4.28 
5000 147.94 6.61 
10000 258.36 9.98 
20000 478.97 21.88 
DAMT*= Dose amount 
Inspection of figure 12 and table 38 shows the linear increase III mean glibenclamide 
concentration as drug dose increased. 
153 
Chlnge in Mean Drug 
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Figure 12: Change in mean plasma glibenclamide levels with dose escalation 
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Graph of dose nonnalized Cmax. Open circles show the geometric 
mean and the vertical lines span the minimum and maximum 
concentrations in 22 subjects. 
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3.2 Dose-response and dose-exposure-response relationships 
Figure 15 below provides a synopsis of the relationship between dose, glibenclamide 
concentration, glucose and insulin. The mean glibenclamide concentration increased in a 
linear fashion as dose increased. The relationship between increasing insulin and decreasing 
mean glucose is valid from 0-2500 ~g. While the insulin concentration increases from doses 
2500-5000 ~g, there is little change in mean glucose. At dose 5000-1 0000 ~g, while insulin 
decreases there is no appreciable change in blood glucose. At drug doses from 10000 to 20000 
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Figure 15: The relationship of dose, glucose, insulin and glibenclamide 
concentration 
The C~ax of glibenclam~de increases in a linear manner as the dose increases (from 
mspectlon of figure 16). ThiS means that a doubling of dose produces a proportionate increase 
in Cmax of glibenclamide. In the case of glucose, there is an initial decrease in Cmax from 
dose 0 to 5000~g, followed by minimal decrease between 5000 and 10000 ~g, and very little 
thereafter to 20000~g. 
The Cmax of insulin increases from dose 0 to 5000~g, followed by a steady decrease to 
1 OOOO~g, with minimal decrease thereafter to 20000~g. 
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The relationship between dose amount of glibenclamide and the Tmax 
of insulin, glucose and glibenclamide 
The Tmax of glibenclamide displays a parabolic relationship with dose amount as shown in 
the figure 17 above. The Tmax of insulin and glucose follow a similar relationship, with a 
parallel relationship from dose 2500 Ilg to 20000 Ilg. At zero dose insulin peaks at 3.13 hours 
compared to 1.57, 2.02, 1.68, and 2.39 hours after 2500llg, 5000llg, 10000llg and 200001lg. 










Table 39: AUC at various time intervals for glucose and insulin with increasing 
doses of glibenclamide 
AlC0-21Ts AlC461Ts AlC0-81Ts 
Rrtial AI.I:: *llism a:n:: Rrtial AI.I:: *llisma:n:: Rrtial AI.I:: *Rm"aa:n:: 
In; au:: In; au:: In; au:: In; au:: In; au:: In; au:: 
J.IIrlILh mrrl/Lh ~ rrrrdIL J.IIrlILh mrrl/Lh ~ rrrrdIL J.IIrlILh mrrl/Lh ~ rrrrdIL 
Man 54.01 38.28 V 19.14 :fl8 34.Of 25.4 17.02 2)1.37 rn6S 25.17 17.33 
~ V .V 8.18 24.54 BE 83.03 32.32 
Man &5.&9 32.4 43.44 16.2 (/).52 2639 34.76 13.2 281.55 110.71 35.19 13.83 
~ 48.53 7B 35.23 10 145.48 35.16 
Man 9:t.25 31.34 47.12 15.67 82.2} 25.~ 41.15 1282 318.5 103.07 39.81 1288 
~ 6141 7.52 43.58 8.15 173.46 Xl4 
Man 77.82 2}.77 38.91 14.88 ffi76 24.37 33.38 1218 252.78 fJ7:E 31.6 1216 
~ 48.25 7.84 2}.19 8.9 119.81 31.49 
Man 1).83 2}.12 39.CJ2 14.56 71.15 24.12 35.57 12~ mCJ2 91.41 33.87 11.43 
~ 47.03 8.48 37.61 9.57 143.03 2616 
* Average concentration was calculated by dividing corresponding AVe by relevant time interval i.e., 2 4 and 8 
hours hours. 
Statistical analysis of the results in table 39 above, show that there is a significant difference 
in the AUCO-2h, AUC4-6h, AUCO-8h and AUCO-8h for insulin between doses 0-2500 ~g 
(p=0.007), 5000-10000 ~g (p=0.033) and 0-2500 ~g (p=0.056) and 5000-10000 ~g (p=0.026) 
respectively. 
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3.2.1 Glucose as the pharmacodynamic response 
The spaghetti plots in figure 18 and 19 below represent the individual profiles of the twenty 
two subjects for each dose. There is a decrease in glucose concentration from 0 to between 
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Figure 19: 
Spaghetti plot of glucose (mmoI/L) vs time (hour) by dose for all 
subjects. Each panel from left to right shows zero, 2.5mg, 5mg, 10mg 
and 20mg respectively. Each subject shown as a separate line. 
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Spaghetti plot of glucose (change from baseline) vs time (hour) by 
dose for all subjects. Each panel from left to right shows zero, 2.5mg, 
5mg, 10mg and 20mg respectively. Each subject shown as a separate 
line. 
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Mean Glucose levels 
Table 40: Change in mean glucose levels between dose increments with 
escalating drug dose 
Dose range Change in mean glucose p Value 
(l1g) (mmoVL) 
0-2500 -3.49 ~0.001* 
2500-5000 -0.44 0.345 
5000-10000 -0.72 0.123 
10000-20000 -0.33 0.468 
.. 
Key: * p Value < 0.05 statistically significant 
All doses of glibenclamide from 250011g to 2000011g decreased mean blood glucose when 
compared to zero dose. The percentage decrease of mean blood glucose from zero dose was 
19.61%; 22.10%, 26.01% and 27.98% for 250011g, 500011g, 100001lg, and 2000011g, 
respectively. The decrease in glucose from dose 0-2500 llg is statistically significant 
(pg).001). The decrease in glucose is not statistically different for doses 2500-500011g, 5000-
1000011g and 10000-20 OOOllg. Figure 20 below is a graphic representation of the changes in 
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Fasting blood glucose 
Table 41: Dose vs mean FBG 
Dose of Drug MeanFBG (±SD) p value 
(pg) (mmoIlL) 
0 15.4 3.84 
2500 12.8 3.51 0.024* 
5000 12.7 3.88 0.919 
10000 11 .5 3.84 0.320 
20000 11.2 4.15 0.782 
* Stati stically significant 
Table 41 and figure 21 show the effect of glibenclamide dose escalation on mean FBG. The 
difference in mean FBG between dose 0 and 2500 ~g is statistically significant (p=0.024). 
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Figure 21: Fasting blood glucose vs Dose 
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Post-prandial glucose 
Table 42: Dose vs mean single point glucose detennination (mmoIlL) 
Mean Postprandial BG (mmol/L) 
Dose of glibenclamide 2hr (±SD) 6 hr (±SD) 
(l1g) 
0 20.81 4.55 17.88 4.42 
500 16.87 4.43 15.38 5.43 
5000 16.55 4.38 13.38 4.79 
10000 15.51 4.26 12.65 4.37 
20000 15.36 4.69 13.22 6.47 
The change in mean postprandial (2 and 6 hour) blood glucose is not statistically significant at 
all doses (p>0.05). Furthermore there is no statistically significant difference between doses. 
When the 2 hour mean glucose level is compared to that obtained at 6 hours, the mean glucose 
level is statistically higher at time 2hr for doses 0 (p=O.O 16), 5000llg (p= 0.020) & 10000llg 
(p=0.027). However, there was no statistically significant differences at 2500llg (p= 0.270) 
and 20000 Ilg (p=O.162). However, 57% of the subjects (presented in table 47) show a 
decrease in PPG. 
AUC glibenclamide vs FBG, PPG and glucose AUC 
AUC Glibenclamide (O-Iast) vs FBG 
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Figure 22: AUCglibenclamide vs FBG 
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Figure 23: 'Effect of glibenclamide AUC on post-prandial glucose 
AUC Glibenclamide (O--Iast) vs AUC Glucose (O--Iast) 
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Figure 24: Effect of glibenclamide AUC on glucose AUC 
The effect of AVC glibenclamide on FBG, PPG, and AVC glucose is presented above in 
figures 22,23 and 24 respectively_ There is a statistically significant difference between AVC 
glibenclamide corresponding to dose 0 and 2500/lg and FBG (p=O_024) and a statistically 
significant difference on AVCglucose (p=O.028) corresponding to the same dose. There are no 
differences at all other AVC's of glibenclamide for FBG, AVCglucose and PPG (both 2 and 6 
hours). 
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3.2.2 Fructosamine as the pharmacodynamic response 
Table 43 and figure 25 below outline the changes in mean fructosamine levels with escalating 
doses of glibenclamide. 
Table 43: Drug vs mean fructosamine concentration 
Drug dose Mean fructosamine Change from dose 0 
(~g) (~moI/L) 
0 466.72 
2500 454 -12.72 (2.72%) 
5000 437.28 -29.49 (6.32%) 
10000 436.03 -30.69 (6.58%) 
20000 423.05 -43.67 (9.36%) 
Table 42 above shows the change in fructosamine from dose 0 to 20000 ~g . shows the 
correlation between the change in fructosamine with increasing doses of glibenclamide. There 
was a statistically significant decrease in mean fructosamine (p=0.001) as the dose of 
glibenclamide increased from 0 to 20000 ~g . The decrease in fructosamine between doses 
ranged from 2.72% to 9.36%. There was no statistically significant change in fructosamine 
between doses of glibenclamide. 
Pearsons' correlation indicates that a significant (p<0.05) inverse relationship exists between 
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3.2.3 Insulin as the pharmacodynamic response 
The spaghetti plots in figure 26 below repre~en~ the. individual p~ofiles .of the twenty two 
subjects for each dose. There is an increase m msulm conce~tr~tlOn~ wIth ~ose ~om 0 to 
5000~g glibenclamide. Thereafter there is no apparent increase m msultn secretIon WIth dose. 
Insulin (iu) vs Time (h) 
Time (h) 
Figure 26: Spaghetti plots of insulin profiles for each dose 
Mean Insulin levels 
Table 44: Change in mean blood insulin levels with escalating drug dose 
Dose range Change in mean plasma p Value 
(l1g) insulin levels 
(~U/mL) 
0-2500 11 .38 SO.001* 
2500-5000 4.15 0.113 
5000-10000 - 7.11 0.05* 
10000-20000 0.82 0.721 
.. 
Key: • p Value < 0.05 statistically Significant 
All doses of glibenclamide from 2500 to 20000 ~g stimulated insulin secretion compared to 
the zero dose. The percentage increase of insulin from zero dose was 51.38; 58.34, 44.41 and 
33.54 % for 2500, 5000, 10000, and 20000~g respectively. The 5000~g dose stimulated 
maximal insulin secretion at time 2.020 hrs. Mean blood insulin increased significantly from 
dose 0-2500 ~g ~ 0.001). However, the increase from 2500-5000~g is not significant 
(p=0.113). Thereafter, insulin decreased significantly from dose 5000 to 10000 ~g (p=0.05). 
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Finally, the change in insulin from dose 10000-20000 \.19 was not statistically significant 
(p=0.721). In summary, mean insulin levels increased from dose 0-5000\.19, decreased steadily 
to 10000\.19 and thereafter paralleled the x-axis to dose 20000\.19 as graphically represented in 
figure 29 below and tabulated in table 43 above. 
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Figure 27: Change in mean insulin levels with dose escalation 
Mean Fasting Blood Insulin 
Table 45: Dose vs mean fasting blood insulin 
Dose of Drug Mean Fasting Insulin (±SD) 
(flg) (flmoIlL) 
0 13.92 6.87 
2500 14.35 6.04 
5000 15.66 8.29 
10000 14.99 6.86 
20000 17.95 8.70 
The change in mean fasting insulin is statistically not significant at all doses (p> 0.05). 
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Figure 28: Fasting blood insulin vs dose amount 
Post-prandial insulin 
Table 46: Dose vs mean single point insulin determination (~moI/L) 
Dose of Drug (Jlg) Mean Single Point* Postprandial insulin 
2hr (±SD) 6hr (±SD) 
0 30.997 17.976 26.433 14.513 
2500 52.221 35.819 35.433 18.993 
5000 56.848 36.448 41.253 20.977 
10000 43.006 23 .089 38.006 17.075 
20000 43.035 26.304 37.016 17.132 
*The single point detennination is derived from the highest value between 1.6-2.0 hours for 2 
hour and 5.6-6.0 hours for 6 hour. 
The change in mean 2 hour single point insulin determination is statistically significant 
between doses 0-2S00 Ilg, (p=0.002) and SOOO-10000 Ilg (p=O.OIS). There is no statistically 
significant difference between doses 2S00-S000 Ilg (p=0.640) and 10000-20000 Jlg (p=0.S37). 
The change in mean 6 hour single point detennination of postprandial blood insulin is not 
statistically significant at all doses. 
167 
Comparison between 2 and 6 hour single point determination shows no statistically significant 
difference except at dose 2500 ~g (p=0.066). The figures below represent the effect of 
glibenclamjde dose on 2 and 6 hr mean insulin levels (postprandial). 
Effect of AUC glibenclamide on FBI, PPI and insulin AUC 
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Figure 30: Effect of glibenclamide AUC on post-prandial insulin 
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Figure 31: Effect of glibenclamide AUC on insulin AUC 
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The effect of AUC glibenclamide on FBI, PPI, and AUC insulin is presented above in figures 
29, 30 and 31 respectively. There is a statistically significant difference between AUC 
glibenclamide on AUC insulin corresponding to dose 0 and 2S00llg (p=0.01) and a 
statistically significant difference on PPI at the corresponding dose of 0-2S001lg (p=0.002) 
and SOOO and 10000 (O.OlS) Ilg· 
There are no differences at all other AUC's for the corresponding doses for FBI, AUCinsulin 
and PPI. 
4 Evaluation of clinical benefit due to glibenclamide 
Table 47 shows the clinical benefit attributable to glibenclamide based on the SEMDSA 
criteria viz. 
• FBG of 4-6 mmoVL (Optimal) and >6-8 mmol/L (Acceptable) control 
• PPG ofS-8 mmoVL (Optimal) and >8-10 (Acceptable) 
The maximum number of subjects who achieved an 'acceptable' level of glycaemic control 
i.e. according to the less conservative definition when using either FBG or PPG was 13 
(S7%). 
Table 47: Summary of clinical control achieved 
SEMDSA 2500p,g 5000p,g lOOOOp,g 20000p,g Total 
Criteria (n=23) 
Optimal I 0 2 2 5 (22%) 
Fasting blood 4-6 mMoVL 
glucose Acceptable 2 4 3 4 13 (57%) 
6-8 mMoVL 
Optimal 1 4 2 2 9 (39%) 
Post-prandial 5-8 mMoVL 
blood glucose Acceptable 3 5 2 3 13 (57%) 
8-10 mMoVL 

















Table 48 above identifies the individual subjects who achieved acceptable FBG and 
acceptable PPG at the individual doses based on SEMDSA criteria. Four of the 23 subjects 
(17%) at 20000)lg and 3 of the 23 subjects (13%) at 10000)lg reached the acceptable value 
for both FBG and PPG (these numbers are exclusive). 
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4.1 Discussion 
Glucose and Insulin Exposure 
In type 2 DM patients, the combination of IR and inadequate basal insulin secretion may 
account for excessive endogenous glucose production (EGP). Therefore restoration of basal 
insulin levels will improve FBG and the daily blood glucose profile. 
The reduction of FBG from zero dose (15.54mmollL) for the 2500l-lg (12.8mmollL), 5000l-lg 
(12.7mmollL), 10000l-lg (11.5mmollL) and 20000l-lg (11.2 mmollL) glibenclamide was 17, 
18, 25 and 27 % respectively. There was a statistically significant reduction in fasting blood 
glucose when the dose 2500 I-lg of glibenclamide was compared to zero dose. However, there 
was no statistically significant difference on FBG between doses (2500, 5000, 10000 and 
20000 I-lg) of glibenclamide. 
Endogenous glucose production (EGP) is a function of insulin resistance and basal insulin 
secretion. Insulin resistance increases EGP which results in increased FBG. Decreased basal 
insulin secretion increases EGP which results in increased FBG. FBG serves as a measure of 
the degree of EGP (De Fronzo et aI., 1992). All doses of glibenclamide reduce FBG and thus 
must also be reducing EGP. Since EGP is related to basal insulin secretion and IR, then the 
effect of glibenclamide must be on either basal insulin release or IR, or a combination of both, 
or extrapancreatic effects. SUs increase both basal and glucose stimulated insulin secretion. 
However, after several weeks of continued therapy, insulin secretion decreases to near pre-
treatment levels. The failure of SUs to sustain the initial increase in insulin secretion suggests 
extrapancreatic mechanisms in regulating blood glucose levels (Feldman, 1971). 
The percentage increase in FBI from zero dose to 2500l-lg, 5000l-lg, 10000l-lg and 20000l-lg 
glibenclamide was 6, 14, 10 and 25%, respectively, although not statistically significant. 
However, the 20000 I-lg dose resulted in a 25 % increase in FBI without producing a 
corresponding reduction of FBG. Doses of glibenclamide above 2500 I-lg did not significantly 
decrease fasting glucose levels but increased insulin levels, which in turn, worsened the 
metabolic state of the type 2 diabetic patient. This finding reinforces the use of low dose 
glibenclamide in type 2 DM. 
The difference in mean FBG from 0 (15.4mmoVL) to 2500l-lg (12.8 mmollL) is 2.6 mmollL 
and would translate to a change of 1.6 % in HbA1c if this difference is maintained over a 
three month period (Nathan et aI., 1984). Similarly the decrease in mean FBG from 2500l-lg to 
5000l-lg, 5000l-lg to 10000 I-lg and 10000l-lg to 20000 I-lg was 0.1 mmollL, 0.8 mmollL, and 
O.3mmollL respectively. This decrease is not statistically significant and does not bring the 
FBG to normoglycaemia or even near normoglycaemia. 
The side-effects of life threatening, protracted hypo glycaemia (Krentz, 1994) and the 
cardiovascular adverse effects (O'Keefe et aI., 1999) that accompany the use of high doses of 
glibenc1amide do not warrant the use of such high dosage. On the basis of this finding, the 
maximal dose of glibenclamide should not exceed 5000 I-lg per day. 
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The change in mean postprandial blood glucose (both at 2 and 6 hours post breakfast and 
post lunch, respectively) is statistically not significant at all doses (p> O.OS). Furthermore, 
there is no statistically significant difference between doses (p>O.OS). However when 
individual response are evaluated 9 (39%) of subjects achieved optimal control. This number 
increases to 13 (S7%) when the less stringent 'acceptable' definition of glcaemic control is 
applied. The addition of insulin sensitizers or insulin to glibenclamide may decrease PPG. 
These findings are similar to the study by Cozma et al. (2002) which compared the effect of 
repaglinide, glipizide and glibenclamide on insulin secretion and postprandial glucose after a 
standardised meal. Glibenclamide had no significant effect in lowering postmeal glucose 
peaks (glucose Cmax) when compared to glipizide and repaglinide. Acute glucose exposure 
(Cmax) may be as important as total postprandial exposure with respect to long term 
complications. 
Prevention of postprandial hyperglycaemia is important as it is implicated in the development 
of macro - and microvascular complications associated with diabetes (Baron, 1998). 
Postprandial hyperglycaemia, rather than fasting blood glucose levels, is related to the risk of 
cardiovascular disease (Hanefield and Temelkova-Kurktschier, 1997). This finding was 
confirmed by the National Health and Examination Survey (NHAES) in the USA which 
reported an association with post-load hyperglycaemia and an increase in all-cause and 
cardiovascular mortality (Saydah et aI., 2001). 
Glibenclamide as monotherapy has no clinically significant reduction in postprandial blood 
glucose levels and therefore will confer no long term beneficial effects in preventing macro-
and microvascular complications. However, it does provide benefit when combined with 
metformin or acarbose as discussed in combination therapy below. 
The change in mean insulin was significantly higher with all doses when compared to 
placebo (O-dose). The change in mean 2 hour postprandial blood insulin is statistically 
significant between doses 0-2S00 I-lg, (p=0.002) and SOOO-10000 I-lg (p=0.01S). There is no 
statistically significant difference between doses 2S00-S000 I-lg (p=0.640) and 10000-20000 
I-lg (p=0.S37). On the other hand, the change in mean 6 hour single point determination of 
postprandial blood insulin is not statistically significant at all doses. These results indicate that 
the stimulation of insulin secretion occurs during the first 2 hours for low dose glibenclamide 
(2S00I-lg-S000I-lg) i.e., an acute insulin response to glibenclamide. However, at 6 hours 
glibencalmide at all doses does not augment food stimulated insulin secretion. 
Comparison between 2 and 6 hour single point determination shows no statistically significant 
difference. Since there is no difference between AUC and single point glucose measurement 
for determining postprandial glycaemia, the single point PPG determination (as for FBG) is 
adequate. This has practical clinical relevance in making decisions on dose adjustment or 
level of control. 
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The effect of glibenclamide AVe on FBG is similar to that found for glibenclamide dose on 
FBG. This result is expected because AUC glibenclamide is a function of dose. Similarly, the 
effect of glibenclamide AVe on PPG is the same as reported for effect of glibenclamide 
dose on PPG i.e., there is no statistically significant difference between all doses of 
glibenclamide. It is thus not necessary to determine AUC of glibenclamide since dose is 
proportional to AUC, assuming patients are compliant with medication. AUC, which is a 
pharmacokinetic parameter, does not show a direct relationship with changes in AUC glucose 
(a pharmacodynamic response). 
There is a significant difference in the AUCo-2h, AUC4-6h, and AUCo-sh for insulin from dose 0-
2500 I1g (p=0.007), 5000-10000 I1g (p=0.033) and 5000-10000 I1g (p=0.026) respectively. 
All doses of glibenclamide stimulate insulin secretion as measured by the AUCo-2h insulin. 
However, there is no statistically sgnificnt corresponding decrease in blood glucose levels as 
measured by the AUCo-2h . 
At 4-6 hours, glibenclamide increases insulin secretion at dose 5000-10000I1g. At 0-8 hours 
insulin secretion increases significantly at doses 0-2500l1g and decreases significantly at doses 
5000-l000011g (as expected since AUCo-sh incorporates AUCo-2h and AUC 4-6h). 
However, at none of these corresponding time intervals is there a significant reduction in 
blood glucose. This sustained high insulin levels without corresponding decreases in blood 
glucose levels is indicative of prevailing insulin resistance in this study population (see 
below). This suggests a lack of relationship between insulin release and blood glucose 
reduction. 
AUCo-2h, 4-6h, O-Sh for glucose did not significantly decrease after administration of 
glibenclamide at all doses. This suggests that glibenclamide therapy in this popUlation does 
not significantly decrease glucose exposure (glucose toxicity). 
Glucose toxicity may be defined as a glucose-induced reduction in insulin secretion and 
action and it has been shown in animal models of diabetes to contribute to the development of 
insulin resistance and impaired insulin secretion. 
In type 2 diabetes in humans, there is considerable evidence indicating that a chronic 
physiological increment in the blood glucose concentration leads to progressive impairment in 
insulin secretion and may also contribute to insulin resistance (Rossetti et at, 1990). Glucose 
toxicity also contributes to the reduction in the bioavailability of SUs, probably via 
impairment of gastric motility and emptying (Luzi and Pozza., 1997). 
In this study, glibenclamide throughout the dose range, does not decrease glucose exposure 
and hence is not likely to contribute to the amelioration of micro- and macrovascular 
complications. In addition, while glibenclamide is producing little effect on glucose exposure, 
its side effects, in particular cardiovascular risk, are nevertheless not diminished. 
The effect of Glibenclamide Ave on FBI is similar to that found for glibenclamide dose on 
FBI. This result is expected because AUC glibenc1amide is a function of dose. Similarly, the 
effect of glibenc1amide AUC on PPI is the same as reported for effect of glibenc1amide dose 
on PPI i.e., no statistically difference between doses. It is thus not necessary to measure AUC 
of glibenc1amide since dose is proportional to AUC, assuming patients are compliant with 
medication. AUC, which is a pharmacokinetic parameter, does not show a direct relationship 
with changes in AUC insulin (a pharmacodynamic response). 
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Since the increase in Cmax of glibenclamide does not produce a proportionate increase in the 
Cmax of insulin (except at doses less than 5000llg), doubling the glibenclamide dose will not 
increase insulin secretion proportionately. This non-linearity is clinically significant in that 
high doses of glibenclamide (> 5000llg) are not likely to achieve a pharmacodynamic 
response i.e., increase in blood insulin. This conclusion is reinforced by the lack of change in 
the Cmax of glucose at a dose greater than 5000llg. Since insulin is required to decrease the 
blood glucose levels, and because high doses of glibenclamide (>5000llg) do not 
proportionately increase insulin, there is very little advantage in trying to decrease blood 
glucose with doses of glibenclamide greater than 5000llg if glibenclamide exerts its effect via 
insulin release. The possible role of glibenclamide in reducing blood glucose through 
extrapancreatic effects has not been exploited. 
The Tmax of glibenclamide does not coincide with the Tmax of insulin and the Tmax of 
glucose. This is an example of a lack of coincidence of pharmacokinetics with 
pharmacodynamics (glucose decrease and insulin secretion). 
This lack of coincidence of pharmacokinetics of glibenclamide with pharmacodynamics 
(blood insulin and glucose levels), means that drug blood levels do not correlate with a 
pharmacodynamic response. Therefore in the case of glibenclamide, (and possibly other 
sulphonylureas), therapeutic drug monitoring is not feasible. 
One of the objectives of this study was to determine the number of subjects who achieved 
glycaemic control with escalating doses of glibenclamide. 
SEMDSA criteria for FBG of 4-6 mmoVL (optimal) and 6-8 mmoVL (acceptable) control and 
PPG of 5-8mmoVL (optimal) and 8-10 (acceptable) were used. FBG was and is still used as a 
determinant of glycaemic control. The Expert Committee of the ADA (2003) encourages the 
use of FBG for diagnosing DM. The number of subjects who achieved glycaemic control in 
total was 13 (57%) based on SEMDSA criteria of 'acceptable' glycaemic control. The dose at 
which this occurred ranged from 2500llg to 200001lg. Therefore the majority of subjects were 
uncontrolled with increasing doses of glibenclamide. Dose escalation in these subjects did not 
produce decrease in FBG. 
The total number of subjects who achieved glycaemic control was 13 (57%) when PPG was 
used as the measure of glycaemic control, based on SEMDSA criteria of 'acceptable' 
glycaemic control. The dose at which this occurred ranged from 2500llg to 200001lg. 
Similarly, 43% of subjects were uncontrolled with increasing doses of glibenclamide. Dose 
escalation in these subjects did not improve PPG levels. 
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When both FBG, and PPG, are evaluated at the same time, then 6 subjects (26%) achieve 
'acceptable' glycaemic control. Both PPG and FBG provide important information regarding 
the risk for both microvascular and macrovascular disease. According this stringent measure 
(FBG and PPG simultaneously) the response to glibenclamide monotherapy is poor. But with 
a less stringent criteria i.e., FBG or PPG the response rate was 57%. The possible reasons for 
this poor response in this study are diabetes of long standing, insulin resistance, monotherapy 
and poorly controlled diabetes. These patients are likely to benefit from the addition of insulin 
sensitizers or insulin. Since only 26% of the subjects achieved 'acceptable' glycaemic control 
when bothe FBG and PPG are evaluated siumultaneously, it may be concluded that 
glibenclamide in this study population is not beneficial in protecting the subjects from micro 
- and macrovascular complications. Furthermore, there is little benefit in prescribing high 
dose glibenclamide as monotherapy. 
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4.2 Non compartmental pharmacokinetics analysis 
4.2.1 Introduction 
NCA provided exploratory data for initial estimates and guides for population PK analysis. 
This analysis included all those subjects (n22) who completed the full dose escalation study 
and from whom sufficient data was available to characterize concentration vs time profiles. 
4.2.2 Results 
Non-compartmental pharmacokinetic parameters for glibenclamide are recorded in Table 49. 
Table 49 Non-compartmental pharmacokinetic parameters for glibenclamide 
Dose (PJ!) N Mean SD Median Min Max CV% 
2500 20.00 l376.58 l339.70 1281.84 435.73 5066.15 88.21 
AUCinf 5000 22.00 1861.22 1700.44 1732.55 580.29 7038.55 78.51 
(ng.h1mJ) 10000 21.00 4276.17 1785.81 4334.46 2270.53 7945.56 40.86 
20000 22.00 7513.63 5632.41 7952.93 3216.50 30514.49 54.52 
2500 21.00 906.77 1036.30 629.48 243.57 3482.59 98.56 
AUClas! 5000 22.00 1416.84 1547.24 1216.97 441.96 6511.81 84.14 
(ng.h1mJ) 10000 21.00 3410.48 1550.99 3496.84 1407.75 7435.80 45.16 
20000 22.00 6333.86 3678.42 6109.36 2958.56 19332.44 50.18 
2500 21.00 1.94 2.46 1.71 0.72 9.49 82.71 
CLif 5000 22.00 2.66 2.20 2.80 0.77 10.58 70.17 
(Lib) 10000 21.00 2.78 1.03 2.86 1.34 5.17 37.34 
20000 22.00 3.09 1.62 2.96 1.03 6.76 51.00 
2500 21.00 157.97 64.28 164.52 61.83 338.27 40.19 
Cmax 5000 22.00 242.22 101.84 250.35 74.06 490.36 45.14 
(ng/mJ) 10000 21.00 422.66 119.49 424.86 278.10 693.81 27.39 
20000 22.00 773.61 391.64 671.62 384.74 1787.62 45 .92 
2500 20.00 5.09 3.62 6.25 0.94 12.50 81.05 
t-half (h) 
5000 22.00 4.42 3.09 4.11 1.60 11 .87 63.82 
10000 21.00 8.08 2.25 7.91 3.87 12.l3 29.91 
20000 22.00 6.56 3.02 7.32 2.58 14.88 51.19 
2500 21.00 2.05 1.77 1.68 0.93 6.90 74.14 
Tmax (h) 
5000 22.00 2.09 2.01 1.90 0.78 7.00 76.58 
10000 21.00 1.62 1.16 1.50 0.83 5.52 51.21 
20000 22.00 2.04 1.69 1.60 1.00 7.00 63.61 
2500 20.00 14.63 17.98 14.61 3.75 88.14 76.07 
Vz!f(L) 
5000 22.00 16.96 8.91 16.64 5.73 41.17 51.74 
10000 21.00 32.48 14.46 32.95 11.01 64.93 45.99 
20000 22.00 29.24 21.80 34.29 7.84 74.87 86.58 
T~s study shows that there is linearity between AUC of glibenclamide with increasing doses 
usmg AUC1ast and AUCinf, using NCA. The corresponding values of Cmax also increased 
linearly. The Tmax ranged from 1.62-2.09 hours. Clearance (ClIt) ranges from 1.94 to 3.09 
Lih while the half life ranges from 4.42-8.08 hours. The volume of distribution (Vzlt) ranges 
from 14.63 to 32.48L. 
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In this dose-escalation study, multiple doses of glibenclaimde were administered to type 2 
diabetic patients, at 14 day intervals. Based on half-lives between 8-12 hours [Marble et aI., 
(1987) and White and Cambell., (1986); (Coppack, 1990); (Fleishaker and Phillips, 1991); 
Jaber., (1994); Jonsonn et aI., (2000a) 7.09; Jonsonn (2000b) 2.0-4.5 hrs for Caucasian and 
Chinese; Courtois et aI., (1999)], steady state was assumed to be achieved at approximately 2-
3 days. 
4.2.3 Discussion of NCA 
NCA provided exploratory data for initial estimates and guides for population PK analysis. 
This discussion provides a comparison of results obtained from NCA in this study to that 
reported in the literature. 
The clearance of glibenclamide in this study population ranges from 1.94 to 3.09 Lih. The 
mean age of this population is 54.1 years, ranging from 39-73 years. The mean creatinine of 
the study population is 64.1 ~mollL which is within the normal range and therefore the study 
subjects are assumed to have normal renal function. The clearance of glibenclamide in this 
study population is within the range reported by other researchers who investigated type 2 
diabetics with normal renal function and of the same age group [Jaber et ai. (1994): 3.2LIh; 
Jonsonn et aI., (2000b): 4.41 Lih (Caucasians) and 4.1 Lih (Chinese); Jonsson et aI., (1998) 
3.7 Llh ]. In patients with impaired renal function (IRF) Jonsson et ai. (1998) reported a 
clearance of 6.3LIh. None of the subjects in this study presented with clearances in this range 
as described for IRF 
The Vz/f (L) of this study population ranged from 14.63 to 32.48L and is consistent with the 
literature. Jaber et ai. (1994) reported values of 20, 41, 51L, after 0, 6 and 12 weeks 
respectively of glibenclamide therapy. Jonsonn et ai. (2000b) in his comparison of Caucasian 
and Chinese subjects reported Vss of 6.31 and 5.491 respectively. 
The half-life (tJ/2) of glibenclamide in this study ranged from 4.42-8.08 hours. Marble et ai. 
(1987) and White and Cambell (1986) reported half-lifes of 6-10 hours. This half-life is 
within the range as reported for type 2 diabetic patients [the half-life for micronised 
glibenclamide ranged from 2.1 hours (Coppack, 1990) to 8.3 hours (Fleishaker and Phillips, 
1991). Jaber et ai. (1994) reported a half-life of 12.2 hrs, Jonsonn et aI., (2000a) 7.09 hrs, 
Jonsonn (2000b) 2.0-4.5 hrs for Caucasian and Chinese. Courtois et ai. (1999) 2.63 hrs (42-59 
years) and 2.78 hrs (71-75 years)] . Frequency of dosage can be determined by the half-life of 
the drug. In the case of glibenclamide the recommended frequency of administration is once 
daily. From this study there is little correlation between half-life and frequency of dosage. 
This implies that blood concentration of glibenclamide (pharmacokinetics) does not correlate 
with the measured effect on glucose and insulin (pharmacodynamics). 
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There is a linear increase in the Cmax of glibenclamide as the dose is increased from 2500l!g 
to 20000l!g viz., 157.97 to 773.61 respectively. 
The Cmax reported in this study is approximately twice that reported for corresponding doses 
by other researchers, namely for dose 5 mg, Fleishaker and Phillips, (1991) reported a Cmax 
of 179 ng/ml; Coppack (1990) reported a Cmax of 241ng/ml and 354 ng/ml for 10 mg 
(fasting) and 20mg (fasting) of glibenclamide respectively; while Jaber et al. (1994) reported a 
Cmax of 278ng/mL for 2.5 mg (in solution) of glibenclamide in solution and Jonsonn 
reported a low max of 69 (Caucasians) and 82 (Chinese) for 2.5mg of glibenclamide. 
However, when given paraenterally the Cmax was appreciably higher (Jonsonn (2000b) 1.25 
mg IVI 376 (Caucasian) and 368 (Chinese)). This wide variation in Cmax is indicative of the 
variable bioavailabity of glibenclamide. This is confirmed by the very high Cmax obtained by 
Jonsonn et al. (1998). It is this variation in biovailabilty that lead to the reformulation of 
glibenclamide (micronisation). However, there is no correlation between the Cmax of 
glibenclamide, glucose and insulin as shown in this study. 
The Tmax of 1.62-2.09 hours is comparable to the values reported in the literature review 
[Jonsonn et al. (1998), Courtois et al. (1999), Jonsonn et al. (2000a and b). Jaber et al. (1994), 
Coppack et al.(1990)]. However, as shown in this study there is no coincidence in the Tmax 
of glibenclamide, glucose and insulin. 
4.2.4 Conclusion 
The PK parameters of glibenc1amide obtained from the NCA are consistent with those 
obtained from the literature. 
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5 Dose-exposure-response relationships evaluated using 
mathematical modeling methodologies 
5.1 Population pharmacokinetic modeling 
5.1.1 Introduction 
The population approach using nonlinear mixed effects modeling as implemented in the 
software NONMEM (Globomax LLC, USA and NONMEM Project Group, University of 
California, San Francisco) was used in this analysis. 
The primary purpose of this analysis was to describe the population PK of glibenclamide in a 
concise mathametical manner so that the estimated PK parameters might be used in the 
subsequent PKPD modeling. For the purposes of these analyses, dose amount of 
glibenclamide is presented in mg. Appendix 6 contains the NONMEM data file. 
5.1.2 Data used for Population PK modeling 
There were 24 individuals in the dataset who contributed a total of 841 observation records. 
Subjects 14, 16, 20 and 24 did not have complete data sets. Appendix 5 contains the 
glibenclamide, glucose and insulin concentrations. 
In the case of subject 14 all 10 samples at dose 2.5 mg and samples at time 0 and 0.5h at dose 
5 mg were lost in transit between the clinical centre and the analytical laboratory. Similary in 
subject 20 who completed all doses, 10 samples at dose 10mg were lost in transit. 
Subject 16 could not proceed with dose escalation beyond 5 mg since blood glucose levels 
were 3.6 nm101/L after 7 hours. Therefore there were no concentration versus time profiles 
sets at dose 10 and 20 mg. 
Subject 20 completed all doses. Subject 24 absconded from the study after dose 2.5 mg. All 
attempts to contact him were unsuccessful. 
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5.1.3 Pharmacostatistical Model development 
The structural phannacokinetic model selected was based on the NONMEM objective 
function value (OF) and diagnostic plots. 
The structural phannacokinetic model was implemented in NONMEM by selecting the 
appropriate ADV AN and TRANS subroutine from the PREDPP library of models. The first 
order conditional estimation method with interaction was used throughout this analysis. 
Unexplained inter-subject variability in structural model parameters was estimated using the 
following model with the random effect lli (Equation 51 and is contained in Appendix 8. 
Equation 5 
Pj = TVP*exp(lli) 
where TVP is the typical value of the phannacokinetic parameter P (e.g., CLlt) in the 
population, Pj is the individual value for P in the jth individual and lli is a random variable 
with mean of zero and variance COp2. This model assumes a lognonnal distribution for the Pj 
values. Estimates of inter-subject variability in P are presented as the square root of COp2, 
which is an approximation of the coefficient of variation of P for a log-nonnally distributed 
quantity. 
The glibenclamide concentration data was log transfonned prior to fitting. The residual error 
model of this log-transfonned data comprised of an additive model as shown in equation 6 
below. 
Equation 6 
C ij = C*ij (1 +Eij) 
where Cij is the ith concentration measured at time ti in the jth individual. C*ij is the 
respective model predicted concentration and the Eij is a nonnally distributed error tenn with 
mean of zero and variances (32. Examples of potential sources of residual variability include 
assay error, deviations from the model specification, and intra-subject variability. 
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5.1.4 Results from population pharmacokinetic modeling 
A two-compartmental disposition model Figure 32 was selected after evaluating 1, 2 and 3 
compartmental models to describe the time course of glibenclamide plasma concentration 
data. The 3 compartment model failed to achieve successful convergence as the 





Schematic representation of the 2-compartmental pharmacokinetic 
model and model equations 
Model Equations 
dA1 / dt = Ka*Oose+k21 * A2-(CUV1 +k12)* A1 
dA2/dt = k12*A1-k21*A2 
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Model diagnostics - observed versus model predicted concentrations 
for the one-compartment model are shown as points on the graph. 
The solid line represents the line of identity . 
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As depicted in the model diagnostic plots Figure 33, the 1 compartment model (Appendix 9) 
gives an adequate description of the data - however the 2-compartment model (Appendix 10) 
provided a better fit as judged by a drop in obj ective function value of 188 (-243 versus -431). 
All attempts to model the entero-hepatic recirculation (ERR) that was observed in the data 
were unsuccessful. The model that was used for ERR is shown in Appendix 11. 
Visual inspection of figure 37 below indicates that subjects 4, 7, 9,10 and 14 all showed ERe 
at 20.0mg and subjects 4, 9 and 10 at 10mg of glibenc1amide. The majority of subjects (19) 
did not show ERe. Furthermore there were not enough data points to fully characterize the 
ERe profile. 
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Figure 34: Model diagnostics - observed versus model predicted concentrations 
from the final two-compartment model are shown as points on the 
graph. The solid line represents the line of identity. 
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The model was implemented in NONMEM as follows. The subroutine ADV AN4, which 
implements an explicit solution for the two-compartment linear model with first order 
absorption, was chosen. Using the subroutine TRANS4, the estimated NONMEMIPREDPP 
model parameters comprised, first order absorption rate constant (Ka); V2/f and V3/f 
(apparent volume of distribution for the central and peripheral compartments); CUf and Q/f 
(apparent clearance from the central compartment and inter-compartmental clearance between 
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Model diagnostics - boxplots of population pharmacokinetic 
parameters versus dose. The clear horizontal. bar in the ~entre of .the 
box shows the median; the box encloses the inter-quartile range I.e. 
50% of the data. The whiskers show the interval of values outside the 
box and values far outside are represented by horizontal dashes 
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The final model was subjected to a posterior predictive check (Yano et al. 2001). In this 
procedure, 500 replications were run using the fixed and random effects from the final 
population pharmacokinetic model and using a study design identical to that used in this 
study. The median AUC for each dose from each replicate was calculated and the distribution 
of AUC values was compared with the median for each dose level calculated using NCA 
methods. Figure 36 shows that the observed (NCA) median AUC falls within the distribution 













Posterior predictive check of final 2-compartment model. Bars show 
the distribution of simulated median AUC calculated from 500 
replications of a dose escalation PK study with 24 subjects (design 
identical to current study). The dashed vertical line shows the median 
AUC observed in the current study 
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Ka = first order absorption rate; Cl1f: apparent clearance; V21f: apparent volume of the central compartment; QJf: apparent 
inter -compartmental clearance; V31f: apparent volume of the peripheral compartment; SE: standard error of the estimate; 
RSE: relative standard error of the estimate; BSV: between subject variability; CV: coefficient of variation 
The pharmacokinetic parameters of glibenclamide from the I-compartment and the final 2-
compartment model are presented in Table 50. The pharmacokinetics of glibenclamide is 
linear after multiple dose administration in the dose range 2.5 to 20 mg as suggested by the 
model diagnostic box plots of population phannacokinetic parameters versus dose (Figure 
35). The clear horizontal bar in the centre of the box shows the median; the box encloses the 
inter-quartile range i.e. 50% of the data. The whiskers show the interval of values outside the 
box and values far outside are represented by horizontal dashes. Figure 35 shows the absence 





























Individual phannacokinetic parameter estimates from the final 2 
compartment model 
Ka (1/h) CUf(Uh) V2If (L) Q/f(Uh) V3/f (L) 
0.63 2.10 10.03 2.77 68.10 
0.70 1.46 9.26 2.92 68.10 
0.67 2.30 9.94 3.56 68.10 
0.57 2.23 11.42 6.05 68.10 
0.43 2.45 12.85 6.88 68.10 
0.72 1.90 9.88 5.77 68.10 
0.40 1.90 13.41 1.88 68.10 
0.50 3.03 11 .80 1.94 68.10 
0.37 1.90 14.61 2.32 68.10 
0.49 1.86 12.28 2.19 68.10 
0.55 2.01 11 .31 2.68 68.10 
0.48 3.95 12.66 6.41 68.10 
0.46 2.58 12.61 7.17 68.10 
0.50 1.83 11 .32 1.30 68.10 
0.55 3.27 11 .26 7.30 68.10 
0.42 1.23 13.41 2.93 68.10 
0.47 1.81 13.07 7.40 68.10 
0.59 1.06 10.68 3.42 68.10 
0.82 3.18 8.87 4.22 68.10 
0.52 3.35 11 .97 7.54 68.10 
0.48 2.23 11 .94 6.11 68.10 
0.43 1.75 12.49 1.46 68.10 
0.56 3.31 11 .53 5.38 68.10 
0.53 2.31 11 .65 4.48 68.10 
Plots of observed log glibenclamide concentrations (open circles), 
population model predictions (dotted line) and individual model 
predictions (solid line) from the final 2 compartment model. Each row 
in the plot represents data for a single subject while each column 
represents data from a specific dose level. Blank cells indicate the 
subjects who did not receive that particular dose. 
Subjects 1 - 4 
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5.1.5 Discussion of Population PK modeling 
Three population pharmacokinetic models (Appendix 9-11) were fitted to the glibenclamide 
PK data using non-linear mixed effects modeling. While both the one and two compartment 
models terminated successfully, and produced similar graphical model diagnostic plots, the 2-
compartment model provided a better comparative fit due to its significantly lower OBJ 
function (MVOF -243.409 vs MVOF -431.164). A 3-compartment model was also attempted 
but was considered over parameterized as the model failed to achieve successful convergence 
due to the inter-compartment transfer rate constants being estimated as infinate. This 
suggested that the third compartment was poorly defmed. 
Despite extensive attempts at model refinement, the enterohepatic recycling (ERC) model did 
not converge successfully. This is possibly due to wide between subject variability (BSV) as 
well as within subject variability (WSV) in ERC i.e. some subjects show evidence of ERC at 
some doses but not at other dose levels. Furthermore there were not enough data points to 
fully characterize the ERC profile in all subjects. This model was eventually abandoned and 
the 2-compartment model was accepted as the final model. It was acknowledged that the 
poorly fitted ERC component of the profile in the final model would contribute to an inflated 
residual variability due to model mis-specification. Despite this drawback however, the 2-
compartment model provided a good fit of the model to the data as confirmed by the PPC. In 
particular, the model was able to provide an estimate of exposure (AVC) to glibenclamide that 
was consistent with the NCA estimates. This was especially important since one use of the PK 
model was to provide an estimate of average glibenclamide concentration (Cpss) for use as 
the driving force in a PKPD model. PPC is a method for the objective assessment of the 
predictive ability of a model. PPC is a robust method for model evaluation. Yano et al. (2001) 
concluded that 'if a PPC invalidates a model, one can be reasonably certain that the model has 
serious deficiencies.' 
The low RSE' s indicate the good precision of the estimated parameters and the anticipated 
relatively high residual variability was also noted (43.5% CV). The residual variability 
comprises of assay error, deviations from the model specification, and intra-subject 
variability. In the final 2-compartment model selected, one source of model misspecification 
is the inability to characterise the ERC of glibenclamide that was noted in several SUbjects. In 
addition, in some subjects the pre-dose glibenclamide concentration was also not well fitted 
by the model. This might reflect the lower degree of confidence in the dosing history 
(compliance with regard to timing and size of dose or even administration) for the un-
supervised doses that contribute to the pre-dose concentration. 
Individual plots of the glibenclamide concentration versus time profiles from the final 2-
compartment model show a very close agreement between the observed and model-
predictions. The relatively low BSV in CL (-34% CV) and V (-23% CV), suggested that 
covariates might not significantly improve the population fit. In addition, graphical 
examination of the PK parameters vs covariates did not reveal any obvious relationships. 
Consequently, no formal covariate analysis was conducted. 
The pharmacokinetic parameters derived from the 2 compartment model are discussed in 
relation to published data. 
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Glibenclamide is completely absorbed after oral administration and the rate and extent of 
absorption is not affected by food (Jaber et aI., 1993). Therefore, estimates for clearance and 
volume of distribution after oral administration are considered to be close approximations of 
those after intravenous administration. In this study, the dose of glibenclamide was taken on 
an empty stomach, 10 minutes before breakfast. Glycomin® (glibeclamide) is bioequivalent 
to the innovator product registered in South Africa i.e. Daonil®. 
Using a 1 compartment model, the Vd was 38.90 L (0.55 L/kg) which approximates that 
reported by Tracewell et al. (1998) [43.7 L; 0.509 L/kg] in their study of glibenclamide 
pharmacokinetics using a one compartment model with first order absorption and first order 
elimination. Other studies quoted by Tracewell et al. (1998) reports Vd values of 0.735 ± 
0.0150; 0.19 ± 0.01; 0.125 ± 0.008, 0.017 ± 0.00714; 0.200 ± 0.032; 0.144 ± 0.0156 ;0.04l3 
± 0.000975 and 0.57 ± 0.57 L/kg. Jaber et al. (1994) reported a Vd of 51 ± 51 Lih using a 1 
compartment model after a 12 week study. The Vd of this population is within the range 
reported in the literature. 
The volume of distribution ± SE of glibenclamide for the 2 compartment model is 11.70 ± 
1.11 Land 68.1 ± 6.0 L for the central and peripheral compartments respectively. This 
difference may be due to the separation of the compartments during modeling. 
The average clearance for glibenclamide is 1.52 ± 0.12 Lih (0.02 L/h/kg) for the 1 
compartment and 2.l6±0.16 for the 2 compartment model. The intercompartmental clearance 
(Q/f) is 3.84±0.58LIh. Tracewell et al. (1998) reported average values for glibenclamide 
clearance of 0.0387 ± 0.00642 L/h/kg in younger diabetics « 60 years) and 0.0525 ± 0.00349 
L/h/kg in older subjects (> 60 years). Other studies quoted by Tracewell et al. (1998) reported 
clearance values of 0.107 ± 0.051; 0.078 ± 0.00516; 0.0634 ± 0.00803; 0.09 ± 0.03; 0.078 ± 
0.029 and 0.0394 ± 0.00891 L/hr/kg. In addition, clearance values ± SE of3.2 ± 2.1,4.41 Lih 
(range 3.38-8.11 for Caucasians) and 4.10 Lih (range 2.91-5.98 for Chinese); and 3.70 Lih 
(1.15) were reported by Jaber et al. (1994); Jonsson et aI., (2000) and Jonsson et aI., (1998) 
respectively. The clearance value obtained for this study [mean age 54.1 ± 9.2 years] fall 
within the range of other reported studies and that of Tracewell et al. (1998) for their study 
population aged < 60 years. 
The average Ka (±SE) is 2.39 ± 0.34 h- I (1 compartment model) and 0.53 ± 0.04 h- I (2 
compartment). Jonsson (1998), Rydberg (1997) and Tracewell et al. (1998) reported Ka's of 
2.68 ± 1.50; 0.756 and 0.057± 0.244 h- I respectively. The variation in Ka's "may be due to 
various problems related to kinetic sensitivity (in reflecting a given change of ka), linearity 
(when considered versus ka), specificity (they depend on other parameters except the ka) 
and/or their precision of estimation of the system. With the currently available methodologies 
and with no ideal absorption rate constant metric available, absorption rate cannot be 
accurately estimated. " (Reppas, 2003). Furthermore the sampling interval in the absorptive 
phase coupled with variations in physiological factors may also contribute to this wide 
variation. 
192 
5.1.6 Conclusions from PK modeling 
Using the population approach and the software NONMEM, the pharmacokinetics of 
glibenclamide in this study population was described by a two compartmental disposition 
model with first order absorption. The pharmacokinetics of glibenclamide in this study 
popUlation is comparable to that reported in the literature, save for Ka. The model was 
subjected to internal validation using the PPC approach and shown to provide acceptable 
model predictions of AUC and hence average glibenclamide concentration. This estimate of 
average concentration will be used to further investigate the pharmacokinetics and 
pharmacodynamics of glibenclamide. 
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5.2 Population pharmacokinetic-pharmacodynamic modeling 
5.2.1 Introduction 
In this study, drug concentration and the corresponding blood glucose and blood insulin 
concentrations were measured. While it is possible to model the full glibenclamide-insulin-
glucose system, the glucose-glibenclamide system was used in this study, in keeping with the 
work of other researchers (Rydberg et aI., 1997 and Tracewell et aI., 1998). In clinical practice 
the effect of glibenclamide on glucose requires less technical skill and is less costly, than with 
insulin. The clinical effectiveness of antidiabetic treatment and hence decisions on 
management of diabetes, is determined by fasting and/or postprandial blood glucose levels. 
Hence, this study utilizes the glibenclamide-glucose system for PKlPD analysis. 
The advantage of using the model-based analysis, is that the dose is treated as a continuous 
variable and the breaking point can be identified by interpolation. 
In this dose escalation study a zero dose (absence of glibenclamide) was employed to 
characterize the insulin and glucose profiles. Insulin and glucose (for the purposes of this 
analysis) are regarded as physiological substances whose production and synthesis are 
interdependent. Hence, the methodology of Kryzyzanski et ai. (2000) using Fourier analysis 
was adopted. Kryzyzanski et ai. (2000) described a mathemathical basis and an algorithm for 
application of Fourier analysis to quantify variable, but biorhythmic, physiologic substances 
in order to generate input functions for use in pharmacodynamic indirect response models. 
This method does not require trial and error non-linear regression analysis to identify the 
optimal number of harmonics that describe the response pattern (Kryzyzanski et aI., 2000). 
The popUlation approach using nonlinear mixed effects modeling as implemented in the 
software NONMEM (Globomax LLC, USA and NONMEM Project Group, University of 
California, San Francisco) was used in this analysis. Appendix 7 contains the NONMEM data 
file for the pharmacodynamic analysis. This model-based analysis was conducted to fully 
characterize the dose-expo sure-response relationship as a monotonic function and thereby 
facilitate interpolation and prediction of response for doses and exposures not formally 
studied or observed. 
In modeling the PKPD relationship, 2 broad categories of models were examined - models 
with glibenclamide dose as the driving force for the PD response variable and models with 
glibenclamide concentration as the driving force. In this way, the role of PK variability on 
the overall variability was examined. The PD response metric that was tested included FBG, 
mean glucose concentration and the full glucose concentration profile. Thus during PKPD 
modeling the following models were tested: 
• Dose as driving force on FBG 
• Cpss as driving force on FBG 
• Dose as driving force on mean glucose concentration 
• Cpss as driving force on mean glucose concentration 
• Dose as driving force on full glucose profile 
• Cpss as driving force on full glucose profile 
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5.2.2 Data for population PKPD modeling 
There were 24 individuals who contributed to the PKPD dataset. All except 2 subjects 
contributed data on all dose escalation steps. Subject 16 could not proceed to a dose escalation 
beyond 5 mg/day due to the presence of symptoms of hypo glycaemia and subject 24 did not 
have complete data sets. 
5.2.3 Models with fasting glucose concentration as PO end-point 
5.2.3.1 Dose as driving force on fasting glucose concentration 
Model description 
The effect of glibenclamide on glucose response was modeled with an inhibitory Emax model 
as shown in Equation 7. 
Equation 7 
Effect = Eo * [(1 - (Dose * Emax)/(Dose + ED50)] 
Where: 
Eo is the baseline glucose concentration 
ED50 is the dose that leads to 50% inhibition of the glucose concentration 
Emax is the maximum response to glibenclamide 
Effect is the fasting blood glucose concentration 
This Emax model has properties that account for the hyperbolic shape of the dose-response 
relationship. The parameters are maximum response (Emax) and potency. The model itself is 
limited in explaining differences between regimens (i.e., different PK inputs) or understanding 
the sources of variability. Differences in ED50 could be due to differences in drug exposure 
(PK) , or differences in PD sensitivity. Hence, to elucidate these questions regarding regimen 
and the underlying variability, PK and PD data need to be modeled. 
Results from model for dose as driving force on fasting glucose 
The observed vs population predicted glucose concentrations shows even distribution around 
the line of best fit, as does the observed vs individual predicted glucose concentrations. While 
these graphical representations suggest that the model is suitable in describing the effect of 
dose on fasting glucose concentrations, it does not consider the changing glucose profile 
throughout the 8 hour study period, nor does it take into consideration the pharmacokinetics 
of glibenclamide. This is co firmed by the coincidence of individual plots of observed glucose 
concentrations (open circles), population model predictions (dotted line) and individual model 
predictions (solid line) from the Dose-Fasting Glucose plots (figure 39). Subject 4 the 
observed and model prediction profiles are superimposable. This suggests that the model is 





Model diagnostics - observed versus model predicted glucose 
concentrations for the Dose-Fasting Glucose Concentration 
pharmacokinetic-pharmacodynamic model are shown as points on the 
graph. The solid line represents the line of identity. 
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Figure 38 is a model diagnostic plot of observed vs predicted FBG concentrations (population 
and individual) and shows an even distribution around the line of identity. These global 
graphical representations suggest that the model provides a satisfactory description of the 
data. In figure 39, however, the model fit at the individual level is shown. While the model 
predictions show a generally good correspondence with the observed data, there are several 
data points in individual subjects that are poorly fitted. 
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Figure 39: Plots of observed glucose concentrations (open circles), population 
model predictions (dotted line) and individual model predictions (solid 
line) from the Dose-Fasting Glucose Concentration PKPD model for 
glucose response to glibenclamide. Each cell represents the data for 
an individual subject shown as a dose-response plot - i.e. y-axis 
shows fasting glucose concentration in mmollL; x-axis shows dose in 
mg. 





Subjects 13 - 24 
Dose (mg) 
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5.2.3.2 Cpss as driving force on fasting glucose concentration 
Model description 
This Emax model has properties that account for the hyperbolic shape of the concentration 
response relationships (equation 4 and 5) rather than the dose response relationship. In 
contrast to the previous dose response model it is now possible to differentiate between PK 
variability (in CLlt) and PD variability. 
Equation 8 
Effect = Eo * (1 - (Cpss * Emax)/(Cpss + EC50)) 
Where Cpss is calculated as per Equation 9 using the CLif estimated from the Population PK 
model (Table 51). 
Equation 9 
Cpss = Dose/(CLlf* 24) 
This model is not very sensItive for understanding differences between regimens (i.e., 
different PK inputs) but may be satisfactory for this data set because this is a steady state 
response. 
Results from model for Cpss as driving force on fasting glucose concentration 
Figure 40: 
3. 
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In Figure 40 the observed versus model predicted FBG concentrations is shown for the model 
that now includes PK variability. The individual predictions from this model are shown in 
figure 41. This model using Cpss as the driving force for the PD response incorporates the 
individual subject's clearance in determining the FBG concentrations i.e., it accounts for the 
individual PK variation which might contribute to the overall PD response. When comparing 
the diagnostic plots for these 2 models (Figure 39 versus Figure 41 and Figure 38 versus 
Figure 40), there does not appear to be any striking difference in the predictions. The poor fit 
of some data points in individual subjects that was observed with the Dose model has not been 
improved by the Cpss model. 
The population model predictions are overestimated in subjects 10, 15, 17, 18,20 and 21 and 
underestimated in subjects 2, 3, 4, 5, 7, 13, 19 and 23. There does not appear to be any 
striking differences in the observed vs predicted or individual subject fits of the model to the 
data when compared to the validity of the dose as driving force on fasting glucose model. 
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Figure 41: Plots of observed glucose concentrations (open circles), population 
model predictions (dotted line) and individual model predictions (solid 
line) for the Cpss-Fasting Glucose Concentration PKPD model for 
glucose response to glibenclamide. Each cell represents the data for 
an individual subject shown as a dose-response plot - i.e. y-axis 
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Table 52: Population pharmacokinetic-pharmacodynamic parameters for the 
models with fasting blood glucose as the PO response 
Eo (mMoI/L) 
Emax 
Dose - Fastin Glucose Model 
Estimate RSE (%) BSV (%CV) 
14.10 6.35 29.05 
0.37 37.47 48.68 
ED50 (mg) 
EC50 (ug/L) •• 
Residual 
variability 
Cpss - Fastin Glucose Model 
Estimate RSE (%) BSV (%CV) 
14.30 6.04 27.40 
0.39 22.64 55.50 
variance 0.02 (15%) 0.02 (14%) 
(%CV) 
Eo = Baseline glucose concentration; Emax = maximum inhibition of glucose concentration; EC50 is the glibenclamide 
concentration producing 50% inhibition of glucose concentration ; ED50 is the glibenclamide dose producing 50% inhibition of 
glucose concentration; RSE: relative standard error of the estimate; BSV: between subject variability; CV: coefficient of variation 
* Derived ED50 = Cpss * Cl/f * 24 where Cpss = 85.20 ug/L and Cl/f = 2.16 Uh 
Comparing Dose vs FBG or Cpss vs FBG as the driving force for the model, the parameters 
are estimated with better precision i.e., lower RSE (6.35% vs 6.04%) for the model with Cpss 
as the driving force. Apart from this, there is little difference in the estimated model 
parameters. There is a low variability in the estimate of potency for dose-fasting glucose 
model (ED50= 4.56mg) as compared to Cpss-fasting glucose model (ED50 derived= 
4.41mg). 
The parameters from the Dose and the Cpss models for FBG as the PD response are compared 
in Table 52. The point estimates for the fixed effects model parameters are essentially the 
same for the 2 models - however the parameters are estimated with better precision i.e., lower 
RSE with the Cpss model. The estimates for BSV are different for all parameters - essentially 
larger for the Cpss model. Of particular interest however, is that the estimate of potency 
(ED50 and EC50) of between 4 and 5mglday does not reflect the expectation from Figure 21 
that the potency should lie between 0 and 2.5mg. In addition, it is disconcerting that there is 
remarkably low variability in the estimate of potency with both models. 
201 
5.2.4 Models with mean glucose concentration as PO end-point 
5.2.4.1 Dose as driving force on mean glucose concentration 
Model description 
The model is as described in Equation 7. However, response is now the mean glucose 
concentration rather than FBG. The mean glucose concentration is calculated as the area 
under the glucose concentration versus time curve divided by the time over which the glucose 
concentrations were measured. The limitations of this model are similar to those mentioned 
for the model described above. Appendix 12 contains the NONMEM code for the Dose/Cpss-
Mean glucose profile. 
Results from model with dose as driving force on mean glucose concentration 
Figure 42 is a model diagnostic plot of observed vs predicted mean glucose concentration 
(population and individual) and shows an even distribution around the line of identity. These 
global graphical representations suggest that the model provides a satisfactory description of 
the data. In Figure 43, the model fit for each individual is shown. These model predictions 
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Figure 43: Plots of observed mean glucose concentrations (open circles), 
population model predictions (dotted line) and individual model predictions (solid line) 
for the dose-mean glucose Concentration PKPD model for glucose response to 
glibenclamide. Each cell represents the data for an individual subject shown as a 
dose-response plot - i.e. y-axis shows mean fasting glucose concentration in mMoI/L; 
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5.2.4.2 Cpss as driving force on mean glucose concentration 
Model development 
The model is as described in Equation 8. However, response is now the mean glucose 
concentration calculated as the area under the glucose concentration versus time curve divided 
by the time over which the glucose concentrations were measured. 
Results from model with Cpss as driving force on mean glucose concentration 
In this model both the pharmacokinetics of glibeclamide (Cpss) and pharmacodynamics 
(mean glucose concentration) are incorporated. There is minimal difference between the 
models: dose vs average glucose concentration and the Cpss vs average glucose 
concentration. In figure 44 the observed vs individual model predicted glucose concentrations 
are symmetrically distributed along the line of best fit. This suggests that the model is 
predictve for individual subjects. In the case of population model predicted glucose 
concentrations there is equal distribution along the line of best fit, depicting the over and 
underestimation of the model. 
However, the pharmacodynamic variability overshadows the pharmacokinetic variability in 
this model (Fig 44). Inspection of figure 45 shows that the model describes the individual 
observed glucose, individual predicted and population predicted glucose concentrations for 
subjects 9, 11 , 12 and 14. It equally underestimates and overestimates the remaining subjects, 
however the model describes the observed mean glucose and individual predicted average 
glucose concentrations. 
Figure 44: Model diagnostics - observed versus model predicted glucose 
concentrations for the Cpss - Mean Glucose Concentration 
pharmacokinetic-pharmacodynamic model are shown as points on the 
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Plots of observed glucose concentrations (open circles), population 
model predictions (dotted line) and individual model predictions (solid 
line) for the Cpss - Mean Glucose Concentration PKPD model for 
glucose response to glibenclamide. Each cell represents the data for 
an individual subject shown as a dose-response plot - i.e. y-axis 
shows fasting glucose concentration in mMolIl; x-axis shows dose in 
mg. 
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Table 53: Population pharmacokinetic-pharmacodynamic parameters for the 







Dose - Mean Glucose Model 
Estimate RSE (%) BSV (%CV) 
16.70 5.74 27.07 
0.34 14.32 50.99 
Variance 0.008 0.008 
(%CV) (8.75%) (8.92%) 
- Mean Glucose Model 
RSE (%) BSV (%CV) 
5.74 26.94 
14.49 50.89 
Eo = Baseline glucose concentration; Emax = maximum inhibition of glucose concentration; EC50 is the glibenclamide 
concentration producing 50% inhibition of glucose concentration; ED50 is the glibenclamide dose producing 50% inhibition of 
glucose concentration; RSE: relative standard error of the estimate; BSV: between subject variability; CV: coefficient of variation 
• Derived ED50 = Cpss • Cllf • 24 where Cpss - 36.00 ug/L and Cllf = 2.16 Uh 
Table 53 shows virtually no difference in the fixed effect parameter estimates from the Dose 
or the Cpss models when mean glucose is the PD response. The random effects parameters are 
also similar - with the exception of the estimate of potency where a decrease in BSV is noted 
i.e. inclusion of PK variabilility in the model by using Cpss as the driving force resulted in a 
decrease in the BSV from 120 % CV for ED50 to 108 % CV for EC50. 
When one compares these models where the PD response is mean glucose concentration with 
the models where FBG was the PD response (Table 52), a higher estimate for the modeled 
baseline glucose concentration (16.70 vs 14.10 mMol/L) is noted. This is to be expected with 
these different PD metrics: FBG versus mean glucose concentration. The maximum effect 
seen with both groups of models is very similar. A more realistic estimate of potency (EC50 
or ED50) is noted in the current model viz. approximately 1850-1870 )lg. In addition, a much 
larger variability is noted in the potency parameters relative to the model where the 
pharmacodynamic response was FBG. By calculating the mean from several glucose 
concentrations, one more closely approaches the subject's 'true' glucose concentration. It 
might be argued that a fasting measurement i.e., one taken when the biological system is not 
being subjected to the known factors that can influence glucose response (e.g. food) would be 
subject to lower variability. This is likely to be true if several FBG measurements were drawn 
rather than a single value i.e. the observed better performance of the current model is more 
likely to be a reflection of the fact that the mean of multiple glucose measurements were used. 
One striking piece of evidence for this is the dramatic decrease in the residual variance from 
0.02 to 0.008 i.e., a decrease of 60%. 
While this model provides a good description of the data and is considered adequate for the 
purposes of this analysis, one further attempt at building a model for the PD effect was 
considered viz. modeling the full glucose concentration versus time profile. 
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5.2.5 Models with full glucose profile as PO end-point 
Description of model for placebo response 
Graphical exploration of the glucose time course data during the placebo phase of the study 
revealed a consistent harmonic pattern. This data was modeled using a combination of sine 
and cosine functions as shown in Equation 10. This placebo model was used to describe the 
full glucose versus time profile. The placebo model response was used to ensure that changes 
in glucose profiles were due to the drug and not to glucose homeostasis. 
Equation 10 
Eo = Ao + Al *COS(2*n*TimelPeriod) + BI *SIN(2*n*Time/ Period) 
+ A2*COS(4*n*TimelPeriod) + B2*SIN(4*n*Time/ Period) 
Ao Represents the baseline glucose concentration (measurement at time 0) 
Al , A2 ,BI and B2 are the coefficients for the harmonic function 
Period was 8 hours viz. the time during which glucose concentrations were measured 
Unexplained inter-subject variability in the baseline glucose concentration (Ao) was estimated 
using the following model (Equation 11) with the random effect llj. 
Equation 11 
AOj = TVP*exp( llj) 
where TVP is the typical value of Ao in the population, Aoj is the individual value for Ao in 
the jth individual and llj is a random variable with mean of zero and variance mAo 2. This 
model assumes an exponential distribution for the Aoj values so as to constrain the estimate of 
the baseline glucose concentration to positive values. 
On the other hand, the coefficients of the harmonic function could take on both positive and 
negative values and were therefore modeled with an additive error distribution as shown in 
Equation 12. 
Equation 12 
Pnj = TVPn+ llj 
where TVPn is the typical value for the coefficient of interest (AI , A2 , BI and B2) in the 
population, Pnj is the individual value for the relevant coefficient in the jth individual and llj is 
a random variable with mean of zero and variance mPn2. The omega matrix for all the 
coefficients was constrained to the same value i.e., the llvalues were drawn from the same 
distribution. The glucose concentration data was log transformed prior to fitting. 
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C ij = C*ij (1 +Eij) 
where Cij is the ith glucose concentration measured at time ti in the jth individual. C*ij is the 
respective model predicted concentration and the Eij is a normally distributed error term with 
mean of zero and variances (52. Examples of potential sources of residual variability include 
assay error, deviations from the model specification, and intra-subject variability. 
Appendix 13 contains the NONMEM code for the Dose/Cpss-Full Glucose Profile. 
Results of model for placebo response 
The fluctuations in glucose concentrations over the observation period were due primarily to 
the response to food. In this study, subjects were given breakfast, followed by lunch 
approximately 4 hours later. The initial peak in glucose corresponds to ingestion of breakfast 
and the subsequent peak 4 hours later, to lunch. Sampling to characterize these two events 
showed two blood glucose peaks at approximately 2 and 6 hours, temporally related to the 
ingestion of food. The model selected to describe this data is empirical and has no 
physiological meaning - the data could also have been fit with a series of spline functions or a 
polynomial to the placebo data. 
The empirical placebo model was used to describe the time course of glucose concentration 
data over the ~8 hour study observation period. It satisfactorily described the data save for 
subjects 2, 13, 16 and 19. In all other subjects, the observed, individual predicted and 
population predicted curves are all almost superimposable, strengthening the validity of the 
model. 
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5.2.5.1 Dose as driving force on full glucose profile 
Model description 
The model is as described in Equation 7. However, response is now the full glucose 
concentration versus time profile modeled using the placebo model shown in Equation 10. 
Results from model with dose as driving force on full glucose profile 
Figure 48 shows that the full glucose profile model adequately describes the data as there is a 
good correspondence between the observed data and the model predictions. The empirical 
placebo model used to describe the time course of glucose concentration data over the ~8 hour 
study observation period was able to satisfactorily characterize the data. 
The concentration and dose response is shown by the shift in the entire glucose concentration 
versus time profile downwards as one progresses from left to right within a row i.e. from 
placebo on the left to the highest dose administered on the right. 
The parameters from this complex full model are shoWn in Table 54. 
As shown for the previous models, Figure 46 provides the global graphical model diagnostic 
plot to indicate a satisfactory description of the observed vs predicted glucose concentrations 
(population and individual). In this model there are more data points because the full time 
course of glucose is being modeled and not a single PD metric such as FBG or the mean 
glucose concentration. In the interests of brevity, the individual subject fits are not shown for 
the dose-full glucose profile model. 
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Figure 46: Model diagnostics - observed versus model predicted glucose 
concentrations for the Dose-Full Glucose Profile pharmacokinetic-
pharmacodynamic model are shown as points on the graph. The solid 
line represents the line of identity. 
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5.2.5.2 Cpss as driving force on full glucose profile 
Model description 
The model is as described in Equation 8. However, response is now the full glucose 
concentration versus time profile modeled using the placebo model shown in Equation 10. 
Figure 47: Model diagnostics - observed versus model predicted glucose 
concentrations for the Cpss-Full Glucose Profile pharmacokinetic-
pharmacodynamic model are shown as points on the graph. The solid 
line represents the line of identity . 
.... 
1.0 1.5 2.0 2.5 3.0 3.5 1.0 1.5 2.0 2.5 3.0 3.5 
PopJtalion Predicted Glucose Cone mMoIIl. IndMdu .. Predicted Glucose Cone mMoIn.. 
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Figure 48: Plots of observed glucose concentrations (open circles), population 
model predictions (dotted line) and individual model predictions (solid 
line) for the Cpss-Full Glucose Profile pharmacokinetic-
pharmacodynamic model. Each row represents the data for an 
individual subject; each column represents a different dose level -
with placebo on the extreme left and increasing doses of 2.5, 5, 10 and 
20 mg in the subsequent columns. 
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Population pharmacokinetic-pharmacodynamic parameters for the 
models with full glucose profile as the PO response 
Dose - Full Glucose Profile Model - Full Glucose Profile Model 
Estimate RSE (%) BSV (%CV) Estimate RSE (%) BSV (%CV) 
15.90 4.71 28.71 15.40 5.40 32.71 
0.95 17.44 120.83 0.97 16.36 7.05 
1.45 36.34 120.83 1.45 34.21 7.05 
-1 .95 -14.26 120.83 -1.86 -15.38 7.05 
2.63 8.75 120.83 2.57 8.05 7.05 
0.34 14.97 5.75 0.31 9.20 45.39 
29.46 
(%CV) 0.02 (13%) 0.02 (13%) 
~ = Baseline glucose concentration; A1• B1• A2• B2 = coefficients of the harmonic function; Emax = maximum inhibition of 
glucose concentration; ED50 is the glibenclamide dose producing 50% inhibition of glucose concentration ; EC50 is the 
glibenclamide concentration producing 50% inhibition of glucose concentration; RSE: relative standard error of the estimate; 
BSV: between subject variability; CV: coefficient of variation 
• Derived ED50 = Cpss • Cl/f • 24 where Cpss = 43.60 ug/L and Cl/f = 2.16 Uh 
The point estimates of the fixed effects PD model parameters (baseline glucose concentration 
(Ao), potency (EC50 and ED50) and Emax are essentially not different in the Dose and the 
Cpss models (table 54). However, there is a difference in the random effects parameters, in 
particular the Fourier coefficients have higher variability while the primary PD model 
parameters have lower variability in the dose model compared to the Cpss model. A likely 
explanation for this is that PK variability is being confounded with PD variability - the dose 
model can only allocate the PK variability into the Fourier coefficients. The variability in 
potency is also much larger in this model than that seen with the model where the PD 
response was the mean glucose concentration (221 % CV versus 108 % CV) [table 53]. 
Thus despite the very good fit of the model to the datai this is likely to be due to the large 
amount of flexibility that is allowed by the large number of model parameters. Consequently, 
the models where mean glucose concentration is the PD response was selected as being 
adequate for this data. 
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5.2.6 Discussion of PKPD modeling 
PKJPD modeling assists in characterizing and predicting the time course of drug effects (both 
intensity and duration) in healthy and diseased subjects (Breimer and Danhof, 1997). The 
PKJPD model helps with dose interpolation. For example, in a clinical trial which utilizes 
conventional methodologies, comment can only be made on the doses tested. It is not possible 
to consider doses other than that actually employed in the study. However, with modeling it is 
possible to interpolate between doses (for example, in this study it is possible to interpolate at 
dose 1.2Smg or 7.S mg, although these doses were not used in the study). 
Graphical exploration of the within-subject drug response shows that there does not appear to 
be any direct acute response to glibenclamide. An examination of crude data of glucose, 
insulin and glibenclamide profiles with increasing doses of glibenclamide shows that there is 
no direct relationship between drug administration and glucose or insulin response i.e., there 
is no acute effect of drug on these parameters. This deduction is in keeping with that made by 
Gin et ai. (198S) that ordinary doses of sulphonyureas will potentiate insulin mediated glucose 
uptake after a latent period of 12 hours (Gin et aI., 1985). Further, Rydberg et ai. (1997) 
observed that at a " .. given concentration of glibenclamide, a more intense effect is observed at 
the later sample time due to additional hypoglycaemic effect of in vivo formed metabolites." 
NONMEM was used to fit the following models: 
• Dose as driving force on fasting glucose 
• Cpss as driving force on fasting glucose concentration 
• Dose as driving force on mean glucose concentration 
• Cpss as driving force on mean glucose concentration 
• Dose as driving force on full glucose profile 
• Cpss as the driving force on full glucose profile 
In comparing Dose vs FBG or Cpss vs FBG as the driving force for the model, the 
parameters are estimated with better precision i.e., lower RSE (6.3S% vs 6.04%) for the 
model with Cpss as the driving force. Apart from this, there is little difference in the estimated 
model parameters. There is a low variability in the estimate of potency for dose-fasting 
glucose model (EDSO= 4.S6mg) as compared to Cpss-fasting glucose model (EDSO derived= 
4.41mg). 
There is no difference in the parameter estimates from the Dose or the Cpss models, where 
the. pharmacodynamic (PD) response is mean glucose concentration. There is a higher 
estImate for the modeled baseline glucose concentration for the dose vs mean glucose 
concentration model as compared to the dose vs FBG model (16.70 vs 14.10 mmol/L). The 
EDSO (1.8S mg) and the derived EDSO (1.87mg) for the dose vs mean glucose concentration 
model are almost identical with a between subject variability (BSV) of approximately 12% 
(120.42-108.17). 
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In addition, a much larger variability is noted in the potency parameters relative to the model 
where the pharmacodynamic response was FBG. By calculating a mean glucose 
concentration, the variability in concentrations during the course of the observation period is 
being brought into the model. Intuitively, one would expect a fasting measurement i.e. one 
taken when the biological system is not being subjected to the known factors that can 
influence glucose response (e.g., food) to be subject to lower variability. FBG is also the 
pharmacodynamic marker directly influenced by the sulphonylureas and is probably the best 
PD response variable to monitor. This accounts for the differences in the estimates of random 
effects parameter estimates. The maximum effect seen with both groups of models is very 
similar. 
The point estimates of the primary PD model parameters for the Dose vs full glucose profile 
and the Cpss vs full glucose profile are not essentially different i.e., baseline glucose 
concentration, (Ao) [15.9 and 15.4 respectively], potency (ED50=2.21 and ED50 derived=2.26 
respectively) and Emax (0.34 and 0.31 respectively). However, there is a difference in the 
random elements, in particular, the Fourier coefficients have higher variability while the 
primary PD model parameters have lower variability in the dose model compared to the Cpss 
model. It seems therefore that the greater freedom allowed to the model with the large number 
of extra parameters results in 'inappropriate' apportioning of relative contributions of 
variability. An attempt was made to resolve this by estimating the Fourier coefficients from 
the placebo data alone and then subsequently fixing these in the estimation step for the full 
data set. However, the model with the full data set failed to converge. 
The Emax of for the 6 models tested varies from 0.37 for the dose vs FBG to 0.31 for the 
Cpss vs full glucose profile models. This means that the maximal benefit of glibeclamide 
therapy in this population would vary from 31 to 37 percent. This translates to a reduction of 
the FBG from 15.4mmoVL to 10.6mmo1/L and 9.7mmoVL respectively. This reduction in 
FBG, while statistically significant, is clinically inadequate for effective control of diabetes 
because this value is higher than that accepted by ADA (4.4-6.6 mmoVL) and SEMDSA (4-6 
mmoVL). 
The ED50 and the derived ED50 for the 6 models described are 4.56 mg, 4.41mg, 1.85 mg, 
1.87 mg, 2.21 mg and 2.26 mg respectively. Analysis of our data which describes the 
relationship between dose, glucose, insulin and glibenclamide concentrations in diabetic 
patients supports a maximum effective dose of 5 mg. In addition, an evaluation of glycaemic 
control in individual patients showed that only 7 (30%) and 4 (17%) subjects achieved 
acceptable and optimal control respectively at doses greater than 5 mg per day. Both the 
observed and the modeled data suggest a maximal dose not exceeding 5 mg in the study 
population. This conclusion is supported by the findings of Rydberg et al. (1997) and Groop 
et al. (1991) that "the maximum effect of glibenclamide would be obtained by 5 mg or less." 
Further increase in glibenclamide dose (as is the current clinical practice in SA, See chapter 1) 
are not likely to produce significant reductions in blood glucose. High dose glibeclamide is 
associated with various side effects two of which are: increased cardiovascular risk and 
masking of the severity of a myocardial infarction (Huizar, 2003). 
In South Africa, the case against the use of high dose glibenclamide was first presented by 
Robertson and Jackson (1989) who showed that a reduction in the dose of glibenclamide 
fro~ ~5 mg/day ~o 2:5 mg/day in 15 type 2 DM subjects resulted in 12 (80 %) subjects 
achIevmg a reductIOn m fasting blood glucose. 
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High dose glibenclamide cannot be advocated because it is therapeutically ineffective, cost 
ineffective and potentially hazardous and subjects on high doses are often eating to 'keep up 
with their glibenclamide'. 
The PK of glibenclamide does not enhance predictability of glibenclamide 
pharmacodynamics. This reaffirms the findings of Tracewell et al. (1998) who concluded that, 
"interpatient variability in response to glyburide is not primarily due to intersubject 
differences in the agents pharmacokinetics." A similar conclusion was reached by Rydberg et 
al. (1997), "there is no simple direct relationship between sulphonlyurea concentrations and 
hypoglycaemic effect." 
This finding vindicates the use of low dose glibenclamide. 
While all models presented adequately describe the experimental data, the dose on FBG 
model is the preffered model for the following reasons: 
• In clinical practice in South Africa, dose adjustment of glibencamide is based on FBG. 
• FBG is a better measure of response to glibenclamide in type 2 diabetics because 
glibenclamide decreases FBG with very little effect on PPG. 
• FBG is also the pharmacodynamic marker directly influenced by the sulphonylureas 
and is probably the best PD response variable to monitor. 
• Cpss of glibenclamide is not a useful determinant of response (blood glucose levels) as 
reported by Rydberg et al. (1997) that there "is no simple direct relationship between 
sulphonlyurea concentrations and hypoglycaemic effect." Furthermore, assays of 
glibenclamide are expensive and not readily available. 
• Insulin determinations in clinical practice are not only expensive but do not contribute 
to dosage adjustment, unlike FBG. 
Application of this model i.e., Dose as a driving force on FBG, can be used for dosage 
optimization in clinical practice. 
Conclusion 
In this thesis, six PKlPD models were developed to characterize dose-effect relationships of 
glib encl amide. These models were developed from NCA which provided exploratory data for 
initial estimates and guides for population PK analysis (using NONMEM). The population 
approach was the primary data analytical method used in this study. 
A 2 compartment model was developed using parameters derived from popUlation PK. The 2-
compartment model provided a good fit of the model to the data as confirmed by the PPC 
(Figure 36). In particular, the model was able to provide an estimate of exposure (AVC) to 
glibenclamide that was consistent with the NCA estimates. This was especially important 
since one use of the PK model was to provide an estimate of average glibenclamide 
concentration (Cpss) for use as the driving force in a PKPD model. 
The model most suitable to describe the data and clinically relevant and practical is the Dose 
on FBG model. The dose derived from this model suggests a maximum of 5 mg of 
glibenclamide per day which coincides with the dose derived from the exploratory analysis. 
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6 Limitations 
• Serial insulin and glucose evaluations were only performed during the study period of 
approximately 8 hours. Ideally, a 24 hour study would have been preferred to full 
characterize these parameters (terminal phase of glibenclamide elimination) but was 
viewed as a major inconvenience by subjects 
• Earlier and more frequent sampling for insulin and glucose would have allowed 
measurements of acute insulin response (AIR). It is recommended that future studies 
should include this in the study design 
• Patient inclusion criteria should have included insulin resistance status 
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7 Recommendations 
• Dose of glibenclamide should not exceed 5-10 mg 
• Patients on high dose glibenclamide should have their dosages reviewed 
• Both FBG and PPG be used as markers of glycaemic control i.e., choice of drug and 
adjustment of dosage 
• Patients not responding to the recommended dose of glibenclamide should receive 
combination therapy, preferably with an insulin sensitizer 
• Future studies should profile the PKJPD of glibenclamide and its metabolites 
• Future studies should validate the modified insulinogenic index as a measure of acute 
insulin release 
• Future studies should include more data points to characterize EHC and the terminal 
elimination phase of glibenclamide 
• Insulin resistance status should be established in inclusion criteria in future studies 
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8 Summary of Findings 
This dose escalation study evaluated the PK and PD and the clinical benefit of glibenclamide 
in type 2 DM subjects. 
Evaluation of clinical benefit from this dose escalation study of glibenclamide revealed that 
only S7% were controlled, using SEMDSA's criteria for acceptable control. Only 17% 
achieved acceptable control when FBG and PPG were evaluated simultaneously. 
Using the HOMA-IR and QUICKI methods, all patients were insulin resistant and did not 
respond effectively to glibenclamide. 
While the mean blood concentration of glibenclamide increased linearly with increasing 
doses, there is no proportional increase in insulin secretion or proportional decrease in blood 
glucose concentration. Evaluation of the pharmacokinetics of glibenclamide, insulin and 
glucose shows no coincidence. This implies that glibenclamide blood levels do not correlate 
with pharmacodynamic response. 
The pharmacokinetics of glibenclamide as determined using NCA and compartmental 
analysis was similar to that reported in the literature. Using the popUlation approach the PK of 
glibenclamide was described by a two compartment model with first order absorption. The PK 
reported in this study was comparable to that reported by other researchers. Validation of the 
model using the PPC approach provided acceptable model predictions of AUC and therefore 
glibenclamide concentration. 
PKPD relationships were modeled using the software NONMEM to fully characterize the 
dose-expo sure-response relationships. Six models using dose as the driving force and 
concentration as the driving force were implemented. On evaluation of the six models the 
dose on FBG was preferred because FBG is the parameter directly influenced by 
sulphonylureas and clinically is the best PD response to monitor. 
PKlPD modeling showed that the maximum mean reduction in blood glucose concentrations 
(Emax) was approximately 34% from a baseline of lSmmol/L. In addition, the glibenclamide 
dose producing SO% inhibition of glucose concentration (ED so) was estimated from the 
models to be in the region of 2.S to Smg. The Emax and EDso confirm that dose escalation of 
glibenclamide in these subjects is unlikely to produce substantial clinical benefit. 
Since most subjects were insulin resistant and are not likely to benefit from glibenclamide 
monotherapy, insulin sensitizers should be added to the regimen of those patients not 
responding to doses greater than S mg of glibenclamide. 
High doses of glibenclamide i.e., 20 mg/day does not produce proportional decreases in blood 
glucose but expose the patients to increased incidence of cardiovascular side effects. 
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Appendices 
1 Packaging records of glibenclamide 
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Centre A CentreD --------
Glibenclamide Unit ofIssue 2000 2001 2002 
28 4245 4980 5960 
42 723 826 504 
56 6894 6165 7738 
84 2620 2400 3220 
112 4728 4514 5694 
TOTAL ('Yo) 19210 (24.6) 18885 (23.9) 23116 (24.6) 
Pack 14 28 42 56 84 112 Total Percentage 
Size Packed of20 mg J 
used 
2002 1104 2391 897 2664 4580 3594 15230 24 
I 
2001 1096 2365 694 2841 4539 2367 13902 17 J 
2000 397 1418 516 1696 3424 628 8079 8 
CentreD 
Pack 14 28 42 56 70 84 112 TOTAL Percentage 
size of20 mg 
used 
2002 4010 12425 1504 11499 . 343 6628 28334 64743 44 
2001 3195 10830 1218 10845 445 5294 27567 60214 46 
CentreE 
Pack 14 28 42 56 70 84 112 TOTAL Percentage 
size of20 mg _ 
used 
-





Pack 14 28 42 56 84 112 TOTAL Percentage I 
size of20mg 
Centre F 
Pack Size 112 TOTAL 
used 
2002 2499 7600 3175 24800 3258 3083 44415 7 200212003 2621 38750 
2001 3650 6042 3426 25360 1950 2120 42548 5 
2000 3383 6336 4202 238QO 1702 1312 40735 3 
1999 3497 9673 10238 25307 2191 2832 53738 5 
1998 3488 5998 9476 14246 1056 1718 35982 5 
2 . Informed Consent form 
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INFORMED CONSENT 
1. Title of Study 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF GLmENCLAMIDE IN NON· 
INSULIN DEPENDENT DIABETES MELLITUS 
2. Investigaton and Contact People 
Dr LI Robenson I Dr L Mavet 
Diabetes Clinic • 
Addington Provincial Hospital 
Durban 4000 
Telephone : 208-6128 
Dr G PilJai 
tleparunent ofPhannacology 
Private Bag X5400 1 
.Durban -1000 
Telephone : 2044908 (w) 
I. Purpose of the study 
Mr V Rambiritch 
Department of Pharmacology 
Private Bag X54001 
Durban 4000 
Telephone : 2044766(w) or 8211S8 (h) 
Thank you for e.'Cpressing interest in this study. You have been selected for inclnsion because ofbeing a 
diabetic on treatment wi th diabetes tablets. 
Medicines fonn an importaDl part ot the treatment of your type of diabetes, when other methods of 
treabDem such as diet modification and e.'Cercise are not successful. 
While the drugs have been widely used, there is linle information on the relationship between the dose and 
its effect on insulin secretion. 1nsulib. is the substance produced by your body that controls blood gluoose 
levels. 'There is also linle agreement among the world authorities as to the maximum dose of the diabetes 
tablets (glibenclamide) thai may be used in patients. 
This study will investIgaze !he dose-response relationship of glibenclamide. 
The study will have immediate benefits to you in that there will be closer mOnitoring and control of your 
diabetes. However, in addition. this study will benefit many other diabetics because we will know how to 
treat them 
2. Procedure 
This study will be conducted :11 the Addington Hospital Diabetes Clinic. A physical examination. a 
complete medical history and specific laboratory tests will be detennined at cenain specified times during 
the trial. 
After recruitment all oruI hypoglycaemic drug treabDent will be stopped for a 2 week washout period. 
During this time. patients will be requested to keep a diabetic diary in which they will record their blood 
glucose levels. . 
Thereafter ImIbDent with gJibenclamide will be given DI doses of2.Smg; Smg; lOmg and 20mg daily for 
periods of 14 days each. At the end of each 1-1 day period. the pltient must repon to the clinic "Itbout 
baving takeD their lIIomlng dose of glibenclomide. The clinic stllff ,viII administer this dose and • series 
of blood tests will be conducted. 
A patiurt will blf not IllU1w1fd to proclflfd to thlf nut doSl! Ine! if 
o Your dtJctor adoisa IIrainst it; 
o any blood glucose leNt Ins than 3 • .1 mmollL is recortkd; or 
o if any $jImptoms of hypoglycumill arlf reportd 
3. RJsIu 
It must be stressed. that this study involves the use of procedures and tests that are conducted in the interests 
of the patient during usual rouline care in medical practice. Dosages of glibenclamide used in this study 
will not exceed the maximum used in Diabetic clinics in South Africa. The only physically invasive 
procedure used in this study will be venepuncture for venous blood collection. 
~. Wltbdra"al from tbe Study 
Participltion in this study is voluntary. 
A participlDt may decide to witbdraw from the trial by withdrawing hislher consent at any time. Patients 
will be allowed to remain in the study only if they do not have hypoglycaemic reactions and if their fasting 
blood glucose concentrations do not fall below 3.S mmoUL during the study. In addition. the principal 
investigator may decide to terminate participation of a subject in the event of logistical difficulties such as 
it being difficult to obtain blood samples. 
5. Confidentiality 
All clinicallnformatlon obtained during this study will be regarded as confidential. In all reports, patients 
will be identified by code number only - the key to which will be known to the Investigators. 
6. Couent Form 










3 Indemnity form 
230 
University of Durban-Westville 
INDEMNITY 
1. the undersigned 
....................................................................................................................................................•.........•......... 
of ...........................................................................................................................................•....................... 
..............................................................•......................................•....................................•.....•.. _ .................. . 
born on •••••••.•••••••••••••..••••••••••••••••••.••••••••••••.•••••.•••••••••••••••••••••• 
Identity No .••••.•••••.•.•..•••.••••.•.....•••••.••.•••••.••••••.•.•••.••••••.•••••.••• -
do hereby indemnify and hold blameless the UNIVERSITY OF DURBAN-WESTVILLE, or any FACULTY • 
. DEPARTMENT. INSTlTUIE or UNIT of the said University of~ Westville or any member or employee of 
the said Univer.;ity for or in respect of any damages sustained by me as a result of. or fonowing any experiment, 
procedure and/or test conducted on me with my consent, as set out in Annexure A hereof. by any Faculty, 
• 
Department, Instirute, Unit. member or employee of the University of Durban-Westville. 
Signed at ..........•.•.••....•.••.•..........•.••....•.•.•.....•.... on this the •...•...•••..... day of •........•••..•••••..••••••.•••••.•••.••... 
19............ in the presence of the undersigned witnesses. 
. .......................... .......... ............................. . 
AS WITNESSES: 
1 .••••...•.•••.•..•...•.•..•.•....•.••..•...•...••.•••••..•.•.•..••••••••..•.•..... 
A.ddress: .••.•...••........•............•.•••..•••.•••.•....••..•...•..•....•.....••.••••.•••..•.•...••.•. ~ •••.••... : •....•..••.•.•••••••• : .•••••.•..••.....••. 
2. . ..... -_ .. __ ................................................................ . 
Address: .............•........•.....•........•............••...•......................................................•.•.......•.•.•.....•••..•.•..•........ 
1. 
4 Permission to Conduct Study and Ethical Clearance 
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• 
DEPARTMENT OF HEALTH 
PROVINCE OF KWAZULU-NATAL 
PtjVB/e Beg )(9051, PieiermarilZbllfg 2200 • 330 LcngmarkEt street. Pie/stmaritzburp 




.. ---.--... -----------~-----"'---..... ---...... --
TO DEPT. OF HEALTH 
ATTEl\TTION MRTPlLLAY 
FROM MRNDRUMMOND 
PGS (INCL.) : 27 JULy 1999 
BE;. SUPPQRTDTABE1'EsSUJDYINKZNBO$plTALS 
I refer to your memo concerning the proposed investigation by Mr V Rambirftch of the Dept. of 
Pharmacology at University of Durban Westville in the use of glibenclamide in diabetes. 
The Department supports the request but would like to be advised as to which Hospital would 
be taking part in this exercise. 
~ SECRETARY! DEPARTMENTOFBEALTH 
KW AZVLU-NATAL 
19lfa.xstan.diabetes 
L.o~q. C ~~1: '2.t,.../' 
DOH· - POrf~ I Vt~J 
P"ccv.~ 
o \'L- ~12. OB~~ 
08-JAN-2004 THU 09:25 RESEARCH ADMIN-UDW 0312044883 P. 03 
' . .... ';' 
: ~ i' 
PRIVATI: SAG X~D01 DURBAN 
University of 
Durban ",Westville 
26 ~o~ember 1995 
Mr V Rambiritoh 
Department of Pharmaeo!ogy 
Dear Mr Rambiritoh 
ETHICAL CLEARANCE: NUMB~R 951ft1A 
«>00 SOUTH MAICA 
rEUOGRAMS: 'lJOWESr 
TELEX: &~~ SA 





I wish to confirm that ethical clearanol! ha. been granted in 
respeot of the following project: . 
"Pharmacokinetics and PharIllacodynarnid8 of Glibenclamide 
in non-insulin dependent diabetes mellit"s" 
Thank you 
, ........ . 
AlDOO 
HEAP: RESEARCH ADMINISTRATION ' 
ps: The following general condition is applicable to all 
projects that have been granted ethical clearanoe: 
TH~ RELEVANT AUTHORITIES SHOULD BE CONTACTED I~ ORDER TO 
OBTAIN 'tHE NECESSJUtY APPROV."U, SHOOLD THE llESE}WCB INVOLVE 
UTI~IZATION OE _ SPACE JL~D/On FACILITIBS AT OTaER 
INSTITDTIONS/ORGANIS~TIONS 
cc: THE HEAD: DEPA~TMEN~ OF PHARMACOLOGY 
5 Glibenclamide, glucose and insulin concentrations 
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1 0.000 10.4 14.9 103.48 0 
20.000 17.8 6.8 47.228 58.38 
30.000 13.7 15.9 110.43 0 
40.000 14.4 6.8 47.226 53.01 
50.000 14.4 4 27.78 0 
60.000 16.4 16.2 126.4 0 10 TIme Glu Ins Inspmo Gtib 
7 0.000 14.9 17.6 121 .S. 0 1 0.000 13 13.2 91 .674 0 
60.000 9.5 9.1 63.2 0 2 0.000 21 .2 ioI.4 30.558 a 
9 0.000 12.1 10.9 75.701 64.95 3 0.000 17.9 18.4 127.79 0 
10 0.000 8.3 14.9 103.48 48.84 4 0.000 16.7 4.8 33.336 a 
11 0.000 12.4 38.9 270.18 34.39 5 0.000 21 .5 6.7 46.632 0 
12 0.000 13.5 9.9 68.756 0 6 0.000 14.1 22.8 158.35 a 
13 0.000 22.5 9.5 66.978 S..76 7 0.000 18.6 13.7 95.147 a 
14 0.000 11.5 17.8 122.23 a 8 0.000 12.4 10.1 70.145 0 
150.000 8.4 19.7 136.82 0 9 0.000 11 .6 1'0.1 70.145 0 
10 0.000 9.9 22.3 1S..87 a 17 0.000 8 4.4 30.558 42.17 
11 0.000 14.9 14.5 100.7 0 180.000 8.9 25.5 1n.1 a 
19 0.000 18.6 24 168.68 0 12 0.000 15.7 5.9 40.976 0 
20 0.000 9.5 22.8 158.96 0 13 0.000 20.3 11.1 77.09 0 
14 0.000 12.9 21 .2 147.23 a 21 0.000 8.8 17.8 122.23 37.91 
15 0.000 9.9 16.5 126.48 0 22 0.000 14.4 24.5 170.15 0 
17 0.000 11 .6 ,3.6 26.391 0 23 0.000 13.7 11.3 78.479 0 
16 0.000 13.5 24.7 171 .54 0 1 0.000 13.7 25.8 179.18 82.16 
19 0.000 21 .8 13.3 92.369 0 20.000 18 8 41.67 93.89 
20 0.000 11 .3 17.1 118.76 0 30.000 13.7 158.57 1101 .3 58.19 
21 0.000 17.6 12.7 68.202 0 40.000 14.7 8.3 43.7S. 84.63 
22 0.000 13.2 23.9 165.99 0 50.000 16.2 3.8 25.002 69.29 
80.000 10.3 18 125.01 69.22 23 0.000 16.9 4.2 29.189 0 
70.000 16.4 16.3 113.2 108.89 1 0.000 11 .2 16.9 110.43 33.15 
2 0.000 15.6 7.6 52.068 61 .4 6 0.000 10.1 12.8 68.698 0 
3 0.000 16.3 19.3 134.04 0 90.000 7.8 9.4 66.283 70.33 
4 0.000 16.1 4 .3 29.664 27.64 10 0.000 6.8 16.2 126.4 39.96 
5 0.000 17.8 3 20.635 0 11 0.000 10.6 24.6 172.24 40,45 
6 0.000 14.9 15.6 107.65 0 12 0.000 12.1 6.6 81 .116 35.06 
7 0.000 17.6 15.1 104.67 0 13 0.000 15.5 12.3 66.424 46.4 
8 0.000 10.5 9,4 65.283 0 14 0.000 9.2 14.1 97.925 62.47 
9 0.000 13.3 15.4 106.95 0 15 0.000 7.5 18.6 116.66 37.07 
10 0.000 4.7 12.7 68.202 55.26 170.000 8.2 12.7 68.202 62.22 
11 0.000 10 17.6 123.62 28.37 16 0.000 5.9 18.7 129.67 133,42 
12 0.000 14.5 10.6 75.006 0 19 0.000 10.5 19 131 .96 32.21 
20 0.000 6.8_ olllllfill 13 0.000 16.5 7.8 S..171 0 
21 0.000 4.6 14.5 100.7 55.25 14 0.000 11 .7 20 138.911l11iii'1 
15 0.000 9.3 26 194,46 0 22 0.000 10.8 30.4 211 .13 62.28 
17 0.000 6.2 6.7 60,422 96.43 23 0.000 17.1 11 .2 77.784 a 
18 0.000 7.5 15.8 109.73 87.64 1 0.000 11.5 30.8 212.52 60.59 
19 0.000 13.7 21 .3 147.93 0 20.000 16.8 5.6 38.692 290.45 
20 0.000 10.6 15.7 109.04 0 20.000 0 
21 0.000 12.4 14 97.23 35,42 3 0.000 12.8 28.3 182.65 95.14 
220.000 14 22.1 153.46 0 40.000 12.2 9.5 65.976 63.54 
23 0.000 15 15.5 107.65 0 5 0.000 18.8 5.1 35.42 139.46 
2 
I. 
60.000 9 34.1 236.82 449.22 14 0.500 12.3 25.9 179.88 317.51 
7 0.000 18.5 23.8 165.29 136.89 15 0.500 8.9 38.6 268.06 179.54 
6 0.000 10.5 11 .3 78.479 46.59 17 0.500 9.6 24.9 172.93 66.92 
90.000 9.1 10.7 74.312 141 .64 20 0.500 6.2~"'{l~ O~~If~~~~i 
10 0.000 6.9 15.2 105.56 76.09 21 0.500 7.1 27.9 193.77 206.71 
11 0.000 11.2 27.4 190.29 161 .67 22 0.500 10.2 28.6 198.63 71.21 
12 0.000 10.4 9.7 67.367 28.95 23 0.500 16.8 27 187.52 100.13 
13 0.000 15.5 13.3 92.369 78.09 1 0.500 13.3 47.3 328.5 294.15 
14 0.000 11 .4 21.3 147.93 76.92 10 0.500 6.3 35.6 247.24 209.98 
15 0.000 6.7 21 .9 152.1 46.24 11 0.500 12.7 72.1 500.73 328 
17 0.000 6.5 8.5 59.033 411 .33 13 0.500 18.8 17.8 122.23 367.46 
18 0.000 5.6 12.1 84.035 520.99 20 0.500 8 .2 45.1 313.22 196.78 
19 0.000 13.2 23.8 165.29 56.47 21 0.500 8 42 291 .69 247.07 
20 0.000 7.3 26.2 181 .98 67.81 22 0.500 11 .8 85.8 594.49 615.5 
21 0.000 4.6 14.3 99.314 56.51 23 0.500 16.1 22.3 154.87 412.09 
22 0.000 11 .4 28.9 200.71 0 150.617 11 .• 58.6 406.98 61.56 
23 0.000 13.6 16.2 105.56 65.06 30.517 13.7 62.6 438.16 38-4.46 
18 0.010 1 • . 1 84.2 564.77 199.88 20.633 26.9 10.7 74.312 0 
8 0.417 11 .• 27 .7 192.38 30.76 30.633 20.6 36.8 254.19 0 
.0 .• 17 1. 15 10 • . 16 147.37 23 0.633 17.7 13.6 96.841 0 
17 0.417 7.3 11 .3 78.479 366.8 80.633 12 21.6 150.01 52.8 
17 0.433 8 .5 16.3 113.2 58.09 18 0.633 10.6 27.1 188.21 103.19 
16 0.433 9.8 16.2 112.61 1074.87 23 0.633 15.9 2 • . 3 168.76 84.6 
5 0.460 17.1 10.5 72.923 50.38 150.633 9.3 69.7 484.07 65.45 
18 0.460 10.8 59.7 414.62 96.19 70.633 20 37.2 258.35 338.75 
23 0.460 15.2 20 .• 141 .68 80.49 150.633 8.6 .8 .• 336.14 329.7 
18 0.460 8.8 .4.6 309.05 290.45 4 0.560 19.1 9.3 84.689 52.49 
19 0.467 12.7 68.2 473.65 175.16 22 0.550 13.7 33.4 231.96 0 
6 0.463 15.7 43.1 299.33 0 50.550 17.1 35.3 245.16 69.92 
11 0.500 17.6 47.8 330.58 0 11 0.567 12.3 87.4 606.99 101 .91 
17 0.600 12.4 19.5 135.43 0 1. 0.567 14.5 45.9 318.78& __ 
22 0.600 12.2 29.4 20-4.18 0 1 0.567 13.9 36.7 254.88 141.76 
30.500 20.3 68.5 475.73 105.86 50.583 21 .1 6.3 43.754 0 
6 0.600 16.4 36.3 265.99 106.12 9 0.583 13.8 17.2 119.45 0 
12 0.500 16.1 32.5 225.71 0 12 0.583 18.6RIiB 0 0 
17 0.500 10.2 23 159.74 123.34 18 0.583 19.5 11 .9 82.646 0 
19 0.600 15.6 82.8 575.05 112.63 20 0.583 12.3 31 .4 218.07 0 
21 0.600 15.1 31 .8 220.85 91 .29 70.583 20.3 « 305.56 46.99 
3 0.600 17.8 71 .6 497.28 101 .9 20 0.563 11.7 39.6 275.02 40.1 
4 0.500 16.3 11 76.395 146.0-4 20.583 19.3 12.4 86.118 288.23 
7 0.500 15.3 18 125.01 27.89 60.583 19 36.2 251 .41 130.63 
12 0.500 15.1 21 .4 148.62 54.32 9 0.583 13.7 20.6 144.48 127.59 
14 0.600 12.5 36.7 254.88 0 10 0.563 12.1 55.98 368.84 121 .98 
20 0.600 10.1 52.3 363.22 64 .97 11 0.583 17.4 106.9 756.31 138.6 
22 0.500 16.3 118.6 823.68 270.69 21 0.583 10.8 40.9 294.05 129.97 
1 0.600 17.6 36.9 256.27 237.78 30.583 17.3 72.74 505.18 291 
4 0.600 15.5 11 .7 81 .257 198.55 80.583 13.9 36.8 255.56 257.56 
5 0.500 19.2 8.9 81.811 184.96 7 0.583 18.9 36.5 253.49 253.22 
8 0.500 10 .8~ 0 0 13 0.563 16.9 22.7 157.65 190.69 
11 0.500 13.8 121 .5 843.82 179.86 14 0.583 13.7 36.1 250.71 250.17 
3 4 
80.600 13.4 23.5 163.21 331 .14 3 1.000 20.3 76.27 529.7 420.57 4 0.617 18.2 22.5 156.26 0 6 1.000 15.4 38.4 268.69 339.111 70.617 22.8 24.7 171.54 0 7 1.000 22.4 32.2 223.63 383.13 9 0.633 10.5 17 118.07 92.04 8 1.000 13.8 50.3 349.33 325.3 10 0.667 12.2 32.7 227.1 0 17 1.000 11 .2 30.4 211 .13 186.25 14 0.867 14.4 38.1 264.6 0 19 1.000 18.8 93.7 850.75 494.31 21 0.867 20.11 16.9 117.37 0 20 1.000 12.7.- O~1 0.661 13.9 28 194.46 145.6 21 1.000 8.9 30.6 212.52 219.41 90.661 14.11 32.1 227.1 53.86 23 1.000 18.9 27.2 188.9 173.19 10 0.667 13.7 65.9 457.68 225.11 1 1.000 17.9 82.3 571.57 627.57 100.667 11 60.4 419.48 298.11 10 1.000 12 42.4 294.47 351 .85 1\ 0.667 21.9 1.2 50.004 299.63 13 1.000 21 .3 16.2 105.56 445.13 120.687 12 26.4 183.35 214.61 
21 1.000 7.6 37 256.97 494.01 19 0.667 16.1 68.6 476.43 687.08 
22 1.000 14.6 118.5 822.98 1328.09 19 0.683 22.4 41 .1 285.44 0 23 1.000 17.2 28.9 200.71 583.44 80.683 16.5 51.8 359.75 871.56 
17 1.017 14.9 22.1 153.48 0 15 0.717 11.4 44.2 306.97 0 
5 1.017 19.8 13.5 93.758 179.65 8 0.733 14.5 15.4 106.95 0 
18 1.017 13.9 29.7 208.27 1586.84 2 0.750 18.2 8.6 59.727 106.01 
7 1.033 27.4 22.9 159.04 0 9 0.750 11 .9 20.3 140.98 242.98 
23 1.033 19.8 23.2 181.12 0 13 0.767 21 .6 26.3 182.65 73.34 
4 1.033 19.6 20.5 142.37 128.39 13 0.763 22.1 16.9 117.37 68.1 
21 1.033 17 36.6 255.58 126.54 19 0.783 22.5 72.8 505.6 307.99 
22 1.033 18 88.6 616.72 31 .61 20.833 21 .4 21;.2 188.9 620.23 
23 1.033 16.9 31 215.3 153.62 12 0.633 14.9 2f.5 149.32 245.78 
17 1.033 8.6 15.3 106.26 141 .88 20.833 24 14.9 103.48 1107.46 
11 1.033 17.7 92.9 645.19 349.51 17 0.867 6.7 13.4 93.063 434.37 
12 1.050 22.3 17.8 123.62 0 1 0.917 19.2 17.5 121 .54 0 
22 1.050 16.1 47.8 330.56 0 13 0.917 24.6 11 .1 77.09 0 
3 1.050 21.8 91 .1 832.69 164.52 6 0.917 17.7 46.1 320.16 226.65 
5 1.050 20.2 6.3 43.754 63.15 8 0.917 13.9 35 243.08 144.15 
16 1.050 12.6 93.5 649.36 94.31 14 0.917 15.9 33.4 231 .96 547.86 
2 1.050 18.8 14.3 99.314 318.09 18 0.917 12.9 59.4 412.53 540.98 
15 1.050 11 .1 93.4 646.88 188.42 19 0.933 19.4 93.3 647.97 169.15 
22 1.050 16.2 138.4 961 .19 264.39 4 0.950 17.1 22.4 155.57 579.94 
3 1.050 18.7 72.2 501.43 1064.81 19 0.950 16.4 71 .6 498.65 738.85 
9 1.063 15.8 21 .4 148.62 0 4 0.967 19.8 18.2 126.4 392.69 
18 1.083 23 28.85 200.36 0 50.967 23.2 9 82.505 294.27 
20 1.083 17.2 88.7 477.12 0 15 0.967 11.5 72.3 502.12 376.73 
21 1.083 19.8 16.1 111 .61 0 2 1.000 28 11 .7 81 .257 0 
20 1.083 13.7 102.2 709.78 85.39 3 1.000 22.4 37.8 262.52 0 
8 1.083 18.8 55.7 368.64 267.94 6 1.000 21 .1 52.7 366 0 
12 1.000 17.2 41 .3 266.63 47.91 9 1.083 16.6 28.7 199.32 258.91 
17 1.000 10.1 24.9 172.93 169.29 11 1.083 17.7 108.9 756.31 237.71 
3 1.000 20.11 103 715.34 289.07 12 1.083 17.7 28.5 164.04 137.78 
4 1.000 18.2 21 .3 147.93 245.05 7 1.083 20.8 43 298.64 71.3 
11 1.100 15.1 59 409.76 151 .23 7 1.000 18.7 33.2 230.57 206.27 
14 1.100 16.2 46.5 322.94~14 1.000 14.11 43.3 300.72 222.59 
20 1.000 14.6 91.3 634.06 161 .24 8 1.100 14.7 38.3 252.1 579.1 
11 1.117 22 35.8 248.63 0 23 1.000 17.1 31 .3 217.38 126.8 
9 1.117 15.6 39.6 275.02 94.84 
S 
6 
21 1.117 13 34.9 242.38 180.85 4 1.467 20.3 20.5 142.37 462.6 
22 1.117 13.4 62.1 431 .28 170.87 4 1.467 18.2 30.6 212.52 611 .6 
11 1.117 17.5 78.4 5<44.49 901 .32 23 1.483 20.6 15.07 10 • . 68 0 
1 1.150 15.7 53.5 371 .56 288.37 2 1.500 28 17 118.07 0 
4 1.167 21.4 26.7 185.43 0 6 1.500 21 .3 69.9 485.46 0 
19 1.167 30.2 45.7 317.39 0 9 1.500 17.9 24 168.68 0 
7 1.167 24.5 48.9 339.61 102.16 6 1.500 18.2 39.9 277.11 228.86 
8 1.167 13.2 35 243.08 117.48 12 1.500 17.6 33 229.19 61 .83 
10 1.167 14.8 84.8 568.9<4 172.61 15 1.500 13.3 83.6 561 .99 82.07 
10 1.167 15.5 105.9 735.48 424.86 17 1.500 10.7 25.6 177.79 138.79 
13 1.167 20.1 13.8 95.841 300.46 19 1.500 20.8 115 798.68 150.94 
9 1.167 15 27 .9 193.77 338.3 20 1.500 13.9 86.1 611.85 85.89 
12 1.167 16.5 22.7 157.65 363.71 3 1.500 18.7 92.5 642.41 279.51 
20 1.167 11 .4 65.9 457 .68 576.31 9 1.500 19.2 37.5 260.« 203.61 
9 1.163 14.9 30.6 212.52 149 12 1.500 16.9 24 .4 169.<48 1<40.19 
16 1.200 14.2 60.2 418.09 175.34 20 1.500 12.9 90.3 627 .13 153.72 
5 1.217 23.2 6.7 48.532 0 71 .500 23.6 51.9 360.45 470.92 
14 1.217 18.6 38.5 267.38 0 8 1.500 12.6 28.4 197.24 421 .34 
1 1.217 22 34.7 240 .99 192.47 14 1.500 15.6 4 • . 4 308.38 564.6 
8 1.250 16.3 21 .2 147.23 0 15 1.600 11.5 61.8 429.9 307.95 
10 1.250 14.6 68.9 478.51 215.67 17 1.500 10.11 35.6 247.24 261 .74 
19 1.250 24 83.7 581 .3 296.47 20 1.500 12.8_ 0ii.tii1it 
2 1.250 21 16.3 113.2 552 21 1.500 9.6 32.7 227.1 245.76 
2 1.250 23.8 21 .3 147.93 1161 .06 23 1.500 19.2 31 .1 215.99 278.1 
15 1.283 14.7 74.9 520.18 0 1 1.600 18.5 82.5 572.96 1159.25 
13 1.300 28.8 31 .8 220.85 119.63 13 1.500 21 .1 16.7 115.98 506.25 
1 1.300 19.3 34.2 237.52 403.56 21 1.500 6.9 40.8 283.36 419.45 
6 1.300 16.2 59.3 411.84 1010.2 22 1.500 13.1 87 604.22 691.76 
14 1.333 14.3 46.3 321 .55 612.16 17 1.517 18.2 31 .3 217.38 0 
15 1.333 11 .7 91 .7 636.86 5<45.39 11 1.517 16.6 67.3 467.4 142.19 
23 1.367 16.3 27.3 189.6 121 .82 5 1.517 22.9 15.9 110.43 196.93 
8 1.383 12.5 46.6 323.64 197.98 8 1.533 11.2 33.7 234.05 130.97 
19 1.383 19.4 112.4 780.82 439.21 18 1.533 14.5 81 .1 563.24 196.68 
2 1.400 19.6 11 .4 79.173 143.07 22 1.633 17 171 .7 1192.5 50.63 
10 1.417 16.2 35.1 243.77 0 15 1.533 11 .7 108.1 750.75 160.45 
4 1.417 22.6 24.2 168.07 124.65 22 1.533 13.3 75.4 523.65 264.86 
18 1.417 12.5 94.6 657 251.46 20 1.550 16.3 63.5 «1 .01 0 
5 1.417 22.6 9.4 65.283 276.69 22 1.550 16.7 24.1 167.37 0 
6 1.417 14.6 42.9 297.9<4 398.9 3 1.550 19.7 63.1 438.23 151 .97 
18 1.417 15.4 86.8 602.83 638.86 5 1.550 23.7 9 62.505 71 .4 
5 1.417 21 .6 7 48.615 383.37 14 1.550 19 64.5 «7.95Wi~ 
19 1.417 21.2 143.1 993.83 1586.62 14 1.550 17.6 56.7 393.76 261.63 
17 1.433 9.7 19 131 .96 206.34 8 1.550 13.7 25.9 179.88 625.96 
16 1.433 16.7 45.8 318.08 1787.62 7 1.567 26.5 32.8 227.8 0 
13 1.450 24 .1 16 111 .12 71 .96 21 1.583 21 .8 19 131 .96 0 
21 1.450 13.2 34.7 240.99 179.5<4 23 1.583 16.5 27 167.52 135.3 
17 1.450 9.6 14.4 100.01 525.55 6 1.583 19.5 63.4 440.31 231.41 
4 1.467 19.5 21 .1 146.5<4 219.12 10 1.583 14 61 .1 424.34 216.13 
7 1.467 22 42.2 293.08 234.45 11 1.583 19.2 83.7 581 .3 213.97 
3 1.467 19.2 83.5 579.91 539.46 22 1.583 14.4 173.6 1205.7 293.17 
7 8 
11 1.583 16.8 63.2 438.92 392.49 6 1.950 18.3 57.3 397.95 227.54 12 1.583 16.3 17 118.07 353.78 15 1.950 9.1 47.2 327.8 278.83 10 1.583 10.9 Se.3 265.99 397.97 17 1.967 10.3 18.3 127.09 227.38 23 1.583 16.8 24 166.68 699.39 4 1.967 19.1 13.4 93.063 414.74 11 1.600 23.3 35.6 247.24 0 21 1.987 7.6 25.7 178.49 254.44 2 1.600 21 .8 20.2 140.29 382.98 4 1.987 15.1 18.1 125.7 484.07 3 1.617 21 .5 28.8 198.63 0 17 1.967 10.1 9.5 85.978 554.45 11 1.617 17.2 94.3 654.91 1051 .06 8 1.983 10 30.8 213.91 138.24 21 1.633 14.3 29.4 204 .18 104.75 22.000 28 16.2 112.51 0 19 1.633 22.8 97 .6 677.83 240.19 9 2.000 16.8 28.9 200.71 0 12 1.650 23.1 16.5 114.59 0 10 2.000 13.9 32.7 227.1 0 4 1.667 23.2 24 .8 172.24 0 20 2.000 15.8 36.7 254.88 0 13 1.667 25 13.3 92.369 0 22 2.000 17.7 48.8 338.92 0 7 1.667 24.3 50.9 353.5 112.21 82.000 17.8 43.2 300.02 154.44 9 1.667 16.7 60.9 422.95 117.52 122.000 15 20.7 143.76 57.84 2 1.667 22.7 0 
172.000 9.4 15.4 106.95 123.35 10 1.667 14 80.5 559.07 358.05 
18 2.000 14.2 93.3 647.97 235.79 2 1.667 25.9 17.2 119.45 1125.37 
72.000 22.8 34.4 238.91 248.54 20 1.667 11 .7 57.7 400.73 5n.53 
92.000 15.9 28.8 200.02 239.1 19 1.683 30.6 18.9 547.96 0 
12 2.000 14.8 13.8 94.452 118.08 10 1.683 13.2 ~0.9 631 .3 247.9 
20 2.000 11 .6 65.7 458.29 116.47 3 1.683 16.2 67.7 470.16 1041 .31 
21 2.000 12.6 28.7 199.32 185.54 7 1.700 21 .1 , 36 250.02 776.95 
32.000 17.5 51 .5 357.87 470.91 12 1.700 14.8 ,16.9 117.37 384.74 
72.000 22.3 48.9 339.61 405.96 1 1.733 14.7 :63.8 443.09 364.58 
10 2.000 10.6 60.3 418.78 343.45 9 1.733 15.5 42.9 297.94 292.64 
14 2.000 15.2 39.7 275.72 553.57 14 1.750 21.3 47.3 328.5 0 
17 2.000 10.4 20.2 140.29 302.18 1 1.750 20.1 37.1 257.66 187.49 
18 2.000 14.7 95.3 661.88 550.78 15 1.750 10.4 46.1 320.16 441 .41 
20 2.000 13.31J!m1Il'}. O~18 1.800 23.5 29.9 207.66 0 
232.000 19 22.9 159.04 273.69 13 1.800 27.1 21 .6 150.01 125.89 
10 2.000 9 36.3 252.1 326.29 5 1.833 24.2 4.3 29.864 0 
19 2.000 19.1 60.9 422.95 634.68 8 1.633 16.5 20 138.9 0 
20 2.000 11 .5 43.8 304.19 484.61 15 1.833 14.5 57.6 400.03 0 
21 2.000 6.1 33.5 232.68 438.49 23 1.833 17.8 31 .7 220.16 142.92 
172.017 17 14.6 101 .4 0 9 1.833 15.2 51 .5 357.67 422.49 
52.017 22.4 6.8 47.228 45.23 14 1.833 14.5 32.3 224.32 627.32 
11 2.017 19.7 84.4 447.26 127.03 1 1.850 20.8 42.9 297.94 418.77 
82.017 9.5 35.7 247.94 171 .09 4 1.867 16.3 12.5 88.813 211 .97 
21 2.033 10.5 23.5 163.21 102.73 6 1.883 16 78 541 .71 872.33 
23 2.033 15.3 22.4 155.57 110.94 1 1.917 20.8 25.9 179.88 0 
3 2.033 17.1 83.5 579.91 267.86 20 1.917 12.7 86 597.27 79.56 
10 2.033 13.6 89.5 621 .58 245.49 5 1.917 22.1 21 .17 147.03 188.82 
13 2.033 23.1 16.3 113.2 74.06 5 1.917 21 .7 6.5 45.143 246.4 
22 2.033 12.6 68.5 461 .84 328.23 6 1.917 16 47 326.42 281 .38 
32.050 17.9 52.2 362.53 123.5 13 1.917 21 .1 13.7 95.147 315.05 
14 2.050 16.2 51 .2 355.58 261 .84 5 1.917 20.2 7.1 49.31 368.45 
19 2.050 13.9 73 506.99 321.2 6 1.933 21 .3 89.9 485.46 0 
32.050 16 38.7 268.77 818.32 4 1.933 21 .8 20.4 141 .68 108.27 
23 2.087 19.6 13.41 93.132 0 2 1.950 20.9 19.3 134.04 165.59 
1 2.087 15.1 58.5 392.39 280.95 
9 
\0 
15 2.067 9.8 85.7 595.19 115.78 5 2.500 19.1 4.5 31.253 385.46 
72.067 21 32.5 225.71 947.58 14 2.500 11.6 30.9 214.6 605.9 
3 2.083 21 .1 18.9 131.26 0 152.500 7.9 38.1 264.6 309.18 
42.063 23.7 43.5 302.11 0 10 2.583 11 22.3 154.87 0 
7 2.083 27 36.3 252.1 0 12 2.667 13.3 13.9 96.536 249.21 
11 2.083 20.5 52.6 365.31 0 1 2.917 17.9 18.7 129.87 0 
12 2.063 18.9 13.5 93.758 0 13 2.917 23.7 12.4 86.118 0 
21 2.083 20.7 18.2 126.4 0 63.500 11 .7 28.7 199.32 183.11 
14 2.083 17.2 46.4 322.25mmrf 9 3.750 11 .6 12.9 69.591 0 
15 2.083 13.9 53.1 368.78 70.59 153.750 5.6 25.6 177.79 244.07 
22.063 22.5 22.3 154.87 434.98 83.783 6.3 24.4 169.46 188.04 
182.063 9.7 75.3 522.96 259.22 183.800 4.9 34.4 238.91 222.71 
8 2.083 10.5 .23.5 163.21 422.06 19 3.800 7.1 11 .9 82.646 173.3 
11 2.063 15.2 91 .7 636.86 426.34 18 3.817 8.4 21 .7 150.71 1098.65 
12 2.083 13.6 14.7 102.09 342.53 14 3.833 14.7 24.3 168.78 0 
1 2.083 18.9 81 .2 425.03 1138.33 93.833 9.6 40.2 279.19 75.82 
11 2.063 14.9 60.3 418.78 765.48 10 3.833 5.8 22.5 158.28 118 
13 2.083 19.3 , 15.3 106.26 416.22 4 3.833 11 .4 9.1 63.2 141 .5 
22 2.083 11 .2 122.9 853.54 1391.59 5 3.833 14.4 10 69.45 107.15 
23 2.083 15.3 18.3 127.09 647.98 21 3.833 3.4 22.4 155.57 160.86 
8 2.100 13 , 29.5 204.88 643.84 14 3.833 8.7 20.2 140.29 661 .27 
18 2.100 14.8 154.3 377.11 1600.73 17 3.833 8.1 8.5 59.033 588.17 
22 2.117 9 80.4 558.38 287.79 23 3.867 16.3 10.1 70.145 0 
7 2.133 24.2 54.2 378.42 122.19 1 3.900 11 .9 36.4 252.8 136.69 
13 2.167 22.9 12.2 84.729 0 8 3.917 13.9 32.8 227.8 0 
9 2.167 15.5 ; 41 .6 288.91 141 .97 73.917 20.3 20.8 144.48 0 
11 2.167 14.4 69.5 482.68 204.77 8 3.917 11 .4 12.6 67.507 0 
19 2.167 22.3 121.2 841 .73 164.08 10 3.917 8.4 13.5 93.758 0 
22.167 27.5 20.7 143.76 1105.15 18 3.917 16.7 13.5 93.756 0 
19 2.163 30.7 40.2 279.19 0 12 3.917 12.5 18.5 128.48 46.41 
22 2.200 13.3 154.8 1073.7 74.99 20 3.917 7.8 29.1 202.1 28.36 
8 2.250 14.3 15.4 106.95 0 17 3.917 7.2 5.7 39.587 1 ..... 81 
14 2.250 20.4 38.7 268.77 0 23 3.917 13.4 21 .4 148.62 81 .9 
18 2.250 24.1 29.8 205.57 0 5 3.917 18.3 5.6 38.892 143.7 
1 2.250 18.7 37.1 257.66 155.08 153.917 4.9 16.8 117.37 125.84 
22.250 20.3 20.4 141 .68 519.62 183.917 8.7 25.411 176.82 330.72 
9 2.250 13.1 50.2 348.64 480.87 10 3.917 4.7 18.8 130.57 445.26 
12 2.250 13.7 14.4 100.01 340.12 23 3.917 12.6 13.7 95.147 300.84 
10 2.300 9.7 49.8 345.88 182.58 17 3.933 12.6 5.7 39.587 0 
13 2.300 25.2 19.3 134.04 88.27 9 3.933 9.7 17.5 121 .54 232.71 
5 2.300 12.6 51 .9 360.45 719.77 12 3.933 10.1 13.2 91 .674 232.08 
1 2.333 19.1 22.7 157.65 0 19 3.950 12.2 40.3 279.88 73.08 
13 2.333 21 .8 15.3 106.26 71 .36 23.967 28.7 28.4 197.24 273.46 
5 2.350 15.1 3.15 21 .877 0 43.967 14 12.4 88.118 74.78 
1 2.350 20.7 33.6 233.35 436.56 13 3.967 18.8 14.7 102.09 77.26 
9 2.350 14.6 38.6 268.08 337.65 63.967 9.7 29.4 204.18 493.65 
152.417 11 .1 31.4 218.07 0 83.967 8.2 16.4 113.9 340.44 
19 2.417 16.7 71 .1 493.79 105.87 23 3.963 12.1 15 104.18 57.78 
2 2.483 15.1 26.3 182.65 235.8 24.000 25 15.5 107.65 0 
13 2.500 20.5 18.1 125.7 350.9 3 4.000 16.1 22.4 155.57 0 
11 12 
44.000 16.4 8.3 57.644 0 24.083 20.9 16.2 112.51 381 .63 20 4.000 10.1 17.3 120.15 0 6 4.083 10.7 25.4 176.4 176.11 21 4.000 16.7 9.7 67.367 0 8 4.083 5.4 23.9 185.99 250.75 1 4.000 14.6 25.5 177.1 87.72 11 4.083 9.7 48.9 339.61 295.58 5 4.000 14.8 3.7 25.697 59.38 124.083 11 .1 13.5 93.758 208.46 64.000 15.5 30.6 212.52 83.04 24.063 24.1 10.5 72.923 664.64 17 4.000 6.5 6.7 60.422 70.92 94.063 6 20.2 140.29 324.92 19 4.000 9 39.6 275.02 64.89 21 4.083 3 17.2 119.45 226.68 22 4.000 7.9 66.4 461 .15 112.37 22 4.063 5.1 71 .9 499 .35 882.44 24.000 21 .5 14.7 102.09 202.1 154.117 6.7 17.3 120.15 0 64.000 13.6 37.2 258.35 153.5 21 4.117 8.3 19.5 135.43 102.03 11 4.000 10.5 40.3 279.88 105.83 4 4.133 11 .8 7.8 64.171 409.7 124.000 11.9 11 76.395 56.93 7 4.187 18.1 35.2 244.46 80.64 14 4.000 10.5 i 26.7 185.43 288.93 3 4.167 13.2 33.9 235.44 255.92 20 4.000 6.7 ' 48.1 334.05 69.13 74.167 15.9 29.4 204.18 338.98 21 4 .000 7.8 19 131 .96 190.51 6 4.167 16.8 4.9 34.031 332.72 104.000 5.1 27.1 188.21 192.69 54.200 18.1 6 41 .67 0 13 4.000 16.6 11 .9 82.646 291 .63 19 4.300 17.8 14.8 102.79 0 144.000 8.6 19 131 .96 469.03 194.300 9.3 15.4 106.95 128.44 17 4.000 6.6 , 12.2 84.729 235.83 18 4.317 10.8 31.5 218.77 1111 .79 20 4.000 7.8~ O~ 9 4.333 11 .5 17 118.07 0 23 4.000 14.3 21 145.85 232.19 14 4.333 15.1 38.8 269.47 0 1 4.000 12.6 . 38.3 265.99 796.03 94.333 10.4 25.9 179.88 89.35 44.000 9 10 69.45 171 .21 44.333 13 13.9 96.538 100.65 11 4 .000 9.8 I 35 243.08 565.53 84.387 8.4 41 .5 288.22 223.81 13 4.000 15.8 I 14.4 100.01 303.6 
54.383 15.4 10.1 70.145 75.35 19 4.000 10.5 ' 31 .1 215.99 613.68 
6 4.383 10 37.1 257.88 520.26 20 4.000 7.3 36.8 255.58 232.79 
104.400 6.1 39.6 275.02 180.6 7 4.017 12.5 30.1 209.04 830.63 
184.400 7.3 53.5 371.56 225.68 74.033 16 38.2 265.3 193.89 
18 4.417 18.3 21 .5 149.32 0 13 4.033 19.3 11.7 81 .257 57.45 
124.417 11 .1 29.6 205.57 51 .69 154.033 4.9 29.8 208.98 88.82 
20 4.417 8.2 45.9 318.78 28.81 22 4.033 7 .7 43.1 299.33 630.88 
17 4.417 7 13 90.285 153.74 11 4.050 9.3 29.2 202.79 122.69 
234.417 11 .9 18.5 128.48 77.54 154.050 5.8 22.2 154.18 84.71 
5 4.417 17.5 8.7 80.422 158.58 184.050 6.5 27.8 193.07 222.1 
21 4.417 4.3 22.1 153.48 165.27 1 4.050 15.3 25 173.63 280.29 
84.433 17.5 69.4 481 .98 0 34.050 9.1 36.9 256.27 597.67 
17 4.433 13.2 17.7 122.93 0 34.067 11.9 40.3 279.88 118.93 
44.433 15.3 14.2 98.619 76.57 1 4.063 16.9 15.2 105.56 0 
84.433 9 24.8 172.24 358.49 11 4.083 13.7 17.1 118.76 0 
17 4.450 7.7 12.4 88.118 502.2 12 4.063 17 10.3 71 .534 0 
23 4.467 15.4 14.7 102.09 0 13 4.083 20.3 8.8 59.727 0 
154.487 5.2 27.8 193.07 142.45 224.083 12 25 173.83 0 
1 4.483 13.2 48.7 336.22 123.35 3 4.063 14.1 35.1 243.77 48.34 
94.463 10 19.7 138.82 204.78 84.083 8.2 17.4 120.84 70.77 
22 4.483 7.1 38.5 253.49 693.81 14 4.063 11 . 1~ O~
4 4.500 18.4 20.9 145.15 0 9 4.083 11 .8 18.7 129.87 267.22 
84.500 10.5 12.2 84.729 0 104.083 8.2 23.5 163.21 424.77 
21 4.500 15.8 14.5 100.7 0 224.083 8 48.2 334.75 228.22 
22 4.500 12.4 23.1 180.43 0 
13 
14 
1 4.500 15.5 37.6 261.13 100.34 194.617 11.1 67.3 467.4 279.55 
3 4.500 13.5 51 .2 355.58 55.5 20 4.617 7.8 SO.9 353.5 260.24 
17 4.500 6 15 104.18 52.43 22 4.617 7.4 90.9 631 .3 792.03 
194.500 8.9 50.9 353.5 44.28 14 4.633 9.3 43.6 302.8~
7 4.500 15.9 38.8 269.47 205.73 22 4.633 7.9 98 680.61 108.69 
124.500 11 .1 21.5 149.32 53.08 24.667 25.9 21 .5 149.32 0 
14 4.500 10.9 36.6 254.19 340.02 54.667 16 6.4 44.448 0 
154.S00 6.4 36.1 2SO.71 59.43 10 4.667 8.2 24.5 170.15 0 
24.500 20.7 22.6 156.96 304.36 124.667 17 20.1 139.59 0 
104.500 7.1 50.5 3SO.72 239.98 154.667 8 .4 31 .1 215.99 0 
13 4.500 16.6 16 111 .12 308.51 2 4.667 19.1 27 187.52 166.81 
144.S00 9.4 30.8 213.91 500.43 11 4.667 10.5 61 .3 425.73 136.95 154.500 5.5 45.1 313.22 105.7 21 4.667 9.9 23.9 165.99 180.44 
17 4.500 7 21 .7 150.71 229.15 64.667 10.8 40.2 279.19 184.18 23 4 .500 14.2 20.9 145.15 2SO.63 34.700 17.4 37.9 263.22 0 44.500 9.4 15 104.18 190.24 184.700 11 .3 53.6 372.25 299.49 10 4.S00 3.6 35 243.08 S03.14 94.7SO 13.5 17.1 118.76 0 11 4.500 9.8 51 .9 360.45 548.13 13 4.7SO 23.6 13 90.285 0 13 4.500 19.3 13.7 95.147 329.25 24.750 21 .4 22 162.79 542.66 14 4.S00 9.9 ' 34.1 236.82 752.56 6 4.7SO 17.6 8.4 58.338 525.69 154.500 7 46.2 320.86 1IM.46 10 4.800 8.3 32.4 225.02 159.43 214.500 2.6 . 27.6 191.66 1IM.58 14 4.833 15.3 47.4 329.19 0 3 4.517 13.3 ' 69.4 481.98 113.42 44.833 16.1 16.3 113.2 119.41 64.533 11 .5 7.4 51 .393 122.84 5 4.833 18.4 11 .8 81 .951 82.64 64.533 16.9 I 40.6 281 .97 74.79 104.833 8.8 62.2 362.63 224.84 23 4.533 10.5 16.2 112.51 33.22 22 4.833 8 .9 100 694.5 239.02 194.533 13 96.5 670.19 69.23 84.833 7.6 30 208.35 273.88 23 4.533 11.7 16.2 112.51 282.37 11 4.833 10.9 51 .8 359.75 232.53 13 4.5SO 20.4 16.1 111 .81 76.78 94.8SO 11 .8 29 201 .41 325.56 64.5SO 16.4 43.2 300.02 100.32 74.8SO 15.6 46.8 323.84 1027.69 20 4.550 6.9 65.2 452.81 75.37 
12 4.867 13.3 33.3 231.27 SO.63 1 4.5SO 14.7 40.4 280.58 337.6 
64.883 14.1 43.5 302.11 437.5 4 4.5SO 10.8 10.7 74.312 242.87 64.900 17.2 89.8 484 .78 0 24.567 24.3 26.3 182.65 220.43 194.917 23 44.1 308.27 0 1 4.583 17.8 22.7 157.85 0 20 4.917 11 .6 47 328.42 0 7 4.583 21 .5 31 215.3 0 84.917 8.5 47.2 327.8 175.76 11 4.583 15.9 37.4 259.74 0 
17 4.917 10.5 18 111 .12 109.98 20 4.583 10.6 31 215.3 0 184.917 9.5 57.1 398.66 198.32 7 4.583 16.3 41.1 285.44 79.75 
5 4.917 20.3 8 55.58 117.87 9 4.583 11.2 30.5 211 .82 411 .18 
12 4.917 12.3 30.6 212.52 198.33 3 4.583 12.4 53.8 373.84 222.84 
144.917 11 .9 40.9 284.05 446.11 74.583 15.7 42.2 293.08 346.48 
154.917 8.4 82 430.59 93.33 20 4.583 sm1®11fI,M O~~ 21 4.917 5.8 19.7 136.82 137.5 1 4.583 13.9 63 368.09 6SO.27 
17 4.933 15 21 .1 146.54 0 94.583 8.1 22.7 157.65 410.81 
34.933 12.9 57.3 397.95 452.91 12 4.583 10.5 29.4 204.18 296.34 
234.950 19 17 118.07 0 84.600 6.5 26.2 181.96 190.9 
154.950 8.4 46 312.53 82.51 11 4.800 10.1 35.1 243.77 190.33 
21 4.9SO 7.8 22 152.79 101 .23 184.617 7.6 30.8 213.91 338.27 
23 4.950 12.2 18.7 129.87 87.38 13 4 .817 18.7 16.5 114.59 67.04 
19 4.967 11.5 80.3 418.78 32.37 
15 
16 
6 Data listing: NONMEM data file contruction -
Pharmacokinetics - only subjects 1 and 2 shown 
233 
#ID TIME AMT DV CMT EVID MDV II ADDL DAMT 
1 0 2500 0 1 1 1 24 12 2500 
1 336 0 33.15 2 0 0 0 0 2500 
1 336.01 2500 0 1 1 1 0 0 2500 
1 336.667 0 145.6 2 0 0 0 0 2500 
1 337.217 0 192.47 2 0 0 0 0 2500 
1 337.75 0 187.49 2 0 0 0 0 2500 
1 338.25 0 155.08 2 0 0 0 0 2500 
1 340 0 87.72 2 0 0 0 0 2500 
1 340.5 0 100.34 2 0 0 0 0 2500 
1 341 0 80.25 2 0 0 0 0 2500 
1 341.583 0 71.57 2 0 0 0 0 2500 
1 343.083 0 55.31 2 0 0 0 0 2500 
1 360 5000 0 1 1 1 24 12 5000 
1 696.01 5000 0 1 1 1 0 0 5000 
1 696.567 0 141.76 2 0 0 0 0 5000 
1 697.15 0 288.37 2 0 0 0 0 5000 
1 697.733 0 364.58 2 0 0 0 0 5000 
1 698.067 0 280.95 2 0 0 0 0 5000 
1 699.9 0 136.69 2 0 0 0 0 5000 
1 700.483 0 123.35 2 0 0 0 0 5000 
1 700.983 0 118.26 2 0 0 0 0 5000 
1 701.567 0 103.35 2 0 0 0 0 5000 
1 702.983 0 54.2 2 0 0 0 0 5000 
1 720 10000 0 1 1 1 24 12 10000 
1 1056 0 82.16 2 0 0 0 0 10000 
1 1056.01 10000 0 1 1 1 0 0 10000 
1 1056.5 0 237.78 2 0 0 0 0 10000 
1 1057.3 0 403.56 2 0 0 0 0 10000 
1 1057.85 0 418.77 2 0 0 0 0 10000 
1 1058.35 0 436.58 2 0 0 0 0 10000 
1 1060.05 0 280.29 2 0 0 0 0 10000 
1 1060.55 0 337.6 2 0 0 0 0 10000 
1 1061.05 0 301.81 2 0 0 0 0 10000 
1 1061.55 0 252.54 2 0 0 0 0 10000 
1 1063 0 167.11 2 0 0 0 0 10000 
1 1080 20000 0 1 1 1 24 12 20000 
1 1416 0 60.59 2 0 0 0 0 20000 
1 1416.01 20000 0 1 1 1 0 0 20000 
1 1416.5 0 294.15 2 0 0 0 0 20000 
1 1417 0 627.57 2 0 0 0 0 20000 
1 1417.5 0 1159.25 2 0 0 0 0 20000 
1 1418.083 0 1138.33 2 0 0 0 0 20000 
1 1420 0 796.03 2 0 0 0 0 20000 
1 1420.583 0 650.27 2 0 0 0 0 20000 
1 1421 0 653.14 2 0 0 0 0 20000 
1 1421.5 0 571.01 2 0 0 0 0 20000 
1 1423 0 332.26 2 0 0 0 0 20000 
2 0 2500 0 1 1 1 24 12 2500 
2 336 0 51.4 2 0 0 0 0 2500 
2 336.01 2500 0 1 1 1 0 0 2500 
2 336.75 0 106.01 2 0 0 0 0 2500 
2 337.4 0 143.07 2 0 0 0 0 2500 
2 337.95 0 165.59 2 0 0 0 0 2500 
2 338.483 0 235.8 2 0 0 0 0 2500 
2 339.967 0 273.46 2 0 0 0 0 2500 
2 340.567 0 220.43 2 0 0 0 0 2500 
2 341.161 {) -1-96.23 2 0 0 0 0 2500 
2 341.583 0 170.92 2 0 0 0 0 2500 
2 342.917 0 158.27 2 0 0 0 0 2500 
2 360 5000 0 1 1 1 24 12 5000 
2 696 0 58.36 2 0 0 0 0 5000 
2 696.01 5000 0 1 1 1 0 0 5000 
#ID TIME AMT DV CMT EVID MDV II ADDL DAMT 
2 696.583 0 288.23 2 0 0 0 0 5000 
2 697.05 0 318.09 2 0 0 0 0 5000 
2 697.6 0 382.98 2 0 0 0 0 5000 
2 698.083 0 434.98 2 0 0 0 0 5000 
2 700 0 202.1 2 0 0 0 0 5000 
2 700.667 0 166.81 2 0 0 0 0 5000 
2 701.083 0 160.49 2 0 0 0 0 5000 
2 701 .5 0 131.07 2 0 0 0 0 5000 
2 702.967 0 90.15 2 0 0 0 0 5000 
2 720 10000 0 1 1 1 24 12 10000 
2 1056 0 93.89 2 0 0 0 0 10000 
2 1056.01 10000 0 1 1 1 0 0 10000 
2 1056.833 0 620.23 2 0 0 0 0 10000 
2 105725 0 552 2 0 0 0 0 10000 
2 1058.25 0 519.62 2 0 0 0 0 10000 
2 1060.083 0 381.63 2 0 0 0 0 10000 
2 1060.5 0 304.36 2 0 0 0 0 10000 
2 1061 0 292.37 2 0 0 0 0 10000 
2 1061.5 0 219.52 2 0 0 0 0 10000 
2 1063 0 167.08 2 0 0 0 0 10000 
2 1080 20000 0 1 1 1 24 12 20000 
2 1416 0 290.45 2 0 0 0 0 20000 
2 1416.01 20000 0 1 1 1 0 0 20000 
2 1416.833 0 1107.46 2 0 0 0 0 20000 
2 1417.25 0 1161.06 2 0 0 0 0 20000 
2 1417.667 0 1125.37 2 0 0 0 0 20000 
2 1418.167 0 1105.15 2 0 0 0 0 20000 
2 1420.083 0 664.54 2 0 0 0 0 20000 
2 1420.75 0 542.56 2 0 0 0 0 20000 
2 1421.333 0 441.34 2 0 0 0 0 20000 
2 1421.75 0 415.79 2 0 0 0 0 20000 
2 1423 0 272.82 2 0 0 0 0 20000 
7 Data listing: NONMEM data file contruction -
Pharmacodynamics - only subjects 1 and 2 shown 
234 
#ID TIME AMT DV CMT EVID MDV II ADDL 
SS DAMT 
1 0 0 0 2 1 1 
0 0 1 0 
1 0 0 13 2 0 0 
0 0 0 0 
1 0.917 0 19.2 2 0 0 0 
0 0 0 
1 1.917 0 20.8 2 0 0 0 
0 0 0 
1 2.333 0 19.1 2 0 0 0 
0 0 0 
1 2.917 0 17.9 2 0 0 0 
0 0 0 
1 4.083 0 16.9 2 0 0 0 
0 0 0 
1 4.583 0 17.6 2 0 0 0 0 
0 0 
1 5.167 0 20.9 2 0 0 0 0 
0 0 
1 5.667 0 20.4 2 0 0 0 
0 0 0 
1 7.25 0 15.4 2 0 0 0 0 
0 0 
1 24 2500 0 1 1 1 24 13 
0 2500 
1 360 0 11.2 2 0 0 0 0 
0 2500 
1 360.01 2500 0 1 1 1 0 0 0 
2500 
1 360.667 0 13.9 2 0 0 0 0 0 
2500 
1 361 .217 0 22 2 0 0 0 0 0 2500 
1 361.75 0 20.1 2 0 0 0 0 0 
2500 
1 362.25 0 18.7 2 0 0 0 0 0 2500 
1 364 0 14.6 2 0 0 0 0 0 2500 
1 364.5 0 15.5 2 0 0 0 0 0 2500 
1 365 0 18.4 2 0 0 0 0 0 2500 
1 365.583 0 19.2 2 0 0 0 0 0 2500 
1 367.083 0 15.2 2 0 0 0 0 0 2500 
1 384 5000 0 1 1 1 24 13 0 5000 
1 720 0 10.4 2 0 0 0 0 0 5000 
1 720.01 5000 0 1 1 1 0 0 0 5000 
1 720.567 0 13.9 2 0 0 0 0 0 5000 
1 721.15 0 15.7 2 0 0 0 0 0 5000 
1 721 .733 0 14.7 2 0 0 0 0 0 5000 
1 722.067 0 15.1 2 0 0 0 0 0 5000 
1 723.9 0 11.9 2 0 0 0 0 0 5000 
1 724.483 0 13.2 2 0 0 0 0 0 5000 
1 724.983 0 15.8 2 0 0 0 0 0 5000 
1 725.567 0 13.8 2 0 0 0 0 0 5000 
1 726.983 0 12.5 2 0 0 0 0 0 5000 
1 744 10000 0 1 1 1 24 13 0 10000 
1 1080 0 13.7 2 0 0 0 0 0 10000 
1 1080.01 10000 0 1 1 1 0 0 0 10000 
1 1080.5 0 17.6 2 0 0 0 0 0 10000 
1 1081 .3 0 19.3 2 0 0 0 0 0 10000 
1 1081 .85 0 20.8 2 0 0 0 0 0 10000 
1 1082.35 0 20.7 2 0 0 0 0 0 10000 
1 1084.05 0 15.3 2 0 0 0 0 0 10000 
1 1084.55 0 14.7 2 0 0 0 0 0 10000 
1 1085.05 0 18.9 2 0 0 0 0 0 10000 
1 1085.55 0 17.6 2 0 0 0 0 0 10000 
1 1087 0 14.5 2 0 0 0 0 0 10000 
1 1104 20000 0 1 1 1 24 13 0 20000 
1 1440 0 11.5 2 0 0 0 0 0 20000 
1 1440.01 20000 0 1 1 1 0 0 0 20000 
1 1440.5 0 13.3 2 0 0 0 0 0 20000 
1 1441 0 17.9 2 0 0 0 0 0 20000 
1 1441 .5 0 18.5 2 0 0 0 0 0 20000 
1 1442.083 0 18.9 2 0 0 0 0 0 20000 
1 1444 0 12.6 2 0 0 0 0 0 20000 . 
1 1444.583 0 13.9 2 -0 0 0 0 0 20000 
1 1445 0 15.8 2 0 0 0 0 0 20000 
1 1445.5 0 18.8 2 0 0 0 0 0 20000 
1 1447 0 14 2 0 0 0 0 0 20000 
2 0 0 0 2 1 1. 0 0 1 0 
#ID TIME AMT DV CMT EVID MDV II ADDL 
SS DAMT 
2 0 0 21 .2 2 0 0 0 
0 0 0 
2 0.533 0 25.9 2 0 0 0 
0 0 0 
2 1 0 28 2 0 0 0 
0 0 0 
2 1.5 0 28 2 0 0 0 
0 0 0 
2 2 0 28 2 0 0 0 
0 0 0 
2 4 0 25 2 0 0 0 0 
0 0 
2 4.667 0 25.9 2 0 0 0 0 
0 0 
2 5.133 0 28 2 0 0 0 
0 0 0 
2 5.583 0 28 2 0 0 0 0 
0 0 
2 6.833 0 25.7 2 0 0 0 0 
0 0 
2 24 2500 0 1 1 1 24 13 0 
2500 
2 360 0 15.6 2 0 0 0 0 0 
2500 
2 360.01 2500 0 1 1 1 0 0 0 
2500 
2 360.75 0 18.2 2 0 0 0 0 0 
2500 
2 361.4 0 19.8 2 0 0 0 0 0 
2500 
2 361 .95 0 20.9 2 0 0 0 0 0 
2500 
2 362.483 0 15.1 2 0 0 0 0 0 2500 
2 363.967 0 26.7 2 0 0 0 0 0 2500 
2 364.567 0 24.3 2 0 0 0 0 0 2500 
2 365.167 0 28 2 0 0 0 0 0 2500 
2 365.583 0 28 2 0 0 0 0 0 2500 
2 366.917 0 25.9 2 0 0 0 0 0 2500 
2 384 5000 0 1 1 1 24 13 0 5000 
2 720 0 17.8 2 0 0 0 0 0 5000 
2 720.01 5000 0 1 1 1 0 0 0 5000 
2 720.583 0 19.3 2 0 0 0 0 0 5000 
2 721.05 0 18.8 2 0 0 0 0 0 5000 
2 721.6 0 21.6 2 0 0 0 0 0 5000 
2 722.083 0 22.5 2 0 0 0 0 0 5000 
2 724 0 21.5 2 0 0 0 0 0 5000 
2 724.667 0 19.1 2 0 0 0 0 0 5000 
2 725.083 0 21.5 2 0 0 0 0 0 5000 
2 725.5 0 23.6 2 0 0 0 0 0 5000 
2 726.967 0 26.5 2 0 0 0 0 0 5000 
2 744 10000 0 1 1 1 24 13 0 10000 
2 1080 0 18 2 0 0 0 0 0 10000 
2 1080.01 10000 0 1 1 1 0 0 0 10000 
2 1080.833 0 21.4 2 0 0 0 0 0 10000 
2 108125 0 21 2 0 0 0 0 0 10000 
2 1082.25 0 20.3 2 0 0 0 0 0 10000 
2 1084.083 0 20.9 2 0 0 0 0 0 10000 
2 1084.5 0 20.7 2 0 0 0 0 0 10000 
2 1085 0 23.6 2 0 0 0 0 0 10000 
2 1085.5 0 24.3 2 0 0 0 0 0 10000 
2 1087 0 24.2 2 0 0 0 0 0 10000 
2 1104 20000 0 1 1 1 24 13 0 20000 
2 1440 0 18.8 2 0 0 0 0 0 20000 
2 1440.01 20000 0 1 1 1 0 0 0 20000 
2 1440.833 0 24 2 0 0 0 0 0 20000 
2 144125 0 23.8 2 0 0 0 0 0 20000 
2 1441.667 0 25.9 2 0 0 0 0 0 20000 
2 1442.167 0 27.5 2 0 0 0 0 0 20000 
2 1444.083 0 24.1 2 0 0 0 0 0 20000 
2 1444.75 0 21.4 2 0 0 0 0 0 20000 
2 1445.333 0 27.3 2 0 0 0 0 0 20000 
2 1445.75 0 33 2 0 0 0 0 0 20000 
2 1447 0 25.3 2 0 0 0 0 0 20000 
8 Inter-subject variability - NONMEM approximations 
235 
If the model is Pj = TVP*exp(rti), then the first order approximation (a Taylor series 
expansion at eta=O) is Pj is approximately TVP * (1 +rti), 
where TVP is a fixed parameter and T] - multivariate N (0, 0). 
Consequently, 
E(TVP) is approximately TVP and var(TVP) is approximately var(TVP) + var(TVP*T]) = 
TVP"'2 * var(T]) = TVP"'2 *0. 
Therefore, 
CV(TVP) = sqrt(var(TVP»/E(TVP) is approximately [TVP * 0"'(1/2)] / TVP = 0"'(1/2). 
http://www.cognigencorp.comJnonmemJnmJ99feb042003.html 
http://www.cognigencorp.comJnonmemJnm/98sep261997.html 
9 NONMEM code for 1-compartment pharmacokinetic model 
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i lcmtlog GP 27Nov2003 
i 1 Cmt Model 
$PROB Glibenclamide PK 
$ INPUT ID TIME AMT DVX CMT EVID MDV II ADDL DAMT WT SEX DV TAD 
$DATA .. \data\virenehc2.csv 
$SUBROUTINE ADVAN2 TRANS2 
$PK 
Typical Parameters 
TVKA THETA ( 1) 
TVCL THETA(2) 
TVV THETA (3) 
Individual Parameters 
KA = TVKA*EXP(ETA(l» 
CL = TVCL*EXP(ETA(2» 
V TVV *EXP(ETA(3» 
Scaling AMOUNT to CONCENTRATION 
S2 = V 
$ ERROR 
DL=O 
IF (F.EQ.O) DL=O.OOl 
W= DL +F 
Y=LOG(W) +EPS (1) 
IRES = DV-F 
IWRE = (DV-F)/F 
IPRE = LOG (W) 
$ THETA (0, 1) i1:KA 
$ THETA (0, 5) i2:CL 
$ THETA (0, 15) i 3:V 
$ OMEGA 
0.9 1 KA 
0.9 2 CL 
0.9 3 V 
$SIGMA 0.9 
$COV 
$EST MSFO = 1cmt.msf MAXEVAL=9999 PRINT=10 METH=COND INTER 
$TABLE FILE = lcmt.fit ID AMT TIME CMT DAMT TAD 
IPRE ONEHEADER NOPRINT 
10 NONMEM code for 2-compartment pharmacokinetic model 
237 
; 2cmtss GP 27Nov2003 
; 2 Cmt Model 
$PROB Glibenclamide PK 
$ INPUT ID TIME AMT DVX CMT EVID MDV II ADDL DAMT WT SEX DV TAD 
$DATA .. \data\virenEHC2.csv 
$SUBROUTINE ADVAN4 TRANS4 
$PK 
Typical Parameters 
TVKA = THETA (1) 
TVCL THETA(2) 
TVV2 THETA (3) 
TVQ THETA (4) 




V2 = TVV2*EXP(ETA(3» 
Q TVQ *EXP(ETA(4» 
V3 TVV3*EXP(ETA(5» 
Scaling AMOUNT to CONCENTRATION 
S2 I: V2 
$ ERROR 
DLI:.O 
IF (F.EQ.O) DL=O.OOl 
W= DL +F 
Y=LOG(W) +EPS (1) 
IRES = DV-F 
IWRE (DV-F)/F 
IPRE = LOG(W) 
$ THETA (0, 0.5) ;l:KA 
$ THETA (0, 3) ;2:CL 
$ THETA (0, 10) ;3 :V2 
$ THETA (0, 2.5) ;4:Q 
$ THETA (0, 50) ;5 :V3 
$ OMEGA 0.9 1 
$ OMEGA 
0.9 2 










$EST MSFO = 2cmt.msf MAX=9999 PRI=10 METH=COND INTER NOABORT 
$TABLE FILE = 2cmt.fit ID AMT TIME CMT DAMT TAD 
IPRE ONEHEADER NOPRINT 
$TABLE FILE 
$TABLE FILE = 
2cmt.par ID KA CL V2 Q V3 DAMT ONEHEAD FIRST NOPRI 
2cmtall.par ID KA CL V2 Q V3 DAMT ONEHEAD NOPRI 
11 NONMEM code for Enterohepatic recycling model 
238 
$PROB ENTEROHEPATIC Circulation for multiple doses - GB Empties after lunch 
iData Description 
Doses of Drug go into CMT=l with ADDL=12 and 11=24 and another dose a day 
later before sampling 
Dummy Dose into CMT=5 
Dummy Dose into CMT=6 
Dummy Dose into CMT=7 










11=24, and AMT=l 
11=24, and AMT=l 
11=24, and AMT=l 
11=24, and AMT=l 
3 compartment model including a depot compartment 
compartment 1 serves as the depot 
if supper as well 
if supper as well 
compartment 2 and 3 serve as a standard 2 cmt model (central + peri.) 
compartment 4 represents the gall bladder (GB) 
To control the 'on' and 'off' of flow to the GB and from the GB to the 
depot a 'change point' modeling technique will be used. This technique 
uses dummy dose compartments 
to allow the estimation of lag times which will be used to control the 
on-off switch for transport to and from the GB. 
flow into the GB (K24) will be 'on' from 0 to 8 hours after each dose 
and then will be turned 'off' until the following dose 
flow from the GB to the depot compartment (K41) will be turned 'on' at 
the time of lunch and dinner(known times) and turned 'off' at an 
estimated time later 
$ INPUT ID TIME AMT DVX CMT EVID MDV II ADDL DAMT WT SEX DV TAD 
$DATA .. \data\virenEHC.csv 
$SUBROUTlNES ADVAN6 TRANSl TOL=5 
$MODEL 







i on GB entry 
i2 central compartment 
i3 peripherial compartment 
i 4 gall bladder 
is dummy cmt to turn on GB exit at lunch 
i 6 dummy cmt to turn off GB exit at lunch 
















ito prevent drug from accumulating in the gall bladder after the gall 
bladder empties 
K24 will be turned off from the last modeled time the gall bladder 
empties for a day 
until the next day 
iK24= flow from central to the gall bladder (this will be turned on 
i and off) 
iK41= flow from gall bladder to depot (this will be turned on and off) 
K24=THETA(6) * EXP(ETA(6» 
K41=THETA(7) 
ifor this model it was assumed that the amount of elapsed time the gall 
bladder exit rate will 
i be on each time it empties will be the same (GBL) 
iALAGS and ALAG7 were set to fixed values based upon the known time of 
lunch and dinner 
0.0001 was added in each case to prevent the possibility of an infinite 
value of OBJ value 
because the dataset had PK samples at time=4 and time=B 
;ALAGS AND ALAG7 could be estimated 
GBL=THETA(B) 
;*EXP(ETA(6» 






ithe following code sets up indicator variables to control K24 and K41 
in the 
; $DES block- JON/JOFF/Z control K41 and GBON/GBOFF/Z2 control K24 
ifirst record in an individual K24 is 'on' and K41 is 'off' 
IF (NEWIND.LT. 2) THEN 





iset the values of the on'off indicator variables 










note that DOSREC(variable)=O except at the time a dose actually enters 
the system 
(doses enter the system at TIME + n*II + ALAG#) 
idose records to cmt 1 should turn on GB entry (K24) 
IF (DOSREC(CMT) .EQ.1) GBON=l 
idose record to cmt 5 should turn off GB entry (K24) 
IF (DOSREC (CMT) .EQ.5) GBOFF=l 
idose records to cmt=5 should turn on GB exit (K41) 
IF (DOSREC(CMT) .EQ.5) JON=l 
idose records to cmt=6 should turn off GB exit (K41) 
IF (DOSREC (CMT) .EQ.6) JOFF=l 
$DES 
K10 CL/V2 







DADT(6) = 0 
$ ERROR 
DL=O 
KA*A(l) + K32*A(3) - K23*A(2) - K24*Z2*A(2) - K10*A(2) 
K23*A(2) - K32*A(3) 
K24*Z2*A(2) - K41*Z*A(4) 
o 
IF (F.EQ.O) DL=O.OOl 






{O, 0.5, 10) 
(0, 5, ) 
(0,10,) 
(0, 3,) 








$ OMEGA 0.9 
$ OMEGA 0.9 
$ OMEGA 0.9 
$ OMEGA 0.9 
$ OMEGA 0.9 
$ OMEGA 0.9 
$SIGMA 0.9 
;V3: theta 6 
; K24 : theta 7 
;K41:theta 8 
;elapsed time GB exit is 'on' (Theta9) 
$EST MSFO = GLIBEHC6.msf MAX=9999 PRI=lO METH=O POSTHOC NOABORT 
$TABLE FILE = GLIBEHC6.fit ID AMT TIME TAD CMT DAMT 
IPRE ONEHEADER NOPRINT 
12 NONMEM code for Dose/CPss - mean glucose 
pharmacodynamic model 
239 
$PROB Glucose Dose Model 
$INPUT ID TIME AMT DVX CMT EVID MDV II ADDL SS DAMT 
$ INPUT WT SEX DV KA CL V2 Q V3 TAD 
$DATA .. \data\meanglu.csv 
$PRED 
i PK Driving Force for Glucose Effect 
CPSS = DAMT/(CL*24) 
Glibenclamide conc 
PD parameters 
EO = THETA (1) 
EMAX = THETA (2 ) 
CsO = THETA(3) 
producing 50% effect 
GAM = THETA (4) 




Trick to prevent divide by zero errors 
SMALL = 0.0000001 
Drug Effect and Time Course of Glucose 
Average steady State 
Baseline 
Maximum drug effect 
Average steady StateConc 
i sigmoid shape of Emax model 
F = EO * (1 - (EMAX * CPSS)/(CsO + CPSS)) 
i$ERROR 
DL=O 
IF (F.LE.O) DL=0.001 
W = DL + F 
Y = LOG(W)+ERR(1) 
IPRE = LOG (W) 
IRES = DV-F 
IWRE = (DV-F)/F 
$ THETA (0,16 ) 
$ THETA (0,0.3 ) 
$ THETA (0,40 ) 
; $ THETA (1 FIX 
$ OMEGA 0.9 
$ OMEGA 0.9 












$EST MAX = 9999 NOABORT METH = 0 POSTHOC PRINT = 1 MSF = 
cpssmeangluOO.msf 
$TAB ONEHEA NOPRI ID TIME TAD MDV AMT CMT IPRE DAMT FILE= 
cpssmeangluOO.fit 
$TAB ONEHE NOPRI FIRS ID EO EMAX CSO FILE=cpssmeangluOO.par 
$OMEGA BLOCK(I) 2 2 Al 
$OMEGA BLOCK(I) SAME 3 BI 
$OMEGA BLOCK(I) SAME 4 BI 
$OMEGA BLOCK(I) SAME 5 BI 
$ OMEGA 0.9 6 EMAX 
$ OMEGA 0.9 7 CP50 
i$OMEGA 0.9 8 GAM 
$SIGMA 0.9 
$ COVARIANCE 
$EST MAX = 9999 NOABORT METH = 0 POSTHOC PRINT = 1 MSF = 
CpssprofilegluOO.msf 
$TAB ONEHEA NOPRI ID TIME TAD MDV AMT CMT IPRE DAMT 
FILE=cpssprofilegluOO.fit 
$TAB ONEHE NOPRI FIRS ID AO Al Bl A2 B2 EMAX CP50 CL 
FILE=cpssprofilegluOO.par 
13 NONMEM Code for Dose/CPss - Full Glucose Profile model 
240 
$PROB Glucose Cpss Model 
$INPUT ID TIME AMT DVX CMT EVID MDV II ADDL SS DAMT 
$INPUT WT SEX DV KA CL V2 Q V3 TAD 
$DATA .. \data\kpdglu . csv 
$PRED 
Placebo Model 
AO THETA (1) *EXP(ETA(l)) 
A1 THETA (2) + ETA(2) 
B1 THETA (3) + ETA(3) 
A2 THETA (4) + ETA(4) 
B2 THETA (5) + ETA(5) 
PK Driving Force for Glucose Effect 
CPSS = DAMT/(CL*24) 
Glibenclamide cone 
PD parameters 
EMAX THETA (6) 
CP50 = THETA (7) 
effect 
* EXP (ETA(6)) 
* EXP (ETA(7)) 
Average steady State 
Maximum drug effect 
Average Glib conc producing 50* 
GAM = THETA (8) * EXP(ETA(8)) i sigmoid shape of Emax model 
Trick to prevent divide by zero errors 
SMALL = 0.0000001 
Cyclical changes to baseline 
CIRC1 AO + A1*COS(2*3.1416*TIME/8) 
CIRC2 A2*COS(2*3.1416*2*TIME/8) 
EO CIRC1 + CIRC2 
IF (EO.LE . O) EXIT 
Drug Effect and Time Course of Glucose 
+ B1*SIN(2*3.1416*TIME/8) 
+ B2*SIN(2*3.1416*2*TIME/8) 
F = EO * (1 - (EMAX * CPSS)/(CP50 + CPSS)) 
i$ERROR 
DL=O 
IF (F.LE.O) DL=O.OOl 
W = DL + F 
Y = LOG(W)+ERR(l) 
IPRE = LOG(W) 
IRES DV-F 
IWRE (DV-F)/F 
i Placebo Parameters 
$ THETA (15.1 ) 
$ THETA (-3.83 ) 
$ THETA (2.14 ) 
$ THETA (-6.90 ) 
$ THETA (1. 86 ) 
$ THETA (0,0.5 
$ THETA (0,85 











$OMEGA BLOCK(l} 2 :2 Al 
$OMEGA BLOCK (l) SAME 3 Bl 
$OMEGA BLOCK(l} SAME 4 Bl 
$OMEGA BLOCK (l) SAME 5 Bl 
$ OMEGA 0.9 6 EMAX 
$ OMEGA 0.9 7 CPSO 
; $ OMEGA 0.9 8 GAM 
$SIGMA 0.9 
$ COVARIANCE 
$EST MAX = 9999 NOABORT METH = 0 POSTHOC PRINT = 1 MSF 
CpssprofilegluOO.msf 
$TAB ONEHEA NOPRI ID TIME TAD MDV AMT CMT IPRE DAMT 
FILE=CpssprofilegluOO.fit 
$TAB ONEHE NOPRI FIRS ID AO Al Bl A2 B2 EMAX CPSO CL 
FILE=CpssprofilegluOO.par 
